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1012-69 Ranolazine, a Late Sodium Current Inhibitor, Markedly 
Reduces Ventricular Arrhythmias in a Model of 
Coronary Occlusion/Reperfusion
Joan Dow, Sharon Hale, John Shryock, Luiz Belardinelli, Arvinder Dhalla, Anil Bhandari, 
Robert A. Kloner, Heart Institute, Good Samaritan Hospital, Los Angeles, CA, Keck 
School of Medicine at University of Southern California, Los Angeles, CA
Background: Safe and effective anti-arrhythmic drugs for ischemic heart disease are few. 
A major concern has been the development of pro-arrhythmia by such drugs in the setting 
of ischemic heart disease. We tested the late sodium current inhibitor and antianginal agent 
ranolazine in a model of severe ischemia/reperfusion-induced ventricular arrhythmias. 
Methods: Sprague Dawley rats were anesthetized with sodium pentobarbital, intubated, 
ventilated and subjected to a ﬁve minute occlusion of the proximal left coronary artery 
followed by ﬁve minutes of reperfusion. This protocol reliably causes severe and complex 
ventricular arrhythmias during the reperfusion period. ECG and blood pressure were 
monitored continuously. Rats were randomized to receive either saline or ranolazine (10 
mg/kg IV bolus) 16 minutes prior to coronary occlusion. Results: Ventricular tachycardia 
(VT) occurred in 9/12 saline-treated and 1/11 ranolazine-treated rats during the ﬁve minute 
reperfusion period (p < 0.003). Sustained VT (> 10 sec) occurred in 5/12 saline-treated but 
in 0/11 ranolazine-treated rats (p < 0.02). Ventricular premature beats (VPBs) occurred in 
12/12 saline-treated and in 5/11 ranolazine-treated rats (p < 0.005). The median numbers 
of episodes of VT during reperfusion in saline- and ranolazine-treated rats were 5.5 and 0, 
respectively (p < 0.001); the median durations of VT were 22.2 and 0.2 seconds in saline- 
and ranolazine-treated rats, respectively (p < 0.001). The median numbers of VPBs were 
16 in saline- versus 0 in ranolazine-treated rats (p < 0.0002). In addition, ranolazine also 
reduced the severity of ventricular arrhythmias during the ischemic phase. Ischemic risk 
zone size, assessed by blue dye injection with the artery brieﬂy reoccluded at the end 
of the protocol, did not differ between groups (31.6 ± 0.5% (mean ± SEM) of the left 
ventricle in the saline versus 34.8 ± 0.8% in the ranolazine group; p = NS). Conclusion:
Ranolazine markedly reduced reperfusion-induced ventricular arrhythmias. Late sodium 
current inhibition may be a promising strategy to reduce ventricular arrhythmias in the 
setting of ischemia/reperfusion.
9:30 a.m.
1012-70 Functional Analysis of NO Production and eNOS 
Transduction by Equine and Naturally Occurring Estrogens
Ana Paula Dantas, Laura Novensà, Merce Roque, Magda Heras, Institut 
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background: Although several research have established that estrogens have beneﬁcial 
cardiovascular effects; clinical trials have shown that estrogenic therapy revealed no 
cardiovascular beneﬁt. One explanation for the discrepancies is that conjugated equine 
estrogens (CEE) used in these trials do not modulate NO generation in the same 
pharmacological manner as naturally occurring estrogens estradiol (E2) and estrone (Est).
Methods: The effects of increasing dose of estrogens on NO generation were evaluated 
in human aortic endothelial cells (HAEC) by measuring in vivo increase in DAF-2 
ﬂuorescence and NOx concentration. The role of estrogens on NO synthase (eNOS) 
activity and expression was determined by 3H-Citruline assay, western blot and real-
time PCR. The transcriptional activity of estrogens on eNOS promoter was measured by 
luciferase reporter gene assay.
Results: Following 48h of incubation we found that while Est was as effective as E2 to 
increase NO production by increasing eNOS activity and expression, the equine estrogens 
equilin (Eq) and equilenin (Eqn) were markedly less effective. Activity of Eq and Eqn on 
eNOS promoter was about 20-30% lower than that of E2, an effect that could explain the 
lower NO production by equine estrogens. E2 can also acutely increase eNOS activity 
by a mechanism that involves the phosphorylation of eNOS at Serine 1177 (pSer1177). 
Following 15min treatment with distinct estrogens we have demonstrate for the ﬁrst time 
that although equines estrogens are also effective in promoting pSer1177-mediated NO 
production, these effects are signiﬁcantly lower than those observed with E2 and Est.
Conclusions: Equine estrogens are less effective to increase NO production than E2 
and Est. These effects can be partially associated to the inability of equine estrogens to 
activate eNOS promoter and induce transduction. Differences on NO production between 
equine and naturally occurring estrogens may contribute to lack of cardiovascular beneﬁt 
observed in clinical trials using CEE treatment regiments. Understanding the mechanisms 
by which estrogens modulate vascular function may ultimately lead to new therapeutics 
for the treatment of cardiovascular disease.
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1012-67 Marked Variability of Monacolin and Citrinin Content of 
12 Readily Available Red Yeast Rice Formulations
Ram Y. Gordon, William Obermeyer, Tod Cooperman, David J. Becker, Chestnut Hill 
Hospital, Philadelphia, PA
Background: Red yeast rice (RYR) is an alternative therapy used for hyperlipidemia and 
contains monacolins that may inhibit HMG-CoA reductase. Like other herbal medications, 
there is limited regulation of RYR products. We analyzed 12 commercially available RYR 
formulations for total monacolin, monacolin K (lovastatin) and monacolin KA content. We 
also tested for citrinin, a possibly nephrotoxic contaminant.
Methods: Lab analysis of RYR products was performed by ConsumerLab (White Plains, 
NY). Each formulation was labeled 600 mg/cap of active product. Analysis of monacolins 
was performed using liquid chromatography. Analysis of citrinin was performed using thin 
layer chromatography.
Results: Results are summarized in the table. There was marked variability of total 
monacolins (0.31 to 11.15 mg/cap), monacolin K (0.10 to 10.09 mg/cap), and monacolin 
KA (0.00 to 2.30 mg/cap). 4 products had elevated levels of citrinin.
Conclusions: RYR is used by millions of patients worldwide as an alternative lipid-
lowering therapy. It has been found to reduce both LDL-C levels and the incidence 
of cardiac events in a secondary population. However, we found striking variability in 
monacolin content and the presence of citrinin in one-third of the products tested. Our 
ﬁndings emphasize the need for improved oversight and standardization of RYR products. 
Until this occurs, physicians should be cautious in recommending RYR to their patients for 
the treatment of hyperlipidemia and cardiovascular disease.
Table: Monacolin and Citrinin Content of 12 Commercially Available 
Red Yeast Rice Products
Red Yeast 
Rice Product
(600 mg/
capsule)
Total Monacolins 
(mg/capsule)
Monacolin K 
(Lovastatin) (mg/
capsule)
Monacolin KA 
(mg/capsule)
Citrinin
(parts per 
million)
Product A 4.18 1.74 1.63 Notdetected
Product B 1.65 1.12 0.22 24
Product C 6.03 3.63 1.22 Notdetected
Product D 0.31 0.10 0.00 189
Product E 6.18 2.50 2.30 Notdetected
Product F 11.15 10.09 0.52 Notdetected
Product G 1.60 0.99 0.23 75.5
Product H 3.97 2.66 0.46 Notdetected
Product I 1.36 0.97 0.19 119
Product J 6.13 3.12 2.07 Notdetected
Product K 5.30 2.53 1.96 Notdetected
Product L 2.16 1.02 0.61 Notdetected
9:30 a.m.
1012-68 Fourteen-Day Treatment With Anakinra Provides Superior 
Protection Against Myocardial Remodeling Versus 7-Day 
Treatment in Experimental Acute Myocardial Infarction
Fadi N. Salloum, Nicholas N. Hoke, Amit Varma, Benjamin Van Tassell, Stefano Toldo, 
Vinh Q. Chau, Antonio Abbate, Virginia Commonwealth University Pauley Heart Center, 
Richmond, VA
Background: Anakinra, recombinant human interleukin-1 receptor antagonist, given 
daily for 7 days during experimental acute myocardial infarction (AMI) reduces myocardial 
apoptosis and cardiac remodeling measured at 7 days after AMI in mice. The aim of the 
current study was to compare the beneﬁt of 7-day versus 14-day treatment with anakinra 
on cardiac remodeling at 28 days after AMI in mice.
Methods: Thirty ICR mice underwent permanent surgical coronary artery ligation. Mice 
received anakinra 1 mg/kg for 7 days (n=10), anakinra 1 mg/kg for 14 days (n=10), or 
NaCl 0.9% for 14 days (n=10). All animals underwent transthoracic echocardiography 
(TTE) before surgery and 24 hours, 7 days, 14 days, and 28 days after surgery.
Results: Both durations of anakinra treatment improved left ventricular end-diastolic 
diameter (LVEDD), end-systolic diameter (LVESD), and fractional shortening (LVFS) 
versus saline at 7, 14, and 28 days after AMI (all p values <0.05 [see ﬁgure]). Compared 
to the 7-day treatment, 14-day treatment signiﬁcantly improved LVEDD, LVESD, and 
LVFS at 28 days after AMI.
Conclusions: Treatment with anakinra provides more favorable cardiac remodeling after 
experimental AMI in mice. A 14-day treatment is superior to 7-day treatment with minimal-
to-null late loss after cessation of treatment. 
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1012-71 Ox-LDL Modiﬁes the Behavior of Bone Marrow Stem 
Cells and Impairs Their Endothelial Differentiation via 
Inhibition of Akt Activation
Ling Chu, Hong Hao, Zehao Liu, Jian Xu, Min Luo, Yu Huang, Zhenyu Chen, Catherine 
M. Verfaillie, Jay L. Zweier, Zhenguo Liu, The Ohio State University Medical Center, 
Columbus, OH
Background: This study was to investigate the effect of oxidized low density lipoprotein 
(ox-LDL) on the behavior of bone marrow stem cells and their endothelial differentiation 
and the underlying mechanisms.
Methods and Results: Adult rat bone marrow multipotent progenitor cells (MAPCs) were 
incubated with ox-LDL (from 10 to 40 μg/ml) for up to 2 weeks. Ox-LDL induced a dramatic 
decrease in cell number in a time- and dose-dependent manner. The reduced cell number was 
due to decreased cell proliferation (by BrdU Cell Proliferation Assay) and increased apoptosis 
by ox-LDL. The expression of stem cell marker Oct-4 was signiﬁcantly inhibited in MAPCs 
exposed to ox-LDL in a dose- and time-dependant manner. When treated with ox-LDL, the 
endothelial differentiation of MAPCs was substantially inhibited as reﬂected by markedly 
decreased expression of endothelial markers vWF, Flk-1, and CD31 by RT-PCR and Western 
blot, as well as vascular tube formation. Ox-LDL-induced cell apoptosis and inhibition of Oct-
4 expression, cell proliferation, and endothelial differentiation of MAPCs were associated 
with signiﬁcant inhibition of Akt phosphorylation. Overexpression of phosphorylated Akt in 
MAPCs with transfection of a constitutively active Akt completely reversed the effects of ox-
LDL on MAPCs including enhanced apoptosis, decreased cell proliferation, suppressed Oct-4 
expression and endothelial differentiation as well as vascular tube formation.
Conclusion: Ox-LDL promotes apoptosis and inhibits Oct-4 expression and self-renewal 
of MAPCs and their endothelial differentiation via suppression of Akt signaling. The 
data may provide a novel mechanism for the development of cardiovascular diseases 
in hyperlipidemia. This study may also has signiﬁcnat clinical impact on patient selection 
for cell therapy with bone marrow stem cells especially for those with poorly controlled 
hyperlipidemia.
9:30 a.m.
1012-72 The Polymorphisms in the Resistin Gene Are 
Associated With Serum Resistin Levels and Correlated 
With Accumulation of Metabolic Syndrome Factors
Hideo Izawa, Hiroyuki Honda, Yasuko Yoshida, Daisuke Tanimura, Akihiro Hirashiki, 
Tsutomu Yoshida, Kenji Yasui, Masanori Nomura, Toyoaki Murohara, Fujita Health 
University Banbuntane Hotokukai Hospital, Nagoya, Japan, Nagoya University MEXT 
Innovative Research Center for Preventive Medical Engineering, Nagoya, Japan
Background: Serum concentrations of resistin, secreted from adipocytes, are associated 
with insulin resistance. We investigated the association of polymorphisms in the resistin 
gene with serum concentrations of resistin and with factors related to the metabolic 
syndrome (MetS).
Methods: The study subjects consisted of 2815 Japanese workers who were employees 
of a manufacturing company (age 42.7 +/- 12.6 years, waist circumference 81.6 +/- 9.0 
cm). We genotyped all subjects for 10 single-nucleotide polymorphisms (SNPs; -638G>A, 
-537A>C, -420C/G, -358G/A, -167C/T, 157C/T, 299G/A, 602C/T, 876C/G, 1084G/A) and 4 
allele types with 5, 6, 7 and 8 ATG dinucleotide repeats, respectively, in the resistin gene. We 
also obtained biochemical measurements including fasting serum resistin concentrations.
Results: Carriers of genotype G/G at position -420 (rs 1862513) had the highest serum 
resistin concentrations, followed by C/G carriers and C/C carriers (p< 0.0001, Figure). 
The ATG dinucleotide repeat polymorphism (rs 3833230) was also associated with serum 
resistin concentrations (Figure). Signiﬁcant correlations (p< 0.0001, respectively) between 
serum resistin concentrations and age, female sex, waist circumference, serum triglyceride 
concentrations, serum HDL cholesterol concentrations and HOMA-IR were found.
Conclusions: Serum resistin concentrations were associated with polymorphisms in the 
resistin gene and correlated with the accumulation of MetS factors. 
9:30 a.m.
1012-73 Assessment of Platelet Function Inhibition Using Flow 
Cytometry After Administration of Glycoprotein IIb/IIIa 
Receptor Blockers in High-Risk Acute Coronary Syndrome 
Patients Undergoing Percutaneous Coronary Intervention
Aniket Puri, Anupama Bansal, Rishi Sethi, Sudhanshu K. Dwivedi, Varun S. Narain, Ram K. 
Saran, Vijay K. Puri, CSM Medical university( fmr King George Med Univ), Lucknow, India
Background:The level of platelet inhibition by a GlycoproteinIIb/IIIa (GpIIb/IIIa) antagonist 
necessary to minimize thrombotic complications in patients undergoing percutaneous 
coronary intervention (PCI) is a subject of debate. The degree of platelet inhibition 
obtained 10 minutes after start of GpIIb/IIIa antagonist therapy predicts adverse events 
after PCI. The aim of this study was to compare occupancy ratio of platelet GpIIb/IIIa
receptors with Eptiﬁbatide and Tiroﬁban using various dose regimens, by ﬂow cytometry 
and correlate with 30 day outcomes in patients presenting with high risk acute coronary 
syndromes (ACS) and undergoing PCI
Methods:The patients were divided into four groups: Eptiﬁbatide two intracoronary bolus 
(180 μg/kg) alone(EB), or two intravenous bolus (180μg/kg) followed by infusion at 2 μg/
kg/min for 24 hours (EB+Inf), and Tiroﬁban standard bolus dose (0.4μg/kg) over 30 minutes 
followed by infusion at 0.1μg/kg/min.(TStd) or at ADVANCE dose bolus (25μg/kg) over 
3 minutes, followed by infusion at 0.1μg/kg/min(TAdv). Number of GpIIb/IIIa receptors was 
assessed by ﬂow cytometry at baseline and 10 minutes after the bolus and percentage 
of free receptors was determined to calculate the occupancy ratio. Patients were followed 
for 30 days for any major adverse cardiac events(MACE).
Results:200 consecutive patients (males 86%, mean age 52.6, Diabetics 20%, 
Hypertensive 32%, hyperlipidemics 32%, Smokers 50%), including 74% with ST Elevation 
MI and 26% with NSTEMI were enrolled. GpIIb/IIIa Occupancy ratios in groups EB (n=48)
and EB+Inf (n=44) were 62.7%+27.2% and 61.4%+6.1% respectively while in the groups 
TStd (n=96) and TAdv (n=12) groups were 35.1% + 17.74% and 68.8%+27.3% respectively. 
The GpIIb/IIIa occupancy ratio were similar in EB, EB+Inf and TAdv groups was signiﬁcantly 
higher than TStd group(p<0.0001). The 30 day MACE rates in EB (4.2%), EB+Inf (4.5%) and 
TAdv (4.2%) were signiﬁcantly lower than TStd group (12.5%) (p<0.01)
Conclusions:Standard dose Tiroﬁban results in signiﬁcantly lower rates of GpIIb/IIIa
receptor occupancy ratio and this correlated with higher incidence of 30 day MACE in 
high risk ACS patients undergoing PCI
9:30 a.m.
1012-74 Estrogen Inhibits Inﬂammation by Accelerating a Negative 
Feedback Loop Within the NFKB/IKB Signaling Pathway in 
TNF-A-Stimulated Rat Aortic Smooth Muscle Cells
Dongqi Xing, Suzanne Oparil, Yiu-Fai Chen, Wenguang Feng, Susan Nozell, University 
of Alabama at Birmingham, Birmingham, AL
Background: The NFKB signaling pathway is critical for the expression of genes involved 
in vascular inﬂammation and in the response to vascular injury. We demonstrated that 
estrogen (17B-estradiol, E2) inhibits expression of these genes in an estrogen receptor 
B-dependent manner in balloon injured rat carotid arteries and in tumor necrosis factor 
(TNF)-A treated rat aortic smooth muscle cells (RASMCs) in vitro. Herein, we test the 
hypothesis and deﬁne the mechanism by which E2 inhibits NFKB signaling. 
Methods: Expression of IKBA was determined using real time RT-PCR and Western blot 
analysis. Interactions between NFKB p65 and the promoters of inﬂammatory mediators 
were evaluated by chromatin immunoprecipitation (ChIP) assay. 
Results: Stimulation of RASMCs with TNF-A caused rapid degradation of IKBA (10-30 min), 
followed by a dramatic evaluation in IKBA mRNA and protein synthesis (40-60 min), indicating 
a negative feedback loop within the NFKB/IKB signaling pathway. E2 enhanced TNF-A
induced IKBA mRNA and protein synthesis without affecting IKBA degradation (Figure A-C). 
ChIP assays conﬁrmed that TNF-A signiﬁcantly increased the levels of p65 at all promoters 
analyzed (at 1hr) but that these levels were reduced by E2 (Figure D). Conclusions: E2-
inhibited expression of inﬂammatory mediators in the setting of acute vascular injury may be 
mediated, in part, by accelerating a negative feedback loop within the NFKB/IKB signaling 
pathway, and inhibiting NF-kB p65 binding to promoters of these genes. 
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1012-75 Baseline Lipid Levels and Progression of Coronary 
Atherosclerosis in Abdominally Obese Patients
Stephen J. Nicholls, Ozgur Bayturan, Amy Hsu, Kathy Wolski, Jean -Pierre Despres, 
John E. Deanﬁeld, John J. Kastelein, Christopher P. Cannon, Bernard Job, Christophe 
Gauidin, E.Murat Tuzcu, Steven E. Nissen, Cleveland Clinic Foundation, Cleveland, OH
Background: Abdominal obesity is associated with an adverse cardiovascular prognosis. 
The factors driving atherosclerosis progression in abdominally obese patients are 
unknown.
Methods: The relationship between baseline clinical characteristics, stratiﬁed 
according to median levels, and progression of coronary atherosclerosis determined by 
intravascular ultrasound in 676 abdominally obese patients with coronary artery disease 
who completed the STRADIVARIUS study, prior designed for comparison of rimonabant 
with placebo, was investigated.
Results: Percent atheroma volume (PAV) increased from 37.5 to 37.9% (p<0.001) over 18 
months in patients (age 57.8 yrs, 67% male, average BMI of 35.2 kg/m2, waist circumference 
117 cm, 36.7% diabetes, 88.6% hypertension, 86.5% hypercholesterolemia). Accelerated 
progression of PAV was observed in subjects with higher baseline levels of LDL cholesterol 
(+0.66 vs +0.09%, p=0.007), triglycerides (+0.65 vs +0.11%, p=0.001), triglycerides/HDL 
cholesterol (+0.66 vs +0.10%, p=0.008) and apoB/A-I (+0.68 vs +0.08%, p=0.004). A 
greater increase in PAV was found in those with greater baseline levels of apoC-III (+0.53 
vs +0.22%, p=0.16) and lower levels of HDL cholesterol (+0.51 vs +0.23%, p=0.19), 
although these failed to meet statistical signiﬁcance. No relationship was observed 
between greater baseline levels of BMI (r=0.005, p=0.90), waist circumference (r=0.001, 
p=0.98), CRP (r=-0.04, p=0.27), leptin (r=0.006, p=0.87) or adiponectin (r=-0.04, p=0.33) 
and progression of PAV. Multivariable analysis revealed that baseline LDL cholesterol 
(p=0.0004) and treatment with either beta-blockers (p=0.03) or thiazolidinediones 
(p=0.008) independently predicted PAV progression, while a triglyceride/HDL cholesterol 
ratio less than 3.0 was associated with less disease progression (p=0.02).
Conclusion: Baseline levels of atherogenic lipids, but not measures of adiposity, 
systemic inﬂammation or adipocytokines, predict progression of coronary atherosclerosis 
in patients with abdominal obesity.
9:30 a.m.
1012-76 Non-HDL-Cholesterol as Valid Surrogate to 
Apolipoprotein B Measurement in Diabetes: 
Discriminant Ratio and Unbiased Equivalence
Michel F. Rousseau, Sylvie A. Ahn, Michel P. Hermans, University of Louvain, Brussels, 
Belgium
Background: Epidemiology suggests that apolipoprotein B (ApoB) may be a better 
marker of cardiovascular risk than LDL-cholesterol (C). Non-HDL-C (total C minus 
HDL-C) may provide a simple unexpensive metabolic surrogate to ApoB measurement, 
since it represents the C transported by lipoproteins that carry a single ApoB molecule 
per particle.
Methods: The Discriminant Ratio (DR) method (Levy JC et al. Am J Physiol 276: E365-
75, 1999) was used to compare the performance of non-HDL-C with that of ApoB to 
rank diabetic patients according to dyslipidemia. The DR is the ratio of the underlying 
between-subject standard deviation (SD) to the within-subject SD. DRs were calculated 
from duplicates sampled on 2 different days. Signiﬁcance of difference in DRs was 
considered at p<0.05. Correlation coefﬁcients between pairs were adjusted in order to 
include an estimate of the underlying correlation, since standard coefﬁcients, due to the 
presence of within-subject variation, underestimate the true correlation between tests 
(attenuation). An unbiased estimation of linear relationship equation between methods 
was also derived.
Results: Total and HDL-C were measured by enzymatic assays and ApoB by 
immunonephelometry. Duplicates samples on 2 different days were collected in 45 diabetic 
subjects with various degrees of dyslipidemia. Mean values [day 1 and day 2 (1SD)] were 
143 (36) and 137 (43) mg/dl for non-HDL-C, and 98 (24) and 95 (27) mg/dl for ApoB, 
respectively. The DR’s of both parameters were similar (1.8) so that ranking discrimination 
between non-HDL-C and ApoB was identical. The measured Pearson’s product-moment 
correlation coefﬁcient between tests was very high (0.94), reaching unity (1.00) once 
values were adjusted for attenuation. The unbiased equation of equivalence relating ApoB 
to non-HDL-C had a slope of 0.65 and an intercept of 6.3 mg/dl. Conclusions: The DR 
methodology demonstrates that the discrimination of non-HDL-C is similar to that of ApoB 
to rank diabetic patients according to atherogenic dyslipidemia. Since true correlation 
between these variables reaches unity, non-HDL-C is an easy, robust and cost-effective 
means to derive ApoB values from routine fasting lipid proﬁle.
9:30 a.m.
1012-77 Metabolic Syndrome and Major Cardiovascular Events 
in Patients With Familial Combined Hyperlipidemia
Constantina Masoura, Ioannis Skoumas, Konstantinos Aznaouridis, Vassiliki 
Metaxa, Athanasios Tsokanis, Lambros Papadimitriou, Fereniki Platsouka, Christina 
Chrysohoou, Christos Pitsavos, Christodoulos Stefanadis, Hippokration Hospital, 
Athens, Greece
Background: Familial combined hyperlipidemia (FCH) is a polygenic lipid disorder 
associated with premature cardiovascular disease. It is unknown whether metabolic 
syndrome (MetS) modulates cardiovascular risk in FCH patients.
Methods: We studied prospectively 644 FCH patients (421 men) for 9.2±3.6 years. 
Demographic characteristics and biochemical parameters were evaluated at enrolment, 
before the initiation of treatment. The diagnosis of MetS was based on the modiﬁed ATP 
III criteria (glucose >100 mg/dl). Hard cardiovascular end-points, like acute myocardial 
infarction (AMI) and cardiovascular death, were recorded during the follow-up.
Results: The 323 patients with MetS were older (50.8±10.2 vs. 46.7±11.0 years, 
<0.001) and had higher triglyceride and glucose levels, but they had lower HDL-C 
levels compared with patients without MetS (all <0.001). There was no difference in total 
cholesterol. The combined endpoint (AMI/death) occurred in 29 patients with MetS and 
in 9 patients without MetS (9.0% vs. 2.8%, P=0.001). Kaplan-Meier analysis showed a 
signiﬁcant difference in the event-free survival between the 2 groups (P=0.005, ﬁgure). 
Multivariate analysis (Cox regression) showed that MetS at enrolment predicts AMI/death 
independent of age, sex or previous cardiovascular disease (adjusted odds ratio 2.25, 
95% CI 1.06-4.75, P=0.034).
Conclusions: MetS represents an independent predictor of major cardiovascular events 
in FCH patients. 
9:30 a.m.
1012-78 Effect of Different Cardiovascular Risk Factors on Age 
at Presentation With First Acute Coronary Syndrome
Carlos T. Aguiar, Jorge S. Ferreira, Investigators of the Portuguese Registry of 
AcuteCoronary Syndromes, Hospital Santa Cruz, Carnaxide, Portugal
Purpose: Understanding the role of risk factors is essential for effective prevention of 
acute coronary syndromes (ACS). We evaluated the inﬂuence of hypertension (HTN), 
smoking, diabetes (DM), hypercholesterolemia (HChol), and obesity on the age at 
presentation for a ﬁrst ACS.
Methods: 10.811 patients (Pts) without a prior history of cardiovascular disease were 
included in a nationwide registry of ACS. Linear regression analyses were used to 
determine the inﬂuence of risk factors on age at time of admission. Further analyses were 
performed to assess whether these associations could be explained by prior medication 
with aspirin, beta-blockers, ACE inhibitors or statins.
Results: Mean age on admission was higher among women (71±12 vs 64±14 yrs; 
P<0.001) and when ACS type was STEMI (63±14 vs 66±13 yrs for NSTE-ACS; P<0.001). 
Men had the ﬁrst ACS 12.2 yrs earlier (95% CI, 11.6-12.7) if active smokers, 3.7 yrs 
earlier (3.1-4.3) if HChol, 3.0 yrs earlier (2.3-3.7) if obese, 4.3 yrs later (3.6-4.9) if DM, 
and 5.2 yrs later (4.6-5.8) if HTN. Women had the ﬁrst ACS 20.3 yrs earlier (18.9-21.8) 
if active smokers, 3.1 yrs earlier (2.3-3.9) if HChol, 2.2 yrs earlier (1.3-3.2) if obese, and 
3.5 yrs later (2.5-4.6) if HTN. The later onset of ACS in HTN Pts was partly explained by 
higher rates of use of aspirin and ACE inhibitors.
Conclusions: Age at onset of ﬁrst ACS is signiﬁcantly inﬂuenced by risk factors, 
especially smoking. HTN is associated with higher age at onset of ACS, partly due to the 
use of aspirin and ACE inhibitors.
Preditors of Age at Presentation
Men Women
Predictor betaCoefﬁcient P Predictor
beta
Coefﬁcient P
Diabetes 1.836 <0.001 Diabetes -0.531 0.201
Hypertension 3.697 <0.001 Hypertension 2.755 <0.001
Hypercholesterolemia -3.625 <0.001 Hypercholesterolemia -3.296 <0.001
Smoking -11.133 <0.001 Smoking -19.830 <0.001
Obesity -3.724 <0.001 Obesity -2.572 <0.001
9:30 a.m.
1012-79 Absolute LDL-C Lowering Is a Better Predictor of Risk 
Reduction Than Percent LDL-C Lowering in Lipid 
Intervention Trials
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas, Tufts Medical Center, Boston, MA
Background: Current lipid intervention guidelines stress the importance of lowering low-
density lipoprotein cholesterol (LDL-C) by 30-40% to reduce the risk of cardiovascular 
(CV) events in moderate to high risk patients. Whether the absolute reduction in LDL-C 
(i.e. mg/dl) is a better predictor of CV risk reduction than % LDL-C lowering is unknown. 
We examined the association of risk reduction with % and absolute LDL-C lowering in 
large randomized controlled trials (RCTs) of lipid intervention therapies.
Methods: A MEDLINE search identiﬁed lipid intervention RCTs with q 1year of follow-up. 
Inverse-variance weighted meta-regressions evaluated the association of % or absolute 
LDL-C change with relative risk reduction in each of the following outcomes: myocardial 
infarction (MI), coronary heart disease (CHD), CHD mortality, cardiovascular disease 
(CVD), CVD mortality, and all cause mortality.
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Results: A total of 32 eligible RCTs were identiﬁed (23 statin, 6 ﬁbrate, and 3 combination 
therapy, with 732,468 person-years of follow-up). There was a signiﬁcant association 
between absolute and % LDL-C lowering and risk reduction of all outcomes considered 
(FIGURE). For each outcome, absolute LDL-C lowering was a better predictor of risk 
reduction than % LDL-C lowering.
Conclusion: In lipid intervention trials, absolute reductions in LDL-C are better predictors 
of risk reduction than % reduction in LDL-C. 
9:30 a.m.
1012-80 Lack of Clinical Utility of Measurement of 
Apolipoprotein B-100 Levels Beyond a Lipid Proﬁle 
in Patients Deemed as High Risk for Atherosclerotic 
Vascular Disease
Anushka Jayasekara, Nargis Rayani, Mano Senaratne, Grey Nuns Hospital, Edmonton, 
AB, Canada
BACKGROUND: Studies have shown that Apolipoprotein B-100 (Apo B) is a better 
predictor of future coronary events than the low density lipoprotein (LDL). However, the 
extra clinical utility provided by a measured Apo B, beyond the values on a lipid proﬁle, 
to modify treatment (Rx) based on current guidelines remains unknown. METHODS: All 
patients who had Apo B levels measured in association with a lipid proﬁle in 2007-08 were 
included in the study. The need for additional lipid lowering Rx was determined based 
on the levels of LDL, triglycerides(TG), cholesterol to high density lipoprotein(HDL) ratio 
(Chol/HDL ratio),non-HDL and the Apo B level. RESULTS: There were 1795 patients 
(age=55.7±13.2 yrs; M=1057; F=738). Based on the current lipid guidelines for high risk 
pts (LDL <1.8mmol/L, TG <1.5 mmol/L, Chol/HDL ratio <4.0 mmol/L, non-HDL <2.6 
mmol/L, Apo B <0.85g/L) the observed LDL, TG, Chol/HDL ratio, non-HDL and Apo B 
levels indicated need for additional Rx in 85.7%, 49.1%, 57.5%, 81.9%, and 59.4% of the 
patients, respectively. Using the goals for any one of LDL, TG and Chol/HDL ratio and any 
one of LDL, TG and non-HDL indicated need for Rx as 93.3% and 92.7%, respectively. 
Cross tabulation analysis revealed that when the LDL, TG, Chol/HDL ratio, non-HDL, a 
combination of LDL-TG-Chol/HDL ratio, and a combination of LDL-TG-non-HDL did not 
indicate need for Rx the Apo B indicated need for Rx in 4.5%, 43.5%, 28.2%, 0.3%, 0.0%, 
and 0.0%, respectively. Conversely when the Apo B indicated no need for Rx the LDL, TG, 
Chol/HDL ratio, non-HDL, a combination of LDL-TG-Chol/HDL ratio, and a combination 
of LDL-TG-non-HDL indicated need for Rx in 32.9%, 24.0%, 17.7%, 27.7%, 36.3% and 
35.9%, respectively. CONCLUSIONS: Measurement of the Apo B level (with the currently 
set goal of 0.85g/L) does not signiﬁcantly affect modiﬁcation of treatment beyond the 
decisions that would have been made based on the values available with a lipid proﬁle. 
Thus routine measurement of Apo B may be deemed as unnecessary.
9:30 a.m.
1012-81 Signiﬁcance of Low-Density Lipoprotein Subfractions 
Assessed by Anion-Exchange High Performance 
Liquid Chromatography in Patients With Essential 
Hypertension
Satoshi Ikeda, Jungo Urata, Seiji Koga, Tomoo Nakata, Tomohiko Yasunaga, Shigeru 
Kohno, Koji Maemura, Department of Cardiovascular Medicine, Nagasaki University 
Graduate School of Biomedical Sciences, Nagasaki, Japan, Second Department of 
Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
Background: Oxidative stress plays a key role in the initiation and progression of 
atherosclerosis or related diseases, yet an accurate and useful index for detecting 
oxidative stress in vivo has not been established. The present study determines whether 
low-density lipoprotein subfractions (LDL-1, LDL-2 and LDL-3) assessed by anion-
exchange high performance liquid chromatography (AE-HPLC) can reﬂect oxidative 
stress in hypertensive patients.
Methods: Eighty-one outpatients were classiﬁed into groups with poorly-controlled 
hypertension (n = 33), well-controlled hypertension (n = 28), and controls (n = 20), 
according to recent blood pressure values and then levels of LDL subfractions were 
compared among them. The relationship between plasma 8-isoprostane, an oxidative 
stress marker, and LDL subfractions was also investigated. Furthermore, the effect of 
olmesartan, an angiotensin II receptor blocker, on the LDL subfractions before, as well as 
3 and 6 months after administration was examined.
Results: Age, gender, body mass index, levels of lipid proﬁles did not differ signiﬁcantly 
among the 3 groups. Levels of LDL-3, the most oxidized LDL subfraction, were signiﬁcantly 
higher in the poorly-, than in the well-controlled hypertension group and controls (5.0 ± 1.4 %, 
4.2 ± 1.3 % and 3.9 ± 1.0 %; mean ± standard deviation, respectively, p < 0.05), whereas the 
latter two groups did not signiﬁcantly differ. LDL-3 was associated with levels of 8-isoprostane 
(r = 0.32, p < 0.05). Three and 6 months of olmesartan administration signiﬁcantly reduced 
levels of LDL-3 (5.9 ± 1.2 % before, 5.0 ± 1.1 % at 3 month after and 4.7 ± 1.1 % at 6month 
after the administration; mean ± standard deviation, p < 0.05 vs. before).
Conclusion: LDL-3 subfractionated by AE-HPLC may serve as a clinically useful index of 
recent oxidative stress in patients with hypertension.
9:30 a.m.
1012-82 Prior Use of Statin Therapy Does Not Inﬂuence 
Progression of Coronary Atherosclerosis in Trials of 
Medical Therapies
Ajai Shreevatsa, Kathy Wolski, Ozgur Bayturan, E. Murat Tuzcu, Steven E. Nissen, 
Stephen J. Nicholls, Cleveland Clinic, Cleveland, OH
Background: The effect of preceding lipid lowering therapies on the artery wall has been 
proposed as a potential reason underlying the ﬁnding that the combination of cholesterol 
absorption inhibitors and statins does not have a beneﬁcial impact on carotid disease 
progression in patients with familial hypercholesterolemia, despite effective lowering of 
both LDL-C and CRP. This study investigated whether prior statin treatment has any 
impact on subsequent progression of coronary atherosclerosis.
Methods: Progression of percent atheroma volume (PAV) and total atheroma volume 
(TAV) was characterized in 3479 patients with angiographic coronary artery disease 
who underwent serial intravascular ultrasound in 7 clinical trials of anti-atherosclerotic 
therapies. Patients treated with (n=2630) and without (n=849) statins prior to entry in the 
study were compared.
Results: During the course of the studies, 95% of patients were treated with a statin. 
Patients who were not treated with a statin prior to entry into the studies (24%) were more 
likely to have a history of angina (61 v 51% p<0.001) and less likely to have a history of 
diabetes (27 v 33% p<0.001), hyperlipidemia (62 v 79%, p<0.001), myocardial infarction 
(25 v 32% p<0.001) and coronary revascularization (40 v 47%, p=0.007). While LDL-C 
levels were greater at baseline in patients who had not been treated with a statin (124±35 
v 97±34 mg/dL, p<0.01), levels were comparable at follow-up (83 ±32.4 v 86 ±31.5 mg/dL, 
p=0.05). Patients not previously treated with a statin had less atherosclerosis at baseline 
with a lower PAV (38.0±9.2 v 38.8±9.0%, p=0.02) and TAV (195±83 vs 190±83, p0.09). 
Following adjustment for differences in clinical characteristics, including baseline LDL-C, 
there was no difference in progression of PAV (0.49±0.27 vs 0.35±0.35%, p=0.26) or TAV 
(-2.1±1.95 vs -3.1±1.9%, p=0.23) in patients treated without or with a statin prior to study 
entry respectively.
Conclusions: Preceding use of statin therapy does not inﬂuence the progression of 
coronary atherosclerosis and does not appear to confound the assessment of the effect 
of medical therapies.
9:30 a.m.
1012-83 Lipoprotein Abnormalities Associated With Smoking 
Intensity in a Large Cohort of Active Smokers
Linda K. Gossett, Heather M. Johnson, Patrick E. McBride, Megan E. Piper, Michael C. 
Fiore, Timothy B. Baker, James H. Stein, University of Wisconsin School of Medicine and 
Public Health, Madison, WI
Background: In small studies, smoking is associated with low high-density lipoprotein 
cholesterol (HDL-C) and small low-density lipoproteins (LDL), however the effects of 
smoking intensity on lipoprotein concentrations and sizes have not been evaluated in 
a large cohort.
Methods: Fasting enzymatic lipid and nuclear magnetic resonance spectroscopy 
lipoprotein panels were obtained in a large cohort of active smokers enrolled in a 
federally-funded smoking cessation trial. Parameters related to smoking intensity 
included: current cigarettes/day; current pack-years; peak pack-years, Fagerstrom Test 
of Nicotine Dependence (FTND) score, and carbon monoxide (CO) levels. Multivariable 
linear regression models were constructed to determine predictors of lipid and lipoprotein 
fractions. All models included age, sex, race, and waist circumference.
Results: The 1,497 subjects (58.2% women, 84% white, 14% African-American) had a 
mean (standard deviation) age of 44.7 (11.0) years (range 18-79 years), a smoking rate 
of 21.4 (8.9) cigarettes/day, mean pack-years 29.4 (20.4), peak pack-years 38.3 (26.4), 
FTND 5.4 (2.1), and CO 25.8 (12.4) ppm. HDL-C [42.0 (13.5) mg/dL] and total HDL 
particles [30.3 (5.9) μmol/L] were low. After adjustment, smoking intensity as measured by 
CO levels independently predicted lower HDL-C (p=0.017) and HDL particles (p=0.002) 
with lower small HDL (p=0.004). CO levels also predicted higher total (p=0.042) and small 
(p=0.044) LDL. The FTND had similar but weaker associations with HDL-C (p=0.051), 
total HDL particles (p=0.028), and total LDL (p=0.046). Other smoking parameters were 
not independently associated with HDL and LDL measures. FTND and CO were not 
associated with serum triglycerides.
Conclusion: In this large study of active smokers, smoking intensity, as measured by 
CO level was independently associated with lower levels of HDL and small HDL particles, 
and increased total and small LDL particles. Nicotine dependence was related to total 
HDL and LDL particles.
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1012-84 Magnitude of Beneﬁt in Statin Trials Is Directly Related 
to On-Treatment Differential in Low-Density Lipoprotein 
Cholesterol
Alawi A. Alsheikh-Ali, Haseeb Jafri, Richard H. Karas, Tufts Medical Center, Boston, MA
Background: Lowering low-density lipoprotein cholesterol (LDL-C) signiﬁcantly reduces 
the risk of cardiovascular disease (CVD). We examined the association of statin beneﬁt 
with on-treatment differences in LDL-C levels between the intervention and control arms 
of large statin randomized controlled trials (RCTs).
Methods: A MEDLINE search identiﬁed statin RCTs with > 1,000 person-years of follow-
up. Using random-effects models, a meta-analysis estimated the average summary 
relative risk (RR) for CVD, and a meta-regression examined the relationship between 
RR of CVD and the absolute difference in LDL-C during follow-up (intervention - control).
Results: In 20 RCTs (594,068 person-years, and 15,417 CVD events), statin therapy 
was associated with a signiﬁcant reduction in CVD risk (RR 0.81, 95%CI 0.77-0.85). The 
extent of CVD risk reduction was linearly related to the absolute difference (intervention 
- control) in on-treatment LDL-C (P 0.004). For each 10 mg/dL decrease in LDL-C, there 
was a 5% relative reduction in RR of CVD (e.g. a 20% relative reduction in CVD risk 
requires ~ 40 mg/dL difference in LDL-C). Findings were similar when RR for myocardial 
infarction, mortality from coronary heart disease, or CVD mortality were examined.
Conclusion: The magnitude of CVD risk reduction in statin RCTs is directly related to 
the on-treatment differential in LDL-C between the intervention and control arms. These 
ﬁndings may have implications for clinical practice and design of lipid intervention RCTs
9:30 a.m.
1012-85 Fenoﬁbric Acid in Combination With Statins Improves 
Multiple Lipid Parameters in Women With Mixed 
Dyslipidemia
Anne C. Goldberg, Jennifer G. Robinson, Carl J. Pepine, Darryl J. Sleep, Carolyn 
M. Setze, Aditya Lele, Maureen T. Kelly, Washington University School of Medicine, 
Department of Internal Medicine, St. Louis, MO, Abbott, Abbott Park, IL
Background: Therapy with a ﬁbrate + statin may be a treatment option for women with 
multiple lipid abnormalities. However, robust clinical trial efﬁcacy and safety data on this 
combination is lacking in women.
Methods: Women with LDL-C q 130 mg/dL, TG q 150 mg/dL, and HDL-C < 50 mg/dL who 
were randomized in 3 studies to receive either fenoﬁbric acid (FA) 135 mg, low-dose statin 
(rosuvastatin [R] 10 mg, simvastatin [S] 20 mg, or atorvastatin [A] 20 mg), moderate-dose 
statin (R 20 mg, S 40 mg, or A 40 mg), high-dose statin (R 40 mg, S 80 mg, or A 80 mg) or 
FA + low or moderate-dose statin, and treated for 12 weeks were included in the analysis. 
The effects of FA + low or moderate-dose statin on HDL-C, TG, LDL-C, non-HDL-C, and 
apoB levels were compared to statin monotherapy.
Results: A total of 1393 women (mean age of 56.5 yrs and mean waist circumference 
of 100.1 cm) were evaluated. FA + low or moderate-dose statin resulted in signiﬁcantly 
greater increases in HDL-C and decreases in TG and ApoB than the corresponding dose 
of statin monotherapy, with similar or smaller reductions in LDL-C. In addition, FA + low or 
moderate-dose statin resulted in signiﬁcantly greater or similar reductions in non-HDL-C, 
compared to corresponding dose statin monotherapy. Combination therapy was generally 
well tolerated. 
Mean % change from baseline to ﬁnal visit in lipid parameters in women 
with mixed dyslipidemia
Fenoﬁbric 
Acid
Low-dose 
Statin
Fenoﬁbric 
Acid +
Low-dose 
Statin
P-value(a)
Moderate-
dose 
Statin
Fenoﬁbric 
Acid +
Moderate-
dose 
Statin
P-value(b)
HDL-C
Baseline 
mean, mg/dL
Mean % 
change (SE)
N=233
41.1
18.3% 
(1.28)
N=215
41.6
8.1% 
(1.33)
N=226
41.2
19.9% 
(1.29)
<0.001
N=209
41.8
7.9% 
(1.35)
N=214
41.4
21.1% 
(1.33)
<0.001
TG
Baseline 
mean, mg/dL
Mean % 
change (SE)
N=256
269.2
-35.7% 
(1.74)
N=226
275.5
-20.2% 
(1.82)
N=252
281.6
-45.6% 
(1.74)
<0.001
N=234
279.2
-26.0% 
(1.81)
N=233
282.2
-44.2% 
(1.81)
<0.001
LDL-C
Baseline 
mean, mg/dL
Mean % 
change (SE)
N=234
161.3
-11.1% 
(1.20)
N=219
159.9
-35.8% 
(1.23)
N=229
161.0
-37.2% 
(1.20)
0.408
N=216
163.3
-42.5% 
(1.25)
N=218
161.4
-39.0% 
(1.24)
0.037
Non-HDL-C
Baseline 
mean, mg/dL
Mean % 
change (SE)
N=233
226.8
-22.1% 
(1.04)
N=215
221.4
-37.3% 
(1.07)
N=226
225.9
-43.7% 
(1.04)
<0.001
N=210
224.6
-43.6% 
(1.09)
N=212
223.0
-45.9% 
(1.08)
0.127
ApoB
Baseline 
mean, mg/dL
Mean % 
change (SE)
N=254
148.2
-21.3% 
(1.03)
N=223
147.2
-32.7% 
(1.08)
N=249
149.5
-39.4% 
(1.03)
<0.001
N=232
149.1
-37.3% 
(1.07)
N=231
148.7
-40.5% 
(1.07)
0.026
(a) Fenoﬁbric acid + low-dose statin vs. low-dose statin monotherapy
(b) Fenoﬁbric acid + moderate-dose statin vs. moderate-dose statin monotherapy
Conclusion: This large, pooled analysis of women with mixed dyslipidemia demonstrated 
that FA + statin combination therapy resulted in greater improvements in HDL-C, TG, and 
ApoB than the corresponding dose of statin monotherapy.
9:30 a.m.
1012-86 Anti-inﬂammatory Effects of Puriﬁed Eicosapentaenoic 
Acid (EPA) in Patients With High C-Reactive Protein 
(CRP) Levels Refractory to Statin Therapy for 
Secondary Prevention
Yoshiki Matsuo, Manabu Kashiwagi, Toshikazu Hashizume, Yasushi Ino, Keisuke 
Satogami, Kenji Nakamura, Yasushi Okumoto, Hideharu Akagi, Tadao Yamamoto, 
Takashi Akasaka, Social Insurance Kinan Hospital, Tanabe, Japan
Background: The dual goals of low density lipoprotein cholesterol (LDL-C) and C-reactive 
protein (CRP) reduction are important for secondary prevention of cardiovascular disease. 
The number of patients who achieve lower concentration of CRP may be suboptimal, 
despite the established efﬁcacy of statins as lowering LDL-C level. Although we reported 
the metabolic syndrome (MetS) is associated with subclinical inﬂammation in patients 
achieving optimal LDL-C (Matsuo Y, et al. Circ J. 2008), therapeutic approaches for CRP 
reduction were not determined. The purpose of this study was to test the anti-inﬂammatory 
effects of puriﬁed eicosapentaenoic acid (EPA) in CAD patients who attained optimal 
LDL-C levels and had low-grade inﬂammation after statin therapy.
Methods: The study population comprised 60 male patients with MetS who had a prior 
history of CAD with optimal LDL-C (95.2 ± 6.5 mg/dL) and high CRP (2.9 ± 0.9 mg/L) 
under statin therapy. Patients were randomized to EPA (900mg/day) therapy or control. 
Lipid proﬁles and vascular inﬂammatory markers, including CRP, ﬁbrinogen, and serum 
amyloid A protein (SAA) were assessed.
Results: After 16-week treatment, plasma concentrations of EPA were signiﬁcantly 
increased in EPA-treated group (p<0.01). In EPA-treated group, total cholesterol, LDL-C, 
and high density lipoprotein cholesterol (HDL-C) were deceased (12%, 14%, and 11%, 
respectively (p<0.05)), although LDL-C/HDL-C ratio was not changed. The levels of CRP 
and ﬁbrinogen were signiﬁcantly reduced (37% and 15 %, p<0.05) and the reduction of 
SAA level was marginally signiﬁcant in patients receiving EPA when compared with those 
in control group.
Conclusions: Additive EPA therapy provides a complementary efﬁcacy that improves 
vascular inﬂammatory markers in CAD patients with subclinical inﬂammation refractory 
to statin therapy.
9:30 a.m.
1012-87 Statin Use Is Associated With Reduced Thirty Day 
Mortality Among Patients Hospitalized for Sepsis 
Irrespective of Atherosclerotic Disease Status
Ahmed Ijaz Shah, Somjot S. Brar, Saman Fakheri, Jiaxiao M. Shi, Serap Sobnosky, 
Albert Yuh-Jer Shen, Michael B. Jorgensen, Kaiser-Permanente Los Angeles Medical 
Ctr, Los Angeles, CA, Kaiser-Permanente, Pasadena, CA
Background: To determine if the non-lipid lowering (pleiotropic) effects of current statin 
therapy are associated with a decreased 30-day mortality among patients hospitalized
with sepsis compared to recent or no statin use whether atherosclerosis is present or 
not.
Methods: We retrospectively identiﬁed a cohort of 23,587 patients aged 50 or older 
hospitalized with sepsis between 1/1/99 and 12/31/04. The cohort was divided into 3 
groups based on statin use: current users [CU] (on statin therapy for at least 2 months 
including on the day of hospitalization), recent users [RU] (evidence of statin use in the 12 
months prior to hospitalization but none at the time of hospitalization) and nonusers [NU] 
(no statin use in the 12 months prior to hospitalization). Sepsis and atherosclerosis was 
identiﬁed by primary discharge diagnosis ICD-9 codes. Random chart review showed the 
PPVs for the sepsis codes and statin use were 87% and 90%, respectively. Each patient 
was followed for 30 days after the index admission or until death. We analyzed the 30-day 
mortality rates adjusting for baseline characteristics and major comorbidities, including 
the Charlson index.
Results: The mean age of the cohort was 72 ± 10 years and 48% were female; 70% were 
NU, 11% RU and 19% CU. Statin users (RU and CU) had more comorbidities and higher 
Charlson’s scores. In our cohort 32% of patients died within 30 days of hospitalization. 
Atherosclerosis was present in 33% of NU, 65% of RU and 66% of CU. Adjusted hazard 
ratios for all cause 30-day mortality of CU and RU compared to NU were:
CU vs. NU 0.732 (0.684,0.782) p<.0001
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CU vs. RU 0.865 (0.790,0.947) p<.0016
CU (Low dose) vs. NU 0.741 (0.679,0.809) p<.0001
CU (High dose) vs. NU 0.722 (0.662,0.789) p<.0001
CU (High dose) vs. CU (Low dose) 0.975 (0.870,1.092) p=0.66
There was no signiﬁcant association between atherosclerosis and death when adjusted 
for statin use HR= 0.953 (0.902,1.008,) p=0.09.
Conclusions: In this retrospective observation, for patients hospitalized with sepsis, 
current statin use is associated with a statistically signiﬁcant lower rate of 30-day 
mortality compared to nonusers and recent users. Prospective controlled studies appear 
warranted.
9:30 a.m.
1012-88 Intravascular Ultrasound Analysis of Coronary 
Atheroma in Patients With and Without Chronic Kidney 
Disease Following Statin Therapy: Insights From 
JAPAN-ACS Study
Nobuaki Kokubu, Mitusru Abe, Yoritaka Otsuka, Yoichiro Kasahara, Yu Kataoka, Hiroshi 
Nonogi, Katsumi Miyauchi, Takeshi Kimura, Takeshi Morimoto, Yoshihisa Nakagawa, 
Masakazu Yamagishi, Yukio Ozaki, Takafumi Hiro, Tetsu Yamaguchi, Satoshi Saito, 
Kazuo Kimura, Hiroyuki Daida, Masanori Matsuzaki, National Cardiovascular Center, 
Suita, Japan
Background: Patients with chronic kidney disease (CKD) have a dramatically increased 
risk for cardiovascular disease and statin therapy reduces the incidence of cardiovascular 
events and mortality. Although prior intravascular ultrasound (IVUS) analysis demonstrated 
regression of coronary atheroma with statin therapy, few IVUS studies revealed the 
coronary atheromatous change in patients with and without CKD following statin therapy. 
Methods: JAPAN-ACS (the Japan Assessment of Pitavastatin and Atorvastatin in Acute 
Coronary Syndrome) study was designated to determine the effects of statin treatment 
on the regression of coronary atherosclerosis in ACS patients. All patients were randomly 
allocated to pitavastatin, 4mg/day or atorvastatin, 20mg/day. IVUS imaging was used to 
assess coronary atheroma at baseline and after 1 year of treatment. In this study, CKD 
was deﬁned as eGFR (estimated glomerular ﬁltration rate) < 60ml/min and patients were 
divided to 2 groups; 54 patients with CKD and 198 without CKD (mean eGFR: 51±7 ml/
min vs. 83±19 ml/min, respectively).
Results: The patients with CKD were older, more frequently presented with peripheral 
artery disease and non-smoker at baseline. The mean LDL cholesterol level in CKD 
patients was comparable to that in non-CKD patients at both baseline (126±34mg/dl vs. 
134±32mg/dl: p=0.08) and follow up (77±25mg/dl vs. 84±26mg/dl: p=0.09). Mean percent 
plaque volume in CKD patients was signiﬁcantly larger than that in non-CKD patients 
at both baseline (55±9% vs. 49±10%: p<0.001 ) and follow-up (48±11% vs. 43±11%: 
p=0.003). Although there was no signiﬁcant difference in the decrease in percent plaque 
volume (-6±6% vs -7±7%: p=0.10), the increase in mean lumen volume in CKD patients 
was signiﬁcantly greater than that in non-CKD patients (5.2±11mm3 vs. 0.8±10mm3:
p=0.008) and the decrease in mean vessel volume in CKD patients tended to be smaller 
than that in non-CKD patients (-4.5±15mm3 vs. -8.5±15mm3: p=0.08).
Conclusion: Statin therapy equally regressed the atheromatous plaque, but the 
regression of coronary atheroma tended to be observed in inner area of vessel walls in 
patients with CKD and in outer area of those in patients without CKD.
9:30 a.m.
1012-89 Statin Treatment Is Insufﬁcient in Diabetes Patients 
Receiving Glucose-Lowering Treatment: A Nationwide 
Study
Helena Dominguez, Tina K. Schramm, Gunnar Gislason, Steen Abildstrom, Lars Kober, 
Thomas J. Guterbaum, Casper Jorgensen, Mette L. Norgaard, Christian Torp-Pedersen, 
Cardiology dpt. and Lab. P, Research Unit, Gentofte University Hospital, Hellerup, 
Denmark
Background: Current guidelines recommend statin treatment in most patients with 
diabetes. We investigated secular changes in statin treatment during an 8-year period in 
a nationwide cohort of patients receiving glucose-lowering medication (GLM).
Methods: All Danish citizens older than 30 who claimed prescriptions on GLM between 
1996 and 2004 were included (174.537) and followed until 2006. Statin treatment was 
registered if a prescription was claimed during the period. By logistic regression we 
identiﬁed factors (age, sex, year of GLM initiation, previous myocardial infarction and 
income) related to initiation of statin treatment.
Results: Less than 5% of the patients on GLM in 1997 received statins, increasing to 
32.7% in 2004 (Fig). In spite of increased initiation, below 60% were using statins at the 
end of follow up. The chance to ever receive statins was lowest if not initiated within 180-
days following the ﬁrst purchase of GLM (odds ratio(OR) 0.75, 95% CI 0.74-0.76. Previous 
myocardial infarction was associated with increased statin treatment (OR 6.87; 95% CI 6.47 
-7.29), while low income jeopardized the use of statins (OR 0.67; 95%CI 0.63-0.71).
Conclusions: Statin treatment in patients with diabetes has increased with time but 
there still remains undertreatment and further improvement is warranted. Focus on early 
initiation of statin treatment in diabetic patients will give long-term beneﬁts.
9:30 a.m.
1012-90 Statin-Mediated Reduction in Risk of Stroke Is 
Independent of the Extent of Low-Density Lipoprotein 
Cholesterol Lowering
Alawi A. Alsheikh-Ali, Haseeb Jafri, Carey Kimmelstiel, Richard H. Karas, Tufts Medical 
Center, Boston, MA
Background: Randomized controlled trials (RCTs) show that statins prevent strokes. 
Whether such prevention is related to the extent of low-density lipoprotein cholesterol 
(LDL-C) lowering remains controversial. We examined the relationship between changes 
in lipid values and statin-mediated reduction in stroke risk in large RCTs.
Methods: A MEDLINE search identiﬁed statin RCTs with q 1,000 person-years of follow-
up, providing rates of incident stroke. Using random-effects models, a meta-analysis 
estimated the effect of statins on risk of stroke, and meta-regressions evaluated the 
relationship between changes in lipid parameters and statin-associated reduction in 
stroke risk.
Results: A total of 17 RCTs were identiﬁed (479,712 person-years of follow-up, and 3,961 
strokes). Statin use was associated with a signiﬁcant reduction in the risk of stroke (RR 
0.84, 95% CI 0.78-0.89). Statin-mediated reduction in risk of stroke was not associated 
with % change in LDL-C (P = 0.43, Figure). Similar ﬁndings were obtained when absolute 
change in LDL-C was examined, or when changes in total cholesterol, high-density 
lipoprotein cholesterol, or triglycerides were considered. Findings were similar when 
secondary and primary prevention RCTs were analyzed separately.
Conclusion: Statin-induced lipid changes are not related to statin-associated reduction 
in the risk of stroke. Non-lipid altering effects of statins may be responsible for their 
protective effects against stroke. 
9:30 a.m.
1012-91 A new Method for Determining Functional LDL-C 
Receptor Activity in Hypercholesterolemic Patients: 
Application of CD3/CD28 Assay in Lymphocytes
Hayato Tada, Masa-aki Kawashiri, Tohru Noguchi, Mika Mori, Masayuki Tsuchida, 
Mutsuko Takata, Atsushi Nohara, Akihiro Inazu, Junji Kobayashi, Akihiro Yachie, Hiroshi 
Mabuchi, Masakazu Yamagishi, Kanazawa University, Kanazawa, Japan
Background: The objective of this study was to develop a new and simple method for 
measuring low-density lipoprotein receptor (LDLR) activity using peripheral lymphocytes 
enabling us to clinically diagnose familial hypercholesterolemia (FH) and ascertain the 
involved mutations (such as K790X mutation), that might not be clearly detected in the 
conventional method.
Methods: Our method comprised the following 2 features: First, we used anti-CD3/
CD28 beads to stimulate T-lymphocytes to obtain a uniform fraction of lymphocytes and 
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maximum up-regulation of LDLR. Second, we excluded the possibility of overestimation 
of lymphocyte signals bound only to its surface, by adding heparin to the cultured 
lymphocytes used for the LDLR assay.
Results: Based on the genetic mutation, the FH subjects were divided into two groups, 
K790X, (n = 20) and P664L, (n = 5), and their LDLR activities was measured by this 
method, which was found to be 55.3 ± 8.9% and 63.9 ± 13.8%, respectively, of that of 
the control group (n = 15). In comparison, the LDLR activity was 86.1 ± 11.6% (K790X) 
and 73.3 ± 6.3% (P664L) of that of the control group when measured by the conventional 
method, indicating that impairment of LDLR function in FH K790X subjects was much 
more clearly differenciated with our method than with the conventional method (paired 
t-test, p < 0.0001). The levels of LDLR expression also showed similar tendencies, that 
is, 89.4 ± 13.2% (K790X) and 76.9 ± 17.4% (P664L) of that of the control group when 
measured by the conventional method, and 78.1 ± 9.7% (K790X) and 70.3 ± 26.5% 
(P664L) when measured by our new method. In addition, we conﬁrmed that there was 
little inﬂuence of statin treatment on LDLR activity among the study subjects when our 
method was used.
Conclusion: These results demonstrate that our new method is applicable for measuring 
LDLR activity, even in subjects with an internally defective allele, and that T-lymphocytes 
of the FH K790X mutation possess characteristics of that allele.
ACC.POSTER CONTRIBUTIONS
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3:30 p.m.
1021-67 Treatment of Patients With Low Response to Aspirin 
With Omega-3 Fatty Acids Versus High-Dose Aspirin
Eli I. Lev, Alejandro Solodky, Aviv Mager, Abid Assali, David Brosh, Alexander Battler, 
Neal S. Kleiman, Ran Kornowski, Rabin Medical Center, Petah-Tikva, Israel, The 
Methodist Hospital, Houston, TX
Background: Low response to aspirin (ASA) has been associated with increased risk of 
adverse cardiovascular events. However, there is no established approach to overcome 
low response to ASA. Omega-3 fatty acids reduce platelet membrane arachidonic acid 
(AA) and indirectly thromboxane A2 formation. We, therefore, evaluated the anti-platelet 
efﬁcacy of omega-3 supplementation vs increasing ASA dose in low responders.
Methods: Pts (n=485) with stable coronary artery disease, taking ASA (75-162 mg) for 
q1 week were screened for ASA response with the VerifyNow assay (Accumetrics®). Pts 
with a score >500 ARU underwent further testing by platelet aggregation. Low response 
to ASA was deﬁned by q2 of 3 criteria: ARUq550, 0.5 mg/ml AA-induced aggregation 
q20% and 10 μM ADP-induced aggregation q70%. Thirty pts (6.2%) had low response 
to ASA, and were randomized to receive 325 mg ASA daily or low-dose ASA + omega-3 
fatty acids (4 capsules a day, each containing 360 mg EPA + 240 mg DHA, Solgar®). After 
1 month treatment pts were re-tested.
Results: Both groups (n=15 each) had similar characteristics (overall 33.3% women, 
age 66.2±9 years, 36.7% diabetes). After 1 month both groups had signiﬁcant reduction 
in platelet reactivity (Table). Twelve (80%) pts receiving omega-3 and 11 (73.3%) pts 
receiving ASA 325 mg became ASA responsive.
Conclusions: Treatment of pts with low response to ASA by adding omega-3 fatty acids 
or increasing the ASA dose appears to improve response to ASA and effectively reduces 
platelet reactivity.
Platelet reactivity at baseline and following one month of treatment
Omega-3
Group
Baseline
Omega-3
Group Post P value
Aspirin 325 
Group Baseline
Aspirin 325 
Group Post P value
VeifyNow 
Aspirin (ARU) 565.7±35 460.9±47 <0.0001 553.8±19 475.9±57 0.0003
Aggregation 
0.5 mg/ml AA 
(%)
19.1±7 13.4±5 0.003 18.9±7 12.9±6 0.01
Aggregation 5 
μM ADP (%) 68.1±10 54.7±11 0.0004 66.3±6 56.7±6 0.0002
Aggregation 10 
μM ADP (%) 77.1±7 65.6±11 0.002 74.7±6 69.5±6 0.006
3:30 p.m.
1021-68 Intensive and Moderate Lipid Lowering Therapy to 
Prevent Progression of Coronary Atherosclerosis in 
Patients With Acute Coronary Syndrome in Japan: A 
Serial Intravascular Ultrasound Study
Naohiro Komura, Kiyoshi Hibi, Fumiyuki Otsuka, Takayuki Mitsuhashi, Noriaki Iwahashi, 
Jun Okuda, Kenngo Tsukahara, Masami Kosuge, Toshiaki Ebina, Satoshi Umemura, Kazuo 
Kimura, Yokohama City University Medical Center, Cardiovascular Center, Yokohama, Japan
Background: Several trials have reported that lipid lowering therapy can halt the 
progression or even induce the regression of coronary atherosclerosis in patients with 
stable coronary artery disease. Although decreased cardiac event rates were observed 
in patients with acute coronary syndrome (ACS) treated with intensive statin therapy 
compared with moderate statin therapy, direct evidence comparing the impact of these 
regimens on plaque behavior in patients with ACS is lacking.
Methods: This is a single center, prospective randomized study to compare intensive 
(atorvastatin or pitavastatin) and moderate (pravastatin or ﬂuvastatin) statin therapies on 
the progression of coronary atherosclerosis in Japanese patients with ACS. Study protocol 
included initial intravascular ultrasound (IVUS) examination following percutaneous 
coronary intervention (PCI) and at 10 month follow up. The primary endpoint was the 
percent change in coronary plaque volume in the target plaque. The target plaque had to 
be a minor lesion (<50% diameter stenosis) and at least 5 mm apart from any PCI site. 
IVUS images were evaluated at an interval of 1 mm for 10 mm length in each plaque.
Results: A total of 50 patients with ACS were randomized to intensive and moderate 
statin therapies. 48 patients (25 intensive) had evaluable IVUS examinations at baseline 
and after 10 months of treatment. As expected, mean LDL cholesterol was reduced by 
47% (from 133 to 71mg/dl) in the intensive group and 33% (from 155 to 104mg/dl) in the 
moderate group (both P <0.01). Analysis of percent change in coronary plaque volume 
revealed a regression of coronary atherosclerosis in the intensive group (9.5% decrease 
from baseline, P <0.01), whereas slight progression occurred in the moderate group 
(5.5% increase from baseline, P =0.09) (P <0.01, compared between the groups).
Conclusions: This is the ﬁrst serial volumetric IVUS study comparing intensive and 
moderate statin therapies in Japanese patients with ACS. Intensive statin therapy 
induced regression of coronary atherosclerosis, whereas moderate statin therapy allowed 
insigniﬁcant progression. This study emphasizes the need for intensive statin therapy for 
secondary prevention in Japan.
3:30 p.m.
1021-69 Diabetes Mellitus Is a Pivotal Determinant of Coronary 
Plaque Regression During Statin Therapy in Patients 
With Acute Coronary Syndrome: Serial Intravascular 
Ultrasound Observations From the JAPAN-ACS Trial
Takafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa 
Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu 
Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki, Department of Medicine and Clinical 
Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
Background and Purpose:
The multicenter JAPAN-ACS trial has revealed that early aggressive statin therapy for 
patients with acute coronary syndrome (ACS) signiﬁcantly reduces non-culprit coronary 
plaque volume. This substudy of the JAPAN-ACS trial was to clarify major determinants of 
the plaque regression during statin therapy.
Methods: Serial observations with intravascular ultrasound (IVUS) over 8-12 months were 
performed in 33 centers in Japan for 252 patients with ACS receiving atorvastatin (20mg 
daily) or pitavastatin (4mg ) immediately after successful PCI. The percentage change 
in non-culprit plaque volume (%$PV) was measured as an index of plaque progression 
or regression (follow-up minus baseline). To specify major determinants of the degree 
of the index, a multivariate analysis with a backward selection was performed regarding 
baseline parameters, including clinical patient characteristics, serum lipid proﬁle, types 
of concomitant drugs, IVUS parameters and associated complications such as diabetes 
mellitus (DM) and hypertension.
Results: Low-density lipoprotein cholesterol (LDL-C) level at baseline (132.3±32.3 mg/dl) 
was signiﬁcantly reduced to 82.6±25.5 mg/dl at the follow-up. Accordingly, %$PV showed 
a signiﬁcant regression of -17.5±14.0%. The multivariate analysis revealed that presence of 
diabetes mellitus, plaque volume at the baseline, and remnant-like particle-cholesterol (RLP-C) 
at the baseline signiﬁcantly affected plaque regression. Diabetes mellitus had an estimate of 
7.3 (95%CI: 3.6-10.9, a positive estimate value corresponded to less likelihood of regression.), 
baseline plaque volume, 0.07 (0.02-0.12), and RLP-C at the baseline, -0.70 ( -1.40 - -0.05). 
There was no signiﬁcant correlation between %$PV and follow-up LDL-C level in patients 
without DM (n= 178), whereas signiﬁcant in patients with DM (n= 73, p<0.05, r=0.4).
Conclusions: The presence of DM was one of the major inhibiting determinants of plaque 
regression during statin therapy in patients with ACS. Moreover, vigorous reduction of 
LDL-C might induce greater regression of plaque volume in patients with ACS and DM.
3:30 p.m.
1021-70 Effects of a Selective Inhibitor of Secretory 
Phospholipase A2 on Atherogenic Lipoproteins in 
Stable Coronary Heart Disease Patients With and 
Without Diabetes
Robert S. Rosenson, Richard M. Bittman, Colin Hislop, University of Michigan Hospital 
and Health System, Ann Arbor, MI, Anthera Pharmaceuticals, Inc., San Mateo, CA
Background: Secretory phospholipase A2 (sPLA2) represents a family of enzymes 
involved in lipoprotein remodeling, LDL oxidation and activation of inﬂammatory pathways. 
This trial investigated the effects of varespladib methyl, a novel reversible inhibitor of 
sPLA2, in CHD patients with diabetes and with normoglycemia who were enrolled in two-
dose ranging trials.
Methods: Phospholipase Levels And Serological Markers Atherosclerosis (PLASMA) 
I and II are Phase II, randomized, double-blind, placebo-controlled parallel-arm, dose-
ranging studies of varespladib (Anthera Pharmaceuticals, San Mateo, CA). This analysis 
included 67 subjects with diabetes and 101 with normoglycemia treated daily for 8 weeks 
with placebo or varespladib 500 mg, the dosage chosen for a clinical outcomes trial.
Results: Varespladib 500 mg decreased sPLA2 mass by 87.1% from baseline, adjusted 
for placebo (p<0.0001). Varespladib decreased LDL-C by 15.1% (p=0.0009), non HDL-C 
by 13.1% (p<0.0001), VLDL-C by 11.3% (p=0.013), VLDL particles by 22.4% (p=0.0041), 
LDL particles by 6.6% (p=0.083), and oxidized LDL by 7.1% (p=0.026). Changes were 
similar in diabetes and normoglycemic subgroups. 
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Diabetes
N=33 (placebo)
N=34 (500 mg)
Normoglycemia
N=55 (placebo)
N=46 (500 mg)
Baseline Week 8 Baseline Week 8
sPLA2
(ng/mL)
Placebo 2.75 (2.10, 4.20) a
2.45 (2.00, 
3.40)
2.00 (1.35, 
2.70)
2.00 (1.20, 
3.00)
500 mg 2.10 (1.50, 3.00)
0.50 (0.10, 
1.00)
2.20 (1.60, 
3.00)
0.30 (0.05, 
0.60)
Percent 
change -87.1 * b
LDL-C
(mg/dL)
Placebo 77.5 (63.5, 108.0)
70.0 (54.5, 
112.5)
73.5 (63.0, 
89.5)
78.5 (62.5, 
98.0)
500 mg 71.0 (44.5, 98.5)
63.5 (36.0, 
86.5)
79.0 (63.0, 
108.0)
72.0 (57.0, 
97.0)
Percent 
change -15.1#
Non HDL-C 
(mg/dL)
Placebo 118.0 (93.0, 156.0)
110.0 (87.0, 
154.0)
100.0 (82.0, 
117.0)
105.0 (84.0, 
121.0)
500 mg 104.0 (71.0, 126.0)
92.0 (60.0, 
125.0)
108.0 (90.5, 
143.5)
98.0 (84.0, 
132.0)
Percent 
change -13.1*
a Median (25th percentile, 75th percentile)
b Placebo-adjusted percent change from baseline (95% conﬁdence interval) based on 
analysis of covariance with all patients
*p<0.0001, # p<0.001
Conclusion: Varespladib 500 mg daily decreases sPLA2 enzyme mass and atherogenic 
lipoproteins in subjects with diabetes, and these changes were similar to those observed 
in normoglycemia subjects. Varespladib may be a potential anti-atherosclerotic agent in 
diabetes and non diabetes patients.
3:30 p.m.
1021-71 Efﬁcacy and Tolerability of a Short Chain 
Polysaccharide (HEP-40) in the Management of 
Hyperlipidemia
John S. Sampalis, Anthony Pellegrino, Nadia Longo, McGill University, Montreal, QC, 
Canada, JSS Medical Research Inc., Westmount, QC, Canada
Background: To assess the efﬁcacy of an enzymatically modiﬁed polysaccharide (HEP-
40) 800 mg TID co-administered with a statin as compared to statin monotherapy in 
patients with moderate to high hypercholesterolemia.
Methods: This was a 12 week, randomized, multi-center, placebo-controlled study. 
Patients were randomized 1:1 to receive HEP-40 or placebo co-administered with a statin. 
Eligible patients were male or female adults at LDL-C levels above target. Statin treatment 
remained unchanged for the duration of the study. Follow-up assessments took place at 
4, 8 and 12 weeks.
Results: Of the 68 patients enrolled into the study, 52 were randomized to receive HEP-
40 (N=25) or placebo (N=27) for a duration of 12 weeks. Of the 52 patients analyzed, 3 
(5.8%) patients were lost to follow-up and an additional 3 (5.8%) discontinued due to a 
non-serious adverse event. Mean (SD) age was 57.1 (11.2) and 73.5% were male. The 
following table describes lipid proﬁle parameters from baseline to week 12. Repeated 
measures analysis of variance showed a signiﬁcant treatment effect over time for LDL-C 
(P=0.029). There were 3 (4.4%) patients who reported 5 non-serious adverse events 
related to treatment (HEP-40: 2; Placebo: 3). There were no serious adverse events 
reported
Conclusions: For patients not at target LDL-C with statin monotherapy the co-
administration of HEP-40 is safe, well-tolerated and signiﬁcantly more effective in reducing 
LDL-C levels when compared to statin monotherapy.
Mean Percent Change in Lipid Parameters for all Visits by Group
Lipids Lipid Proﬁle Week 4 Week 8 Week 12
LDL-C HEP-40 Placebo HEP-40 Placebo HEP-40 Placebo
LDL-C % Change (SD)
-16.6
(18.1)
.23
(39.2)
-16.6
(21.2)
14.2
(40.1)
-14.9
(21.1)
10.7
(39.3)
P-value 0.056 0.002 0.008
Total 
Cholesterol
% Change 
(SD)
-19.1
(36.5)
4.33
(47.7)
-15.9
(39.1)
17.9
(48.3)
-15.5
(40.7)
6.1
(45.5)
P-value 0.055 0.013 0.094
HDL-C % Change (SD) 3.7 (10.5)
4.6
(18.9) 3.9 (12.3)
.03
(10.6) 6.7 (16.5) -.12 (8.5)
P-value 0.830 0.258 0.081
Triglycerides % Change (SD)
-11.3
(24.1)
11.5
(42.5)
-1.16
(42.7)
28.0
(91.9)
-8.6
(33.9)
24.9
(47.0)
P-value 0.023 0.180 0.008
3:30 p.m.
1021-72 Propranolol and the Risk of Severe Myopathy Among 
the Elderly
Soko Setoguchi, John M. Higgins, Vamsi K. Mootha, Helen Mogun, Jerry Avorn, Brigham 
and Women’s Hospital, Boston, MA, Massachusetts General Hospital, Boston, MA
Background: A recent integrated analysis of high-throughput chemical biology and 
gene expression studies raised the hypothesis that propranolol may increase the risk 
of myopathy induced by mitochondrial toxcity. We tested that hypothesis using two large 
population-based databases in the elderly.
Methods: A cohort study was conducted using data from Medicare and drug beneﬁt 
programs in two states (1994-2005). To avoid biases induced by including prevalent 
users, we identiﬁed new users of propranolol and other beta-blockers (BBs) aged 
q 65. The primary endpoint was severe myopathy or rhabdomyolysis, deﬁned as a 
hospitalization with primary/secondary diagnosis of myopathy or rhabdomyolysis. We 
controlled for demographic variables, risk factors for myopathy, other comorbidities, and 
health service use measures, and used stratiﬁed Cox proportional hazards regression 
to estimate the effect of propranolol compared to other BBs. We also assessed whether 
co-use of propranolol and statin further increase the risk by including interaction terms for 
concurrent use of propranolol and statins.
Results: We identiﬁed 8,801 initiators of propranolol and 116,353 initiators of other 
BBs. There were 29 cases of hospitalized myopathy in 14,685 person-years (PYs) of 
propranolol use and 461 in 312,020 PYs of other BB use. Comparing propranolol with 
other BB use, the adjusted hazard ratio (HR) was 1.53 (95% CI 1.04 - 2.23) for myoapthy 
and 1.59 (95% CI; 0.85-2.95) for rhabdomyolysis. When we restricted the analyses to the 
outcome window after October 2003 (when a speciﬁc ICD-9 code was ﬁrst used), the 
adjusted HR was 2.56 (95% CI;1.17-5.61). There were 16% of patients who used statins 
at the same as propranolol, but we did not ﬁnd any interaction between these drugs. As 
sensitivity analyses we repeated the same analyses by comparing new propranolol users 
to new users of angiotensin blockers, calcium channel blocker or thiazide diuretics; this 
provided similar results.
Conclusions: These data suggest that propranolol may be associated with an increased 
risk of severe myopathy in the elderly. Our study provides a direct link between large-scale 
integrated molecular analysis and population-level analysis.
3:30 p.m.
1021-73 In-Hospital Initiation of Statins Therapy Improves the 
Clinical Outcomes in Patients With Acute Ischemic Stroke
Po-Sheng Chen, Yi-Heng Li, Kai-Wen Cheng, Yea-Huei Kao Yang, National Cheng Kung 
University College of Medicine and Hospital, Tainan City, Taiwan,ROC
Objectives: Recent evidences suggest that statins use is beneﬁcial in secondary 
prevention for acute ischemic stroke. But the timing to initiate statins therapy is not well 
investigated. We assessed the effect of in-hospital initiation of statins therapy in patients 
with acute ischemic stroke. Methods and Results: We screened the databank of the Bureau 
of National Health Insurance in Taiwan from January 2000 to December 2002. Patients 
(n=18,834, mean age 69 years, male 57%) due to their ﬁrst diagnosis of acute ischemic 
stroke and without prior statins therapy were included in this study. The study end point 
was the composite outcome of recurrent ischemic stroke, hemorrhagic stroke, transient 
ischemic accident and myocardial infarction. All eligible patients were followed up for one 
year and Cox proportional hazards models were used to evaluate the effect of the statins 
therapy at discharge on clinical outcomes. There were 2000 (11%) patients receiving 
statins at discharge and the other 16,834 patients didn’t receive statins at discharge. 
At one year, 5,723 patients had q 1 component of composite outcome, including 490 
patients (25%) in group with statins therapy at discharge and 4,783 patients (28%) in 
group without statins therapy at discharge. In multivariate Cox regression model, gender, 
previous diagnosis of hypertension, hyperlipidemia, atrial ﬁbrillation, and coronary artery 
disease, Charlson index and statins therapy at discharge were the independent factors 
of composite outcome after adjustment for other clinical factors. Statins use at discharge 
had signiﬁcant effect on the composite outcome at one year after discharge (odds ratio: 
0.52; 95% conﬁdence interval: 0.47 to 0.58). Conclusions: Our study demonstrated that 
statins prescription rate is low in patients with acute ischemic stroke and in-hospital 
initiation of statins therapy is beneﬁcial in patients with acute ischemic stroke. 
3:30 p.m.
1021-74 RVX-208 a Small Molecule That Induces Apolipoprotein 
A-I Production Progresses to Phase Ib/IIa Clinical Trials
Allan Gordon, Ravi Jahagirdar, Jan Johansson, Gregory Wagner, Dana Bailey, Henrik 
Hansen, Kevin McLure, Larbi Krimbou, Jacques Genest, Jr., Norman C.W. Wong,
Resverlogix Corporation, Calgary, AB, Canada, McGill University, Montreal, QC, Canada
Background: Recent advances in apoA-I and HDL biology show that in addition to higher 
levels, functionality is equally vital to enhance reverse cholesterol transport. Thus a novel 
small molecule, RVX-208 known to induce apoA-I production in rodents was tested in 
African Green monkeys (AGM) followed by a human phase I trial.
Methods: AGMs were given RVX-208 (15-60 mg/kg/days [d]) orally for 70 d. In a phase I 
trial, 80 healthy volunteers took 1-20 mg/kg/d as a single or multiple oral dose(s) for 7 d. 
Ex-vivo serum cholesterol efﬂux activity and 2-D PAGGE gel HDL proﬁles from controls, 
treated AGMs or humans were assayed.
Results: In AGMs we observed a dose and time dependent increase in serum apoA-I 
and HDL cholesterol (HDL-c). At 60 mg/kg/d on day 4, apoA-I and HDL-c rose to 13% 
and 32%, respectively with peak values of 42% and 72% after 28 d that were sustained 
to 70 d. Upon stopping RVX-208, apoA-I and HDL-c returned gradually to starting levels. 
Cholesterol efﬂux activities mediated by SR-B1, ABC-A1, and ABC-G1 were ~2-fold 
higher in treated AGMs vs controls. Phase I human data showed oral RVX-208 was safe, 
well tolerated and had proportional plasma exposure. In 18 subjects given RVX-208 vs 6 
controls we saw increased apoA-I, preB-HDL and ABC-A1 mediated cholesterol efﬂux of 
11, 42 and 11%, respectively that were signiﬁcant but a10% rise in HDL-c was not.
Conclusions: RVX-208 given orally to human for 7 d increases apoA-I (11%) and preB-
HDL (42%), these ﬁndings parallel those in AGMs treated for 4 d with rises of 13% and 
32%, respectively. These increases underlie enhanced functionality as shown by higher 
serum cholesterol efﬂux activity in both models. These data form the foundation for 
an ongoing phase Ib/IIa trial. RVX-208 may potentially be the ﬁrst in its class of new 
compounds to lower risk of CVD and possibly regress atherosclerosis. 
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1021-75 Signiﬁcant Difference in LDL-Cholesterol Lowering 
Using Two Readily Available Red Yeast Rice 
Formulations
Ram Y. Gordon, David J. Becker, Chestnut Hill Hospital, Philadelphia, PA, University of 
Pennsylvania, Philadelphia, PA
Background: Red yeast rice (RYR) is an alternative therapy for hyperlipidemia and 
contains monacolins that inhibit HMG-CoA reductase and lower LDL-cholesterol (LDL-C). 
There is limited regulation of RYR products. We evaluated 2 formulations for monacolin 
content and LDL-C lowering efﬁcacy.
Methods: 68 patients with high LDL-C levels took RYR, 4-6 capsules/day (600 mg/
cap) from 2 manufacturers (Table). Analysis of monacolin content was performed by an 
independent lab. The primary outcome was LDL-C lowering at 12 weeks.
Results: Laboratory analysis of RYR is shown in the table. Patients in Group 1 (n=37) 
had a mean LDL-C of 154 mg/dl. After 12 weeks, LDL-C decreased a mean of 67 mg/
dl (42%)(p<.0001). Patients in Group 2 (n=31) had a mean LDL-C of 163 mg/dl. After 
12 weeks, LDL-C decreased a mean of 44.5 mg/dl (27.3%) (p<.001). Between group 
analysis revealed a signiﬁcant decrease in LDL-C lowering in Group 2 compared with 
Group 1 (p<0.001). 2 patients in Group 1 and no patients in Group 2 stopped RYR due 
to myalgias.
Conclusions: Both RYR products were safe and effective in lowering LDL-C, suggesting 
that RYR may be an effective alternative therapy for hyperlipidemia. However, there was 
marked variability in monacolin content and a signiﬁcant difference in LDL-C lowering 
between products. Increased regulation of RYR is necessary to assure equivalence of the 
many formulations available to consumers. Physicians should be aware that different RYR 
products may have signiﬁcantly different LDL-C lowering effects.
Table: Chemical Analysis of Two Formulations of Red Yeast Rice
Group 1 Group 2 
RYR Manufacturer N3 Oceanic, Inc, Palm, PA Sylvan Bioproducts, Inc, Kennett Square, PA
Content Amount Amount
Total Monacolins 5.3 mg/capsule 2.16 mg/capsule
Monacolin JA 0.0267 mg/capsule 0.0120 mg/capsule
Monacolin J 0.00413 mg/capsule 0.0186 mg/capsule
Monacolin XA 0.0558 mg/capsule 0.00799 mg/capsule
Monacolin KA 1.96 mg/capsule 0.607 mg/capsule
Monacolin LA 0.0190 mg/capsule 0.0802 mg/capsule
Monacolin X 0.0760 mg/capsule None detected
Monacolin K (Lovastatin) 2.53 mg/capsule 1.02 mg/capsule
Monacolin L 0.122 mg/capsule 0.0546 mg/capsule
Monacolin M 0.0285 mg/capsule 0.00650 mg/capsule
Dihydromonacolin K 0.473 mg/capsule 0.212 mg/capsule
Other Components
Citrinin None>1,000 ppm detection limit
None>1,000 ppm detection 
limit
3:30 p.m.
1021-76 Association of Free Leptin Balance With Diverse 
Clinical Blood Pressure Phenotypes: a Cross-Sectional 
Study in Nonobese Subjects
Costas Thomopoulos, Dimitris Papadopoulos, Athanassios Bratsas, Ourania 
Papazachou, Spiros Massias, Elena Michalopoulou, Maria Daskalaki, Areti Komnou, 
Areti Komnou, Thomas Makris, Department of Cardiology, Elena Venizelou Hospital, 
Athens, Greece
Background: We aimed to investigate leptin (L) and human soluble leptin receptor (hsLR) 
levels (i.e. free leptin balance parameters) among non-obese subjects in relationship to 
different clinical BP phenotypes resulting from the pairing of clinic and ambulatory BP 
measurements.
Methods: We studied 311 consecutive never treated subjects, aged 44±5 years with 
body mass index (BMI) 24.8±2.6 Kgr/m2. Exclusion criteria included disturbed glucose 
metabolism, and history of cardiovascular diseases. All eligible to participate (n=247) 
with respect to the mean clinic and ambulatory BP, were divided in: hypertensives (n=83), 
white coat hypertensives (n=41), masked hypertensives (n=33) and normotensives 
(n=90). Fasting blood samples were taken for assessment of metabolic proﬁle, serum 
L and hsLR levels.
Results: Pairwise comparisons after Bonferroni correction had similar BMI, waist 
circumference and metabolic proﬁle (overall p>0.008 for all). With respect to the median L 
(3.5 ng/ml) and hsLR (21UI/ml) we constructed the conjoint variable of high L and low hsLR. 
In seriatim, hypertensives and masked hypertensives demonstrated increased log(10)(L) 
in tandem with decreased log(10)(hsLR) levels compared to white coat hypertensives and 
normotensives respectively (overall p<0.001 for all comparisons), while the prevalence of 
the conjoint high L and low hsLR differ between the groups (73% and 52% compared to 
12% and 10%, respectively, overall p<0.001). In stepwise regression models correlates 
of L remained 24h systolic/diastolic BP (beta=0.25/0.18) and heavy alcohol consumption 
(beta=0.13), while for hsLR, 24h systolic/diastolic BP (beta= -0.27/-0.20) and 24 hour 
heart rate (beta= -0.18). In a forward logistic multivariable model after adjustment for 
confounders the conjoint high L and low hsLR was predicted by hypertensive and masked 
hypertensive with respect to normotensive status by OR (95% CI) of 28.4 (11-68) and 
9.64 (3.5-26.1), respectively, p<0.001 for both.
Conclusions: Masked hypertension predicts increased serum L and decreased 
hsLR independently of body adiposity and metabolic parameters, whereas white coat 
hypertensive phenotype failed to predict such outcome.
3:30 p.m.
1021-77 Predictors Of Cerebrovascular Disease Following 
Myocardial Infarction: Role of Non-HDL Cholesterol In 
Risk Stratiﬁcation
Nitin Mahajan, Luis Afonso, Pratik Bhattacharya, Ramesh Madhavan, Judith Dunn, 
Frank M. Sacks, CARE trial investigators, Wayne State University, Detroit, MI, Harvard 
University, Boston, MA
Background:Cardiovascular disease is a major risk factor for cerebrovascular disease 
(CVD) ranking third after age and hypertension. The role of different cholesterol subtypes 
in prediction of CVD following MI is less well deﬁned. This study was aimed at exploring 
predictors of CVD following MI.
Methods:A secondary analysis of data collected for the placebo arm (n=2078) of the 
Cholesterol and Recurrent Events (CARE) trial was done. The CARE trial was a placebo 
controlled trial aimed at testing the effect of pravastatin on patients after MI. Regression 
analysis was performed to identify predictors of CVD.
Results:At the end of 5 years, 124 (6%) patients had CVD (stroke-76, transient ischemic 
attack-48). Two-thirds of these events occurred 2 years after the index MI. Stepwise 
regression showed that non HDL cholesterol is a better predictor of CVD compared to 
LDL, HDL and total cholesterol/HDL. Other predictors included increasing age, presence 
of hypertension, angina, prior stroke, continued smoking and low left ventricular ejection 
fraction (a40 %).There was a trend toward higher incidence of CVD in diabetics (p=0.2). 
After adjustment for potential confounders, the hazard ratio for the highest quartile of non-
HDL cholesterol was 2.31 (Figure 1) compared to 1.27 for LDL cholesterol. This held true 
in both diabetics and non diabetics.
Conclusions: Non HDL cholesterol is a better predictor of incident CVD in patients with 
established coronary heart disease, compared to other cholesterol subtypes. 
3:30 p.m.
1021-78 The Association Between Switching From Atorvastatin 
to Simvastatin and LDL Goal Attainment in the 
Secondary Prevention Setting
Herbert D. Aronow, Gregory Hess, Jerold Hill, Andreas Kuznik, Larry Z. Liu, Michigan 
Heart & Vascular Institute, Ann Arbor, MI, Pﬁzer, New York, NY
Background: Compared to atorvastatin, higher mg doses of simvastatin are required to 
achieve a similar degree of LDL-lowering. Whether therapeutically equivalent simvastatin 
doses are selected when patients are switched from atorvastatin to simvastatin in general 
practice is unknown. We observed the dosage chosen when switching from atorvastatin 
to simvastatin and the association between switching and LDL measurements/attainment 
of treatment goals.
Methods: 56,987 atorvastatin-treated patients who had q1 available LDL measured 
between 1/1/2005 - 5/30/2006 were identiﬁed from a 36-state electronic medical record 
database. Of these, 6,182 switched to simvastatin between 6/1/2006 - 7/15/2007, 383 of 
whom had known coronary heart disease (CHD) or CHD risk equivalents and q1 recorded 
LDL measurement (‘switched’). These patients were compared to a 10:1 randomly 
selected age-, gender- and baseline LDL-matched sample (n=3,830) of patients with 
CHD or CHD risk equivalents who remained on atorvastatin during the entire study period 
(‘controls’). Switched and control patients were compared with respect to changes in LDL 
between the two study periods and likelihood of reaching LDL <100 mg/dl.
Results: Compared to controls, switched patients were less likely to reach an LDL 
<100 mg/dl (Odds Ratio [OR] 0.76, p=0.041) and had higher measured LDL (3.5 mg/dl, 
p=0.003). Those who switched but were not prescribed a higher mg equivalent dose of 
simvastatin (n=122, 32%) were signiﬁcantly less likely to reach an LDL <100 mg/dl (OR 
0.55, p=0.006) and had higher LDL (6.9 mg/dl, p=0.001) than controls. The likelihood 
of reaching an LDL <100 mg/dl was similar between patients that switched to a higher 
mg dose of simvastatin and controls (OR 0.90, p=0.5); LDL values were not signiﬁcantly 
different (1.9mg/dl, p=0.17) between these two groups
Conclusions: Secondary prevention patients who switched from atorvastatin to 
simvastatin were signiﬁcantly less likely to meet LDL treatment goals compared to 
patients who remained on atorvastatin. This difference was largely driven by the use of 
less than therapeutically equivalent doses in approximately one third of patients who 
switched from atorvastatin to simvastatin.
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1021-79 Treatment With Omega-3 Fatty Acids Reduces 
Serum C-Reactive Protein Levels: Results From a 
Randomized, Double-Blinded, Placebo-Controlled Trial
Kamran I. Muhammad, Thomas Morledge, Ravish Sachar, Kathy Wolski, Deepak L. 
Bhatt, Cleveland Clinic, Cleveland, OH
Background: Studies have demonstrated that patients with diets high in omega-3 fatty 
acids have a lower risk of adverse cardiovascular events. Omega-3 fatty acids have 
been shown to have anti-inﬂammatory properties. C-reactive protein (CRP), a marker 
of inﬂammation, is a strong predictor of future cardiovascular events. We tested the 
hypothesis that treatment with omega-3 polyunsaturated fatty acids (PUFA) would reduce 
serum high-sensitivity (hs) CRP levels.
Methods: Fifty-three healthy adult patients seen at an outpatient primary care center were 
randomized in double-blinded fashion to PUFA (27 patients each receiving 1350mg of 
eicosapentaenoic acid and 300mg of docosahexaenoic acid daily) or placebo (26 patients) 
for 8 weeks. Patients with active infection, inﬂammatory disease, baseline hs-CRP q 10 
mg/L, or those started on statin therapy during the study period were excluded. Baseline 
hs-CRP was drawn at randomization and follow-up hs-CRP was drawn at 8 weeks.
Results: There were no signiﬁcant differences between the PUFA and placebo arms at 
baseline with the exception of more frequent use of lipid lowering therapies in the placebo 
group (38.5% of patients vs. 14.8%, p=.05). At 8 weeks, the percent reduction in mean 
hs-CRP from baseline in the PUFA group was greater (-40.3%, p=.009) than that seen 
with placebo (-16.4%, p=NS) (Figure).
Conclusions: In our study, the administration of omega-3 fatty acids for 8 weeks was 
associated with a signiﬁcant percent reduction in mean hs-CRP from baseline. 
3:30 p.m.
1021-80 Discordant Effects of Rosiglitazone on Novel 
Biomarkers Associated With Atherosclerosis
Andrew W. Owens, Anand Rohatgi, Raphael See, Shuaib M. Abdullah, Colby Ayers, 
Amit Khera, James A. de Lemos, Darren K. McGuire, University of Texas Southwestern 
Medical Center, Dallas, TX
Background: We have previously demonstrated independent associations between 4 
novel biomarkers and atherosclerosis: lymphotoxin B receptor (LTBR); peptidoglycan 
recognition protein-1 (PGLYRP-1); macrophage inﬂammatory protein 3 (MIP-3); and 
(inverse association) soluble receptor for advanced glycation end products (sRAGE). In 
the context of recent meta-analyses suggesting increased coronary heart disease (CHD) 
risk with rosiglitazone, we assessed its effect on these markers.
Methods: In a sub-study of a randomized, blinded, placebo-controlled trial evaluating the 
cardiopulmonary effects of rosiglitazone, we analyzed selected biomarker concentrations 
at baseline and after 6 months of study therapy. The Wilcoxon signed-rank test was used 
to assess within-group changes.
Results: Data from 111 subjects (median age 55; 41% women; 66% nonwhite) completing 
the 6-month study were analyzed, including 55 treated with rosiglitazone and 56 with 
placebo. Rosiglitazone had the unfavorable effects of increasing LTBR (p=0.002) (Figure), 
PGLYRP-1 (p=0.012), and MIP-3 (0.024), and the favorable effect of increasing sRAGE 
(0.003). Placebo did not signiﬁcantly affect any of these measures.
Conclusion: Rosiglitazone has discordant effects on novel markers of atherosclerotic 
risk. Whether these observations underpin the observed CHD risk with rosiglitazone and 
whether they represent a drug-speciﬁc or class effect warrant further investigation. 
3:30 p.m.
1021-81 Simvastatin and Ezetimibe Treatments Result in Distinct 
Plasma Lipid Proﬁles and Altered Lipid Loading of HDL 
Reijo Laaksonen, Minna Janis, Kirill Tarasov, Arvind Verma, Reini Hurme, Matej Oresic, 
Marcus Stahlman, Jan Boren, Heiner K. Berthold, Ioanna Gouni-Berthold, Kim Ekroos, 
Zora Biosciences oy, Espoo, Finland, University of Cologne, Cologne, Germany
Background: Many new lipid-lowering candidate compounds are aimed to be used in 
combination with statins, in order to gain a more potent decrease in LDL-cholesterol. 
Ezetimibe has been recognized as the ﬁrst agent in a class of novel cholesterol absorption 
inhibitors, which act by inhibiting the action of a recently identiﬁed intestinal cholesterol 
transporter protein Niemann-Pick C1 Like 1 (NPC1L1). In this study we characterized the 
lipidomic proﬁles of patients treated with ezetimibe, simvastatin, and their combination to 
evaluate in detail the treatment effects on the lipid metabolism.
Methods: Sequential lipoprotein ultracentrifugation in sucrose gradients was applied for 
HDL isolation. HDL fractions were analyzed by state-of-the-art mass spectrometry based 
shotgun lipidomics. Also, analyses were carried out on total plasma samples obtained 
in this randomized clinical trial including 72 patients either on ezetimibe (10 mg/day), 
simvastatin (40 mg/day) or their combination (10 + 40 mg/day).
Results: The lipidomic analyses revealed that cholesteryl esters (CE) were most efﬁciently 
lowered by the combination treatment with a reduction of 30% while the CE decrease in 
the simvastatin group was 20%. This is in agreement with the enzymatically measured total 
and LDL cholesterol values. However, when measured by shotgun lipidomics ezetimibe 
seemed to increase total plasma diacyl and ether linked phosphatidylcholines (PC, PC-O) 
and sphingomyelin (SM) concentrations which all decreased in the simvastatin and in the 
combined treatment groups. In depth shotgun lipidomic analysis of the ezetimibe group 
revealed the presence of different responder types for this drug. Furthermore, simvastatin 
treatment showed an increase in the lipid content of LDL and VLDL. Similar results could 
be observed with the combined treatment. However, ezetimibe treatment increased the 
lipid content of HDL while decreasing the lipid content of LDL and VLDL.
Conclusions:Ezetimibe treatment appears to increase the lipid loading of the apoA1 
normalized HDL content. This may result in the production of dysfunctional HDL and 
inhibition of HDL mediated reverse cholesterol transport.
3:30 p.m.
1021-82 Glycemic and Lipid Effects and Cardiovascular Safety 
of a Novel Dual Peroxisome Proliferator-Activated 
Receptor A/G Agonist
A. Michael Lincoff, Robert R. Henry, Sunder Mudaliar, Cathy Chognot, Michael Rabbia, 
Matthias Herz, Cleveland Clinic, Cleveland, OH, University of California, San Diego, San 
Diego, CA
Background: Aleglitazar (ALE) is a dual peroxisome proliferator-activated receptor 
(PPAR) G (insulin sensitizing) and A (dyslipidemia) agonist. Some previous PPAR agonists 
have been associated with increased risk of cardiovascular (CV) complications.
Methods: In a multicenter, double-blind, dose-ranging study, 332 pts with type 2 diabetes 
(either drug-naïve or pre-treated with <3 oral agents) were randomized to 1 of 4 doses 
of ALE (50, 150, 300, 600 μg), placebo, or open-label pioglitazone (PIO) 45 mg od for 16 
wks. The primary endpoint was change in HbA1c; secondary endpoints included effects 
on lipids and select CV events. Because congestive heart failure (CHF) and ischemic 
cardiac events are known adverse effects of some PPARG agonists, a Cardiac Adjudication 
Committee reviewed possible cases of heart failure and other deﬁned CV events.
Results: A signiﬁcant dose-related beneﬁcial effect of ALE was observed on HbA1c and 
lipid proﬁles (Table). At the 150-μg dose level, ALE produced similar reduction in HbA1c 
and positive effects on lipids from baseline compared with the maximum-dose PIO. At 
doses of ALE below 300 μg, CHF by adjudication did not occur, the incidence of edema 
was the same as placebo, and maximal body weight gain was similar to PIO.
Conclusions: The CV safety proﬁle of ALE 150 μg daily appears positive while providing 
a signiﬁcant effect on glycemic control and lipids similar to or greater than with maximum-
dose PIO.
Placebo ALE50 μg
ALE
150 μg
ALE
300 μg
ALE
600 μg
PIO
45 mg
No. of pts 55 55 55 55 55 57
$ HbA1c (%) 0.35 0* -0.49*** -0.60*** -0.99*** -0.35***
$
Triglycerides 13.7 -14.1** -29.7*** -35.0*** -37.9*** -8.6**
$ LDL-C 5.5 -3.5 -10.0** -7.6* -20.4*** 5.3
$ HDL-C 4.4 12.6* 25.1*** 27.3*** 26.1*** 16.5**
Edema (% 
of pts) 5 2 4 13 11 7
CHF (% of 
pts) 0 0 0 2 2 0
$ Weight (kg) -0.85 -0.24 0.52* 1.18** 2.72*** 1.06**
*p<0.05 vs 
placebo
**p<0.005
vs. placebo
***p<0.0001 vs. 
placebo
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rosuvastatin (R) on multiple lipid variables in patients with atherogenic dyslipidemia.
Methods. This multicenter, randomized, double-blind, parallel group study was conducted at 
144 US centers. A total of 760 patients with LDL-C q130 mg/dL, TG q150 mg/dL, and HDL-C 
<40 mg/dL (<50 mg/dL for women) were randomized for a 12-week treatment period to FA 
(135 mg), R (5 mg), or the combination of FA (135 mg) and R (5 mg). The primary efﬁcacy 
comparisons were mean percent (%) changes in HDL-C and TG (FA+R vs. R), and LDL-C 
(FA+R vs. FA). Secondary endpoints included non-HDL-C, VLDL-C, Apo B, TC, and hsCRP.
Results. FA+R resulted in signiﬁcantly greater increases in HDL-C and decreases in 
TG and LDL-C compared with prespeciﬁed monotherapies and also improvement in all 
secondary endpoints (Table). Combination therapy was generally well tolerated with a 
safety proﬁle consistent with the individual treatments. No unexpected hepatic, renal, or 
muscle safety signals were identiﬁed with combination therapy vs. monotherapy. 
Percent change from baseline to ﬁnal visit in primary and secondary 
efﬁcacy endpoints
Variable FA 135 mg(n=245)
R 5 mg
(n=241)
FA 135 mg +
R 5 mg
(n=236)
P-value
HDL-C, mg/dL
Baseline mean
Final mean
% change (SE)
40.6
48.6
20.8 (1.31)
40.8
45.1
12.4 (1.32)
40.2
49.1
23.0 (1.33)
<0.001a
TG, mg/dL
Baseline mean
Final mean
% change (SE)
271.2
161.6
-35.0 (1.87)
289.9
209.5
-17.5 (1.88)
284.1
150.6
-40.3 (1.89)
<0.001a
LDL-C, mg/dL
Baseline mean
Final mean
% change (SE)
154.7
142.6
-4.1 (1.31)
149.1
103.5
-28.6 (1.31)
147.1
102.4
-28.7 (1.33)
<0.001b
Non-HDL-C, mg/dL
Baseline mean
Final mean
% change (SE)
219.2
180.4
-16.0 (1.05)
215.6
145.8
-31.8 (1.05)
214.4
132.0
-37.4 (1.06)
<0.001b
<0.001a
VLDL-C, mg/dL
(n)
Baseline mean
Final mean
% change (SE)
(n=244)
64.6
37.9
-31.1 (3.51)
(n=239)
66.8
42.4
-22.2 (3.53)
(n=235)
67.2
29.5
-41.3 (3.56)
<0.001a
Apo B,
mg/dL
(n)
Baseline mean
Final mean
% change (SE)
(n=242)
135.1
115.4
-13.6 (0.99)
(n=238)
133.5
97.7
-26.4(0.99)
(n=233)
131.9
90.5
-30.9 (1.00)
0.001a
Total-C,
mg/dL
Baseline mean
Final mean
% change (SE)
259.7
229.0
-10.3 (0.84)
256.4
190.9
-25.0 (0.84)
254.5
181.1
-28.1 (0.85)
0.007a
hsCRP,
mg/dL
(n)
Baseline median
Median % change
(n=244)
0.30
-8.7
(n=240)
0.30
-11.4
(n=235)
0.33
-28.0
0.012a
aFA + R vs. R monotherapy
bFA+R vs. FA monotherapy.
Conclusion. The combination of 135 mg fenoﬁbric acid + 5 mg rosuvastatin resulted in 
comprehensive improvement in the lipid proﬁle of patients with atherogenic dyslipidemia 
without additional adverse events.
3:30 p.m.
1021-86 The Effects of Sex Hormones on Lipid Levels in 
Children and Adolescents
Mehmet A. Agirbasli, Nihat B. Agaoglu, Nilay Orak, Hatice Caglioz, Tuba Ocek, Oytun A. 
Baykan, Marmara University Medical Center, Istanbul, Turkey
Background: Hyperlipidemia starts early in life, therefore it is of interest to explore the 
effects of sex hormones and puberty on lipid levels.
Methods: We investigated the relation between sex hormones including estradiol, 
testosterone, free androgen index (FAI), free estradiol index (FEI), and sex hormone-
binding globulin (SHBG) and lipid levels in a cross sectional study of 365 healthy children 
and adolescents.
Results: Signiﬁcant correlations existed between sex hormones and lipid levels. After 
controlling for age, HDL-C positively correlated with log SHBG in girls (R= 0.29 and 
p<0.001) and boys (R= 0.28 and p<0.001). HDL-C negatively correlated with log FAI (R= 
- 0.26 and p<0.001) and log testosterone (R= - 0.14 and p=0.05) in girls and with log FEI 
(R= - 0.30 and p<0.001) and log estradiol (R= - 0.19 and p=0.01) in boys. After adjusting 
for age, anthropometric parameters, sex hormone levels; log SHBG was the strongest 
predictor of HDL-C among children and adolescents (model R= 0.461, p<0.001). In 
contrary, low density lipoprotein cholesterol (LDL-C) (R= - 0.22 and p=0.003 for boys) 
and log triglycerides (R= -0.16 and p=0.04 for boys, and R= -0.23 and p=0.002 for girls) 
negatively correlated with log SHBG.
Conclusions: Sex hormone levels and SHBG have important effects on lipid levels 
(particularly HDL-C) in children and adolescents. SHBG was associated with higher 
HDL-C and lower LDL-C and triglycerides. This association may help us to understand 
the underlying reasons of low HDL-C in adulthood.
3:30 p.m.
1021-83 Efﬁcacy and Safety of Rosuvastatin Therapy for 
Children With Familial Hypercholesterolemia: Results 
From the PLUTO Study
Hans J. Avis, Barbara A. Hutten, Claude Gagne, Gisle Langslet, Brian W. McCrindle, 
John J. Kastelein, Evan A. Stein, Academic Medical Center, Amsterdam, The 
Netherlands, Metabolic and Atherosclerosis Research Center (E.A.S.), Cincinnati, OH
Background: Familial hypercholesterolemia (FH) is a relatively common inherited 
condition characterised by high low-density lipoprotein (LDL-C) levels and premature 
atherosclerotic cardiovascular events, preceded by detectable vascular abnormalities, 
such as increased carotid intima thickening (cIMT), present from childhood onwards. Prior 
trials have shown that LDL-C levels can be lowered signiﬁcantly with statins, and cIMT 
reduced. However, statins and doses investigated in children to date were of limited efﬁcacy 
in terms of LDL-C lowering, ranging from 24% to 41%, and many children did not achieve 
optimal LDL-C control. Therefore, we investigated efﬁcacy and safety of rosuvastatin, 
the most potent statin available, in pubertal children aged 10-17 with FH. Methods: The 
study comprised a 12 week double-blind randomized placebo-controlled trial followed by 
a 40 week titration to goal extension-phase. In the ﬁrst phase, patients were randomized 
to either placebo or rosuvastatin 5, 10 or 20 mg once daily in a 1:1:1:1 ratio. In the second 
phase, the dose of rosuvastatin was titrated to an LCL-C goal of 110 mg/dL (2.8 mmol/l) 
with a maximum dose of 20 mg. Results: A total of 177 patients were randomized. 
LDL-C was signiﬁcantly reduced by 39%, 44% and 50% with rosuvastatin 5, 10 and 20 
mg respectively (p<0.001 for each group when compared to placebo). 174 Participants 
continued into the open-label dose titration extension phase in which 40% of patients 
achieved the predeﬁned treatment goal of LDL-C<110 mg/dL. Muscle symptoms were 
reported by some rosuvastatin-treated patients, particularly in conjunction with physical 
activity, but none required permanent discontinuation of study medication. No adverse 
renal or hepatic effects, or impairment of expected growth and sexual development were 
observed. Conclusion: Rosuvastatin provided the most effective reductions in LDL-C yet 
seen in children with FH. However, even with an average reduction in LDL-C of 50%, only 
40% of patients attained the currently recommended treatment goal. The doses tested 
were well tolerated, growth and development progressed as anticipated during the one-
year trial and there were no short-term safety concerns.
3:30 p.m.
1021-84 The Perimenopausal Atherosclerosis Transition: 
Relationships of Calciﬁed, Noncalciﬁed, and Carotid 
Plaque to Risk Factors and Hormone Levels
Allen J. Taylor, Jamalah Munir, Jody Bindeman, Kelly Bauer, Carole Byrd, Hongyan Wu, 
Irwin Feuerstein, Walter Reed Army Medical Center, Washington, DC
Background: Women of perimenopausal age experience an upwards transition of 
cardiovascular risk. Among mechanisms for this, one includes the relationship between 
hormonal status and atherosclerosis. We examined the cross sectional relationships 
between coronary (calciﬁed and noncalciﬁed), carotid, aortic plaque and menopausal 
hormone levels among asymptomatic perimenopausal women.
Methods: ATHENA (Assessment of the Transition of Hormonal Evaluation with 
Noninvasive Imaging of Atherosclerosis) was a prospective substudy of the PACC project. 
We screened 125 asymptomatic perimenopausal women, mean age 50 years, (range 
45-60) with contrast-enhanced CT angiography and carotid ultrasound. Women were 
original participants of the screening cohort of the PACC project and had EBCT data 
from 5-10 years earlier. Measures included CV risk factors, serologic hormonal levels, 64 
slice MDCT (calcium scanning and CTA) and carotid ultrasound (IMT and plaque). The 
predeﬁned primary endpoint was the relationship between menopausal status and the 
distribution of atherosclerosis extent.
Results: The prevalence of any coronary plaque was 33.8%. The prevalence of CAC 
was 23.1%. Mixed coronary plaque and noncalciﬁed plaque were each seen in 18% of 
subjects. Solely noncalciﬁed plaque was the only ﬁnding in 10.7%. CAC was associated 
with free testosterone, the Framingham risk score, and glycohemoglobin. Conversion 
from a prior CAC score of 0 to a positive score was associated with standard risk factors. 
In contrast, noncalciﬁed plaque was only related to levels of sex hormone binding globulin 
(SHBG); this relationship persisted in logistic models controlling for CV risk factors, and 
insulin resistance. Similar relationships were seen for carotid arterial plaque (prevalence 
30%) and SHBG, whereas there was no relationship of SHBG with calciﬁed plaque. 
Estradiol, LH, and FSH were unrelated to plaque presence or extent.
Conclusions: Coronary and carotid arterial plaque is prevalent in asymptomatic 
perimenopausal women. The relationships between calciﬁed and noncalciﬁed plaques 
are different, including an independent association of SHBG with carotid and noncalciﬁed 
coronary plaque.
3:30 p.m.
1021-85 A Phase III Study Evaluating the Efﬁcacy and Safety 
of 135 mg Fenoﬁbric Acid (ABT-335) in Combination 
With 5 mg Rosuvastatin in Patients With Atherogenic 
Dyslipidemia
Eli M. Roth, Robert S. Rosenson, Dawn M. Carlson, Sandra M. Fukumoto, Carolyn M. 
Setze, James W. Blasetto, Nardev S. Khurmi, James C. Stolzenbach, Laura A. Williams, 
Sterling Research Group, Cincinnati, OH, Abbott, Abbott Park, IL
Background. Patients with atherogenic (mixed) dyslipidemia often need combination 
therapy to achieve desired levels of LDL-C, HDL-C, and triglycerides (TG). This study 
evaluated the effects of 135 mg fenoﬁbric acid (ABT-335, FA) in combination with 5 mg 
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men and women free from coronary heart disease at study entry reduced the risk of all-
cause mortality by 13% (HR 0.87, 95% conﬁdence interval 0.76 to 0.97, p<0.001). There 
was no strong evidence of heterogeneity between studies [I2 = 26.1%, p=0.23]. In absolute 
terms one death was prevented for every 200 individuals treated with statins for 5 years.
Conclusions: This literature-based meta-analysis demonstrates unequivocally for the 
ﬁrst time that the use of statin therapy in individuals without pre-existing coronary heart 
disease signiﬁcantly reduces all-cause mortality. 
3:30 p.m.
1021-89 Effect of Baseline Phytosterol Levels on Aortic Valve 
and Ischemic Cardiovascular Events and the Incidence 
and Mortality of Cancer in the Patients With Aortic 
Valve Stenosis: The SEAS Trial
Antero Y. Kesaniemi, Dieter Lütjohann, Anne B. Rossebø, Ingar Holme, Terje R. 
Pedersen, for The SEAS Investigators, University of Oulu, Department of Internal 
Medicine, Oulu, Finland, Ullevål University Hospital, Center of Preventive Medicine, 
Oslo, Norway
Background: The Simvastatin plus Ezetimibe in Aortic Stenosis (SEAS) study was a 
randomized placebo-controlled clinical trial in 1873 patients with asymptomatic aortic 
stenosis, aimed at evaluating the effect of intensive lipid -lowering therapy on disease 
progression. Unexpectedly, cancer and cancer-related deaths occurred more frequently in 
the actively treated group than in the placebo group.The cholesterol absorption inhibitor, 
ezetimibe, also affects the absorption of phytosterols that have been suggested to be risk 
factors for both cardiovascular disease and cancer.
Methods: Serum levels of phytosterols, sitosterol(sito) and campesterol(campe) were 
determined in 1619 patients in the SEAS trial.The relationship between baseline levels of 
these phytosterols and the development of aortic and ischemic cardiovascular events, and 
the incidence and mortality rate of cancer were assessed by Cox regression method.
Results: The mean baseline levels of serum sito and campe were 284.6 (118.0, SD) 
and 444.7 (240.1) microg/dl, and sito/cholesterol (chol) ratio and campe/chol ratio were 
1.29 (0.50) and 2.01 (1.03) microg/mg, respectively.Baseline levels of sito and campe 
and of sito/chol and campe/chol ratios, were not related to the development of aortic 
valve (sito p=0.962; campe p=0.643; sito/chol p=0.668; campe/chol p=0.440) or ischemic 
cardiovascular (sito p=0.063; campe p= 0.515; sito/chol p=0.124, campe/chol p=0.672) 
events nor to incidence (sito p=0.229; campe p=0236; sito/chol p=0.590; campe/chol 
p=0.561) or mortality rate (sito p=0.438; campe p=0.989; sito/chol p=0.651; campe/chol 
p= 0.243) of cancer. The reduction of plasma cholesterol levels with ezetimibe is known 
to be closely correlated to the reduction of phytosterol levels. There was no signiﬁcant 
relationship between cholesterol levels reached during the trial and the risk of cancer-
related deaths. 
Conclusions: These data show that the baseline phytosterol levels were not related to 
aortic valve and ischemic cardiovascular events nor to the incidence or mortality rate of 
cancer among these patients with aortic valve stenosis.
3:30 p.m.
1021-90 A Novel Approach to Lipid-Lowering in Patients With 
Statin-Associated Myalgias: A Randomized, Placebo-
Controlled, Double-Blind Trial
David J. Becker, Ram Y. Gordon, Steven C. Halbert, Daniel J. Rader, Chestnut Hill 
Hospital, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA
Background: Statin-associated myalgias (SAM) are common and result in patient 
non-compliance in the treatment of hyperlipidemia. Currently, there is no consensus on 
optimal lipid-lowering therapy for these patients.
Methods: 62 patients (22M/40F) with a history of intolerance to at least 1 statin (average 
1.94/patient) participated in a 12 week Therapeutic Lifestyle Change (TLC) program 
and were randomized to red yeast rice (RYR) or placebo. They were monitored for an 
additional 12 weeks. Primary outcome measurement was change in LDL-cholesterol 
(LDL-C). Secondary outcome measurements included effect on other serum lipoproteins, 
weight loss, and tolerability and safety of the regimen. Outcome measures were obtained 
at baseline, 12 weeks, and 24 weeks
Results: Mean baseline LDL-C of the RYR group was 163±27 mg/dl and weight 81 
kg. Mean baseline LDL-C of the placebo group was 165±32 mg/dl, and weight 82 kg. 
The post treatment RYR group had a mean decrease of LDL-C of 44.5 mg/d (-27.3%) 
(p<0.001) at 12 weeks and 35.4 mg/dl (-21.3%) (p<0.001) at 24 weeks. Weight loss was 
3:30 p.m.
1021-87 Effects of Statins on the Concentration of High-Density 
Lipoprotein Cholesterol and Its Relation to Change in 
Low-Density Lipoprotein Cholesterol: Results From the 
VOYAGER Database
Philip J. Barter, Gunnar Brandrup-Wognsen, Mike K. Palmer, Steve J. Nicholls, Heart 
Research Institute, Sydney, Australia
Background: The relationship between statin-induced increases in concentration of high-
density lipoprotein cholesterol (HDL-C) and statin-induced decreases in concentration of 
low-density lipoprotein cholesterol (LDL-C) is unknown. In this study we investigate the 
HDL-C raising effects of individual statins across their dose ranges and relate them to the 
corresponding reductions in LDL-C.
Methods: The effects of different statins on HDL-C levels and the relationships between 
changes in HDL-C and changes in LDL-C have been investigated in an individual patient 
meta-analysis of 33,841 dyslipidemic patients included in 37 randomized studies using 
rosuvastatin (RSV), atorvastatin (ATV) and simvastatin (SIM).
Results: Effects of RSV, SIM and ATV on HDL-C and LDL-C are shown in the table. 
HDL-C increased in a dose dependent fashion with RSV and SIM but not with ATV where 
the increase was less at higher doses. A subgroup analysis of 9,297 diabetic patients 
revealed consistently smaller increases in HDL-C at all doses of all statins. There was 
no apparent relationship between the reduction in LDL-C and the increase in HDL-C, 
whether analyzed overall for all statins (Spearman’s rank correlation coefﬁcient=0.005) 
or for each statin individually.
Conclusions. Increases in HDL-C were positively related to statin dose with RSV and 
SIM but inversely related to dose with ATV. The magnitude of statin-induced increases in 
HDL-C is unrelated to the magnitude of the decrease in LDL-C. 
Dose
(mg)
Least-square mean % 
change from baseline in 
LDL-C (n)
Least-square mean % change 
from baseline in HDL-C (n)
Rosuvastatin 5 -38.8 (668) 5.5 (670)
10 -44.1 (11650) 6.1 (11690)
20 -49.5 (3551) 7.0 (3554)
40 -54.7 (2981) 7.9 (2983)
Atorvastatin 10 -35.5 (7804) 4.5 (7837)
20 -41.4 (3896) 3.5 (3908)
40 -46.2 (1324) 2.4 (1324)
80 -50.2 (2070) 2.3 (2072)
Simvastatin 10 -27.4 (165) 4.2 (165)
20 -33.0 (2923) 5.0 (2929)
40 -38.9 (542) 5.0 (548)
80 -45.0 (478) 5.3 (479)
3:30 p.m.
1021-88 Statins and All-Cause Mortality in Men and Women 
Without Pre-existing CHD: A Meta-analysis of 7 Trials 
and 209,000 Person Years of Follow-up
Kausik Kumar Ray, Sreenivasa R k Sheshasai, Sebhat Erqou, Naveed Sattar, University 
of Cambridge, Cambridge, United Kingdom, University of Glasgow, Glasgow, United 
Kingdom
Background: It is presently unclear whether treatment with statins in individuals without 
pre-existing coronary heart disease results in signiﬁcant reductions in all-cause mortality 
when compared with placebo.
Methods: We conducted a literature-based meta-analysis of randomized placebo-
controlled trials of statin therapy performed in individuals free from pre-existing coronary 
heart disease at baseline (i.e. primary prevention) and which reported details, or could 
supply data, on all-cause mortality. Effect estimates were pooled across studies using 
random-effects meta-analysis and heterogeneity was assessed using the I2 statistic.
Results: A total of 7 randomized placebo controlled trials involving 44 960 participants were 
included, providing information on 209 000 person-years of follow-up. The use of statins in 
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after stenting. The test meal contains 75g ﬂour starch, 24g fat and 5.9g protein in a total 
560 kcal, by which glucose intolerance, diabetes, postprandial dyslipidemia and insulin 
resistance would be detected. Measurements of several parameters were performed at 
baseline, 1 hour, 2 hours and 6 hours following meal test. The primary end point was 
MACE including restenosis and late events of myocardial infarction, revascularization to 
new lesions and death.
Results: Follow-up catheterization was performed at 8 months after PCI and in-stent 
restenosis was documented in 40 patients (19%). During long-term follow-up with 96% 
follow-up rate, PCI to new lesion was performed in 28 patients, 10 myocardial infarction 
occurred, three death and 2 patients underwent CABG. Postprandial hypertriglyceridemia 
and a prolonged elevation with delayed clearance of triglyceride was observed in patients 
with restenosis (p=0.03). Postprandial glucose spike evaluated by using subtracted value 
of plasma glucose at 1 hour point from baseline (65 vs. 34 mg/dl ; p=0.017) and low 
HDL level (29 vs. 39 mg/dl p=0.01) were independent contributing factors of myocardial 
infarction and signiﬁcant delayed peaked insulin secretion was observed in patients who 
had undergone new lesion PCI (p=0.04).
Conclusions:Postprandial hypertriglyceridemia and delayed triglyceride clearance as 
well as glucose spike after meal were independent predictors for late adverse outcome 
in PCI patients. Metabolic stress test using meal test was useful to detect long-term 
prognosis in patients with coronary artery disease.
9:30 a.m.
1030-68 Statins and Tendon Rupture: A Case Control Study
Abhimanyu Beri, Francesca Dwamena, Ben Dwamena, Michigan State University, East 
Lansing, MI, University of Michigan, Ann Arbor, MI
Background: Reports have previously been published regarding an association 
between statin therapy and tendon rupture with no comparative studies done in this ﬁeld. 
We designed this study to assess whether statins lead to an increased risk of tendon 
rupture.
Methods: A retrospective chart review of the Electronic Medical Record database at 
the multi-specialty clinics at Michigan State University was done for patients presenting 
with tendon rupture between January 2002 and December 2007. Tendon rupture was 
diagnosed according to ICD codes. Patients with no documented information about 
medication use were excluded. We obtained age and sex matched controls in a ratio 
of 3:1 for each case from the same database. The primary outcome of interest was to 
compare the use of statins between cases and controls. We collected information and 
controlled for other risk factors for tendon rupture including diabetes, rheumatologic 
disease, steroid use, hyperparathyroidism and chronic kidney disease. We also sought to 
do sub-group analysis according to sex and site of tendon rupture.
Results: We obtained 93 cases of tendon rupture after excluding 12 that had missing 
documentation about medications. Multivariable regression analysis in the entire cohort 
showed there was no signiﬁcant difference in statin use between cases and controls. In 
women, statin use was found to be a signiﬁcant risk factor on univariable (OR 3.09, 95% CI 
1.04-9.25) and multivariable (OR 3.76, 95% CI 1.11-12.75, p=0.03) analysis. Men did not 
show a signiﬁcant relationship between statin use and tendon rupture. Patients with biceps 
tendon rupture were more likely to be on statins than other sites of tendon rupture (p=0.007).
Conclusions: Statin therapy is related to higher risk of tendon rupture in women. This 
effect was not seen in men in our study.
9:30 a.m.
1030-69 Impact of Gender in Primary Prevention of Coronary 
Heart Disease With Statin Therapy: A Meta-Analysis
Pierluigi Costanzo, Pasquale Perrone-Filardi, Mario Petretta, Enrico Vassallo, Stefania 
Paolillo, Cinzia Monda, Andrea Petretta, Caterina Marciano, Gianluca Caiazzo, Massimo 
Chiariello, Department of Internal Medicine, Cardiovascular and Immunological Science, 
Naples, Italy
Background: Evidence of lipid-lowering from clinical trials that included women is 
adequate to support their use in secondary prevention in women with known coronary 
disease. However the role of statin therapy in primary prevention is still controversial, in 
particular for female gender. The aim of our study is to perform a meta-analysis comparing 
by gender the cardiovascular outcomes related to statin therapy in primary prevention
Methods: We performed a meta-analysis including 8 randomized controlled trials (19,052 
and 30,194 men, mean follow-up 3.9 years) that assessed the cardiovascular outcomes 
related to statin therapy, including studies that provided sex-speciﬁc results. MEDLINE 
and the Cochrane Database, were searched for articles published in English and other 
languages up to March 2008.
Results: Statins do not appear to have a beneﬁcial effect on total mortality for both men and 
women in primary prevention over the 2.8 to 5.3 year study period (men: 95% Conﬁdence 
Interval (CI) 0.83-1.04 comparison p= 0.22; heterogeneity p=0,4. Women: 0.96; CI 0.81-1.13, 
p= 0.61; heterogeneity p=0.21). Statin therapy reduced the risk of coronary heart disease 
(CHD) events in men (0.59; CI 0.48-0.74, p= 0.0001; heterogeneity p=0.001), however in 
women this risk reduction was weakly signiﬁcant (0.89 CI 0.79-1.00, p= 0.05; heterogeneity 
p=0.3) and disappeared when in sensitivity analysis, trials not entirely of primary prevention 
were excluded (HPS, PROSPER) (0.95 CI 0.78-1.16, p= 0.56; heterogeneity p=0.39).
Conclusions: Our study showed that statin therapy reduced the risk of CHD events in 
men without prior cardiovascular disease, but not in women. Statins did not reduce the 
risk of total mortality both in men and women.
-3.5 kg (-4.0%) (p<.001) at 24 weeks. The post treatment placebo group had a mean 
LDL-C decrease of -10.9 mg/dl (-5.7%) (p=0.01) at 12 weeks and -15.3 mg/dl (-8.7%) 
(p=0.01) at 24 weeks. Weight loss was -4.2 kg (-5.0%) (p<.01) at 24 weeks. Between 
group comparison demonstrated a signiﬁcant difference in favor of RYR in LDL-C 
lowering (p=0.01) at 24 weeks. There was no signiﬁcant difference in the incidence of 
myalgias between the RYR and placebo groups.
Conclusions: In this double-blinded, randomized, placebo-controlled trial of subjects 
with prior SAM, patients enrolled in a TLC program had signiﬁcant reductions in LDL-C 
when taking RYR compared with placebo. Both groups achieved equivalent weight loss. 
The regimen of RYR and TLC was effective and well-tolerated and may offer a treatment 
option in this population.
3:30 p.m.
1021-91 Two Polymorphisms in the Human Resistin Gene Are 
Major Determinants of Plasma Resistin Levels in a 
Japanese Aged Cohort (KING Study)
Hiroyuki Asano, Hideo Izawa, Kohzo Nagata, Masakazu Kobayashi, Akihiro Hirashiki, 
Yosuke Murase, Takashi Yamada, Kazumasa Unno, Takao Nishizawa, Daisuke Tanimura, 
Xian Wu Cheng, Masahiro Nakatochi, Keiko Naruse, Tatsuaki Matsubara, Toyoaki 
Murohara, Mitsuhiro Yokota, Department of Cardiology, Nagoya University Graduate 
School of Medicine, Nagoya, Japan, Department of Genome Science, Aichi-Gakuin 
University School of Dentistry, Nagoya, Japan
Background: Resistin is a cytokine derived from adipose tissue and is implicated in the 
pathogenesis of obesity-related insulin resistance and dyslipidemia. Polymorphisms of 
the resistin gene have been shown to affect the plasma resistin levels. We investigated the 
relations between plasma resistin concentration and eleven polymorphisms of the resistin 
gene and other metabolic parameters in a Japanese cohort.
Methods: We recruited 3133 subjects aged 50 years and above to a population-based 
prospective cohort study (KING study) and obtained written informed consent from each subject. 
Plasma resistin concentration, physical ﬁndings, and metabolic parameters were measured in 
all subjects. Eleven polymorphisms of the resistin gene, including -638G A in the 5’ ﬂanking 
region and an ATG repeat and +1084G A in the 3’ untranslated region, were genotyped.
Results: One-way analysis of variance and Scheffe’s method revealed that the plasma 
resistin level was signiﬁcantly higher in subjects with the -638A allele and in those with 
the +1084G allele than in the corresponding individuals without these alleles (P <1×10-15
and P = 5.32×10-6, respectively, Figure).
Conclusions: The -638G A and +1084G A polymorphisms of the resistin gene were 
robust and independent determinants of plasma resistin concentration in this population. 
Hereditary hyperresistinemia may thus lead to insulin resistance and dyslipidemia linked 
to obesity. 
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9:30 a.m.
1030-67 Postprandial Hypertriglyceridemia and Glucose Spike 
Predict Late Adverse Outcome After Coronary Stent 
Implantation
Sugao Ishiwata, Susumu Tao, Minoru Yorozuya, Jun Masuda, Yoshinao Yazaki, Tetsu 
Yamaguchi, Toranomon Hospital, Tokyo, Japan
Background:The inﬂuence of numerous polymorphisms on late outcomes after coronary 
bare metal stenting is discussed controversially. Objective of this study is to evaluate the 
potential metabolic markers to predict late outcome after coronary angioplasty.
Methods:Our study investigated 218 consecutive patients who had undergone 
successful percutaneous coronary interventions (PCI) using bare metal stents and was 
followed up over 4 years (mean: 49 months). All patients ingested test meal next morning 
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incidence of new-onset diabetes, deﬁned as the usage of glucose-lowering agents and/or 
HbA1cq6.5% in 2452 patients who did not have diabetes at baseline.
Results: Baseline characteristics as well as follow-up blood pressure did not differ 
between valsartan group (n=315) and non-ARB group (n=314). Primary composite 
endpoints of cardiovascular morbidity and mortality were 68% fewer in valsartan group 
as compared with non-ARB group (95% CI 0.19-0.55). In non-diabetic counterparts, the 
primary endpoints were 26% fewer in valsartan group (n=1226) than in non-ARB group 
(n=1226) (95% CI 0.56-0.99). Among the latter two groups, the treatment of valsartan was 
associated with 28% lower risk of development of diabetes (95% CI 0.52-0.99).
Conclusion: Beneﬁt of Valsartan treatment in diabetic patients was conﬁrmed in Japanese 
population. Likewise, as previously noted in studies from western countries, valsartan 
reduced the incidence of new-onset of diabetes in this cohort.
9:30 a.m.
1030-73 Association of Hypokalemia With Cornell Product Left 
Ventricular Hypertrophy Independent of Treatment and 
Blood Pressure in Hypertensive Patients: Implications 
for the Development of New Diuretic Antihypertensives
Peter M. Okin, Sverre E. Kjeldsen, Lars H. Lindholm, Björn Dahlöf, Richard B. Devereux, 
Weill Cornell Medical College, New York, NY
Background: Hypokalemia (HypoK) increases blood pressure and has adverse 
cardiovascular effects, and correction of hypoK can prevent development of LVH in animal 
models. However, whether hypoK is independently associated with ECG LVH has not 
been examined.
Methods: Baseline and yearly Cornell product LVH levels were examined in relation to 
hypoK (serum K a3.90, the lowest quartile) in 8586 patients (72% previously treated) in 
the LIFE study with baseline K levels. Patients were randomized to losartan vs atenolol-
based treatment and additional hydrochlorothiazide (HCTZ) therapy as needed.
Results: The association between hypoK and increased mean Cornell product LVH 
was highly signiﬁcant at baseline and at years 1 to 3 of the study. Multivariate logistic 
regression analyses revealed that hypoK was associated with a statistically signiﬁcant 22 
to 40% increased risk of LVH by Cornell product criteria at baseline and at years 1 to 4.
Conclusions: HypoK is independently associated with a greater likelihood and severity of 
Cornell product LVH during antihypertensive therapy. These ﬁndings suggest that hypoK 
per se may be a stimulus to the persistence of ECG LVH during treatment. 
Time
-EAN #ORNELL PRODUCT ,6( MMsMS	
Risk of Cornell product LVH q2440
MMsMS 7ITH (YPOKALEMIA
Hypokalemia
K a3.90
Normal K
K >3.90
Adjusted
p value Hazard Ratio 95% CI
Adjusted
p value
Baseline 2898±1058 2801±1028 0.001* 1.24 1.11 - 1.38 <0.001*
Year-1 2711±1056 2610±1060 0.001** 1.40 1.23 - 1.59 <0.001**
Year-2 2641±998 2548±1063 0.002** 1.32 1.16 - 1.50 <0.001**
Year-3 2638±1044 2538±1066 0.003* 1.26 1.10 - 1.44 0.001**
Year-4 2616±1066 2559±1080 0.212** 1.22 1.07 - 1.40 0.003**
*adjusted for age, sex, race, prior antihypertensive treatment, losartan vs atenolol 
therapy, HCTZ use, body mass index, serum glucose and creatinine, baseline diastolic 
and systolic pressure
**also adjusted for baseline Cornell product and changes in diastolic and systolic pressure 
between baseline and year of measurement
9:30 a.m.
1030-74 The Prognostic Role of Nocturnal Blood Pressure in 
Dipper Hypertensives: Focusing on Absolute Values in 
Addition to Day to Night Variability
Dimitris Syrseloudis, Costas Tsiouﬁs, Vanessa Tzamou, Eirini Andrikou, Anastasia 
Mazaraki, Elli Stefanadi, Dimitris Soulis, Theodoros Papaioannou, Christodoulos 
Stefanadis, First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, 
Greece
Background: The absence of nocturnal blood pressure (BP) fall has been associated with 
accelerated target organ damage (TOD) in subjects with essential hypertension. Whether 
the blunted BP fall or the absolute values of nocturnal BP underlie this association is not 
elucidated. We investigated the effect of nocturnal hypertension in various indices of TOD 
among dipper subjects with essential hypertension
Methods: We studied 75 (50 male) subjects with stage I -II, newly diagnosed 
untreated essential hypertension. All subjects underwent ambulatory BP monitoring, 
echocardiographic examination, pulse wave velocity (PWV) estimation by a computerized 
method (Complior SP) and albumin to creatinine ratio (ACR) assessment, as the mean 
of two morning spot urine samples. Metabolic proﬁle determination was performed in 
one morning blood sample. The study population was divided in dipper nighttime 
hypertensives (NH, n=40) (if nighttime systolic BP q120 mmHg) and dipper nighttime 
normotensives (NN, n=35) (if nighttime systolic BP <120 mmHg)
Results: NH compared to NN did not differ regarding age, BMI and smoking habits, (p=NS 
for all cases). NH compared to NN were predominantly male (80% vs 51.4%, p= 0.01) and 
had increase waist to hip ratio (WHR) (by 0.04, p=0.02) and triglyceride levels (by 60 mg/
dl, p<0.0005). They also had higher values of 24h systolic and diastolic BP (by 20 and 6 
mmHg, respectively, p<0.0005 for both) and 24h pulse pressure (by 13 mmHg, p<0.0005).
NH compared to NN exhibited higher values of left ventricular mass index (LVMI) (by 12.8 
g/m2, p=0.008), PWV (by 0.8 m/s, p<0.008) and ACR (by 15 mg/g, p<0.004)
By multiple regression analysis models it was revealed that nocturnal systolic BP was 
independent predictor of all studied indices of TOD (LVMI , PWV, ACR) as well as low 
grade inﬂammation (hs-CRP).
9:30 a.m.
1030-70 Lipid Levels Prior to Pregnancy and During Gestation 
and the Association With Adverse Pregnancy 
Outcomes: Population Based Study
Victor Novack, Lena Novack, Arnon Wiznitzer, Soroka University Medical Center, Beer-
Sheva, Israel
Background: The present study evaluates lipids proﬁle changes before conception, 
during pregnancy in complicated and non-complicated pregnancies.
Methods: Study population consisted of 9,273 women without co-morbidities, with lipid 
proﬁles assessed between 12 months prior to gestation and delivery. Preconception 
triglycerides levelq150mg/dL and high density lipoproteins (HDL) level<50mg/dL were 
regarded as abnormal. During the pregnancy 75th and 25th percentiles for triglycerides 
and HDL for a respective gestational month were deﬁned as cut-off points. The effect of 
lipids proﬁle on adverse pregnancy and perinatal outcomes was estimated by a composite 
of preeclampsia and gestational diabetes mellitus (GDM).
Results: During the index pregnancy GDM was diagnosed in 636 women (6.3%), 
preeclampsia in 625 pregnancies (6.3%) and composite endpoint occurred in 1209 women 
(12.2%). Preconception hypertriglyceridemia (9.8%) and low HDL (55.7%) were associated 
with a signiﬁcantly increased relative risk (RR) of 2.21 and 1.76 of preeclampsia and RR of 
1.93 and RR of 1.72 of GDM (P<0.05 for all). Multivariate analysis showed that both pre-
conception HDL levels<50 mg/dL and triglycerides lq150 mg/dL are signiﬁcantly associated 
with the risk of the composite outcome (odds ratio of 1.86 and 1.72 respectively).
Lipid levels during gestation varied substantially with a nadir following conception and a peak 
prior to delivery. Pregnant women with triglyceridesq75th percentile adjusted for gestational 
age (895/3,524) had higher incidence of a composite endpoint, as compared to women with 
triglycerides levels between 25th and 75th percentile and <25th percentile: 22.0%, 10.8% and 
8.2% respectively, p<0.001. Mulitvariate analysis adjusted for maternal age, parity, history of the 
repeated abortions and infertility treatment showed that higher gestational triglycerides levels 
are associated with a risk of the composite endpoint: odds ratio 1.7 (95%CI 1.35-2.16).
Conclusions: Lipid level change substantially during gestation. Abnormal levels of 
HDL and triglycerides before or during pregnancy are associated with adverse perinatal 
outcomes.
9:30 a.m.
1030-71 Small Artery Structure During Long-Term Therapy Is 
an Independent Predictor of Cardiovascular Events in 
Uncomplicated Essential Hypertension
Michael N. Praestholm, Ole N. Mathiassen, Morten Fenger-Gron, Niels Henrik Buus, 
Inger Sihm, Niels Kristian Thybo, Birgitte Morn, Anne Pauline Schroeder, Kristian 
Thygesen, Christian Aalkjaer, Ole Lederballe, Michael J. Mulvany, Kent L. Christensen, 
Institute of Pharmacology, University of Aarhus, Aarhus, Denmark, Department of 
Medicine and Cardiology, Aarhus University Hospital, Aarhus, Denmark
Background: Hypertensive changes in small arteries occur early in the disease 
process and predict cardiovascular events in various populations of previously untreated 
hypertensive patients. Whether small artery changes during treatment carries prognostic 
information has not previously been investigated.
Methods: We conducted a follow-up survey of 134 moderate-risk patients with essential 
hypertension, who had gluteal biopsies taken and analyzed after twelve months of 
antihypertensive therapy. The cohort represented a total of 1410 years of follow-up.
Results: 26 patients suffered a cardiovascular event during follow-up. For the patient group with 
small artery media:lumen ratio (M:L) above the population mean value (q 0.075), the relative risk 
(RR) was 2.63 (p<0.05). Likewise for those with M:L above mean + 2 standard deviations of a 
normal population (q 0.098), the relative risk was signiﬁcantly elevated (RR=2.35, p<0.05).
Both results were adjusted for Heart Score (a 10-year mortality risk estimate integrating 
age, gender, smoking status, cholesterol level and systolic blood pressure). Patients with 
baseline M:L q 0.098 responding to treatment with a fall in M:L above the group mean had 
a borderline signiﬁcantly higher event-free survival than non-responders (p=0.074).
Conclusions: For the ﬁrst time, we have shown that structural changes in resistance 
arteries, measured after 12 months therapy, independently predict cardiovascular events 
in moderate-risk patients with essential hypertension. Small artery structural changes 
seem important to monitor during therapy, and may possibly be an important target for 
therapy to ensure correction of haemodynamics, to restore and normalize organ blood 
supply during therapy and ultimately to prevent cardiovascular events.
9:30 a.m.
1030-72 Valsartan Was Effective in Diabetic Patients and 
Reduced New-Onset Diabetes: Post-Hoc Analysis of 
JIKEI Heart Study
Katsunorik Ikewaki, Mitsuyuki Shimizu, Michihiro Yoshimura, Bjorn Dahlof, Seibu 
Mochizuki, National Defense Medical College, Saitama, Japan, Jikei University School 
of Medicine, Tokyo, Japan
Background: Renin-angiotensin-aldosterone system inhibition has been shown to beneﬁt 
diabetic patients as well as reduce the incidence of new-onset diabetes. However, it is not 
clear whether these effects are observed in Asian populations. We therefore performed 
post-hoc analysis to investigate the effects of valsartan, angiotensin receptor blocker 
(ARB), on cardiovascular outcomes in diabetic patients and the incidence of new-onset 
diabetes in JIKEI heart study.
Methods: As part of JIKEI heart study, a randomized, open-label, blinded endpoint 
morbidity-mortality study, we examined a group of 629 patients with diabetes who 
were assigned either to valsartan or to non-ARB treatment. Second, we assessed the 
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the hypothesis that the cardiac biomarker N-terminal pro-brain natriuretic peptide would be 
elevated in hypertensive disorders of pregnancy, with an increase in levels of this biomarker 
across increasing gradations of disease severity. Methods: We performed a case-control study 
of women admitted to labor and delivery at the Hospital of the University of Pennsylvania 
between 24 and 42 weeks of gestation. Cases were women with hypertension that developed 
after 20 weeks of gestation, and controls were normotensive women presenting for delivery. 
N-terminal pro-brain natriuretic peptide levels were compared between cases (n=83) and 
controls (n=290). Cases were sub-classiﬁed into gestational hypertension (n=20), mild (n=15) 
and severe preeclampsia (n=48), and N-terminal pro-brain natriuretic peptide levels were 
compared between these subgroups. Results: Our results demonstrated that N-terminal 
pro-brain natriuretic peptide levels were higher in cases than in controls (81 pg/ml versus 
37 pg/ml, p<0.001), with a graded increase in levels from gestational hypertension (64 pg/
ml) to preeclampsia (89 pg/ml) to severe, preterm preeclampsia (157 pg/ml) (p <0.001). 
Conclusions: We conclude that N-terminal pro-brain natriuretic peptide levels are increased in 
hypertensive disorders of pregnancy and discriminate between sub-categories of disease.
9:30 a.m.
1030-78 Characterization of Adipokines Synthesis in 
Subcutaneous, Femoral and Pericardial Adipose Tissue 
in Patients with Advanced Atherosclerosis: Effects on 
Arterial Blood Pressure
Constantinos Bakogiannis, Charalambos Antoniades, Dimitris Tousoulis, Alexios S. 
Antonopoulos, Antigoni Miliou, Constantinos Psarros, Nikolaos Koumallos, Nikos Sfyras, 
Costas Triantafyllou, George Ekonomopoulos, Themistoklis Psarros, Christodoulos Stefanadis, 
1st Department of Cardiology, Hippokration Hospital, Athens University Medical School, 
Athens, Greece, Department of Cardiac Surgery, Hippokration Hospital, Athens, Greece
Background: Adipokines such as interleukin-6 (IL-6), monocyte chemoattractant protein 
1 (MCP-1), and adiponectin are synthesised in adipose tissue (AT) and may affect the 
development of hypertension. We characterised the synthesis of these adipokines in 
subcutaneous, femoral and pericardial AT of patients with advanced atherosclerosis, and 
we examined their impact on arterial blood pressure.
Methods: Fifty patients undergoing elective CABG (14 hypertensives, 36 non-
hypertensives) were recruited. Subcutaneous AT was collected from the site of CABG 
insertion, femoral AT was collected from the area surrounding the saphenous vein 
(perivascular) and pericardial AT was collected from the site close to the right ventricle. AT 
was transferred to the lab within 30 minutes and was cultured ex-vivo for 4 hours. MCP-1, 
IL-6 and adiponectin were measured in AT culture supernatants by ELISA.
Results: Pericardial AT was associated with higher IL-6 (14.7±1.8 vs 10.0±1.5 pg/mg 
p<0.05), MCP-1 (7.07±1.2 vs 2.7±0.6 pg/mg p<0.05) and adiponectin (229.5±15.9 vs 
168.9±19.3 pg/mg p<0.05). Importantly, hypertension was not associated with femoral IL-6 
(10.9±1.3 vs 11.9±2.2 pg/mg p=NS), subcutaneous IL-6, (6.9±1.0 vs 8.4±2.1 pg/mg p=NS), 
femoral MCP-1 (5.7±0.8 vs 4.0±1.1 pg/mg p=NS), femoral adiponectin (174±34 vs 221±26 
pg/mg p=NS), subcutaneous MCP-1 (2.37±0.29 vs 3.3±1.5 pg/mg p=NS) or subcutaneous 
adiponectin (175±18 vs 182±23.2 pg/mg p=NS) AT synthesis. Diastolic (but not systolic) 
blood pressure was strongly correlated with IL-6 in femoral (rho=0.492, p=0.038) and 
subcutaneous (rho=0.659, p=0.04) but not pericardial (rho=0.386, p=NS) AT.
Conclusions: Adipokines (IL-6, MCP-1 and adiponectin) synthesised in pericardial 
adipose tissue are closely associated with the presence of arterial hypertension in 
patients with advanced atherosclerosis. However, adipokines synthesised in femoral and 
subcutaneous adipose tissue are strongly associated with the variability of diastolic but 
not systolic blood pressure.
9:30 a.m.
1030-79 Abnormal Geometry With Increased Left Ventricular 
Mass and Not Concentric Remodelling Is Associated 
With Abnormal Left Ventricular Function in 
Hypertensives: A Population Study
Navtej Chahal, Tiong K. Lim, Piyush Jain, John C. Chambers, Jaspal S. Kooner, Roxy 
Senior, Northwick Park Hospital, Harrow, United Kingdom, Imperial College London, 
London, United Kingdom
Background: Remodelling of the left ventricle (LV) is associated with adverse 
cardiovascular events but the mechanism of these effects remains undeﬁned. We 
investigated the relationship of abnormal LV geometry to LV function in a large cohort of 
hypertensive subjects.
Methods: We studied 1,075 hypertensives recruited from the London Life Sciences 
Prospective Population (LOLIPOP) cohort study. Subjects with cardiovascular disease 
were excluded. All subjects underwent echocardiography (Philips IE33) for derivation of 
left atrial volume index (LAVI) and LV mass index (LVMI). The tissue Doppler parameters 
of peak systolic velocity (Sa), diastolic velocity (Ea) and the ratio of Ea to transmitral E 
wave (E/Ea) were measured. Using regional wall thickness subjects were categorised 
as having either: concentric hypertrophy (CH); eccentric hypertrophy (EH); concentric 
remodelling (CR) or normal geometry.
Results: Abnormal LV geometry was present in 424 individuals. Ea was signiﬁcantly 
lower and E/Ea higher amongst subjects with CH, EH and CR compared to controls 
(table1). After adjustment for age, race, sex, BP and anti-hypertensives (ANCOVA) these 
differences persisted in subjects with CH and EH (p<0.001). Differences in LAVI and 
Sa were observed only in those with EH and CH which remained after adjustment for 
covariates (p<0.001 for LAVI, p=0.04 for Sa).
Conclusion: In hypertensives abnormal geometry with increased LV mass, and not 
concentric remodelling, is associated with abnormal LV function.
Conclusion: Nocturnal hypertension even in the setting of dipper hypertensive subjects is 
accompanied by pronounced target organ damage. These ﬁndings accentuate the importance 
of the amount of nocturnal BP reduction as regards the risk stratiﬁcation in hypertension.
9:30 a.m.
1030-75 Erectile Dysfunction Is Accompanied by an Impairment 
of Left Ventricular Diastolic Properties in Male 
Hypertensives
Apostolis Kakkavas, Costas Tsiouﬁs, Dimitris Tsiachris, Eirini Andrikou, Panayiotis 
Agelopoulos, Athanasios Trikas, Ioannis Kallikazaros, Christodoulos Stefanadis, First 
Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
Background: Males with erectile dysfunction (ED) are at greater cardiovascular risk. Our 
aim was to investigate the impact of ED status on left ventricular (LV) structural and 
functional adaptations in males with essential hypertension.
Methods: We studied 142 consecutive, newly diagnosed and untreated, hypertensive males 
(mean age=50.6 years, ofﬁce BP=151/98mmHg). All subjects were non-diabetics, without any 
clinical evidence of atherosclerotic disease and were divided by means of the International 
Index of Erectile Function score (IIEF-score) into those with ED (IIEF-score<26, n=43, 30.3%) 
and those without ED (IIEF-scoreq26, n=99). All participants underwent 24hour ambulatory 
BP monitoring and complete echocardiographic study including left ventricular (LV) diastolic 
function evaluation by means of tissue Doppler Imaging (TDI), averaging diastolic mitral 
annular velocities (Em, Am) from 4 separate sites of measurement.
Results: Hypertensive men with ED compared to those without ED were older (54±9 
vs. 49±7 years, p<0.05) and exhibited lower ofﬁce diastolic BP (94.5 vs. 98.7 mmHg, 
p=0.031), 24hour diastolic BP (80.7 vs. 84.9 mmHg, p=0.014) and greater 24hour pulse 
pressure (50.5 vs. 47.1 mmHg, p=0.030) whereas no difference occurred regarding 
smoking status, body mass index and metabolic proﬁle (p=NS for all). The two groups 
did not also differ with respect to LV mass index, left atrial diameter and transmitral ﬂow 
derived E/A (p=NS for all). In contrast, hypertensives with ED had signiﬁcantly lower 
TDI derived Em and Em/Am (7.2 vs. 8.5 cm/s, p=0.003 and 0.70 vs. 0.81, p=0.031, 
respectively) and higher E/Em (10.4 vs. 8.8, p=0.011) even after adjustment for age. In the 
entire study population, score ED was positively correlated with Em (r=0.241, p=0.010), 
Em/Am (r=0.227, p=0.015) and negatively with E/Em (r=-0.194, p=0.039) and 24hour 
pulse pressure (r=-0.259, p=0.005).
Conclusions: Hypertensive males with ED compared to those without ED are 
accompanied by more deteriorated diastolic function and higher LV ﬁlling pressures 
related with increased ambulatory pulsatile load. The above ﬁndings may contribute to 
the interpretation of ED-related cardiovascular risk.
9:30 a.m.
1030-76 Introducing the Role of Relaxin in Hypertension: 
Association With Cardiovascular Damage
Dimitris Tsiachris, Costas Tsiouﬁs, Alexandra Gennadi, Maria Selima, Kyriakos 
Dimitriadis, Dimitris Syrseloudis, Dimitris Tousoulis, Christodoulos Stefanadis, First 
Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
Background: Relaxin is emerging as a hormone with antiﬁbrotic, anti-inﬂammatory 
and vasodilatory actions. Our purpose was to examine association of relaxin with 
cardiovascular parameters in the setting of essential hypertension (EH).
Methods: Our population consisted of 80 newly diagnosed untreated non-diabetics 
with stage I/II EH (46 men, aged 51 years, ofﬁce blood pressure (BP) =151/99 mmHg). 
All participants underwent ambulatory BP monitoring, complete echocardiographic 
examination and aortic stiffness evaluation on the basis of carotid to femoral pulse 
wave velocity (PWV), by means of a computerized method (Complior SP). Venous blood 
samples were drawn for estimation of lipid proﬁle and relaxin levels. The distribution of 
relaxin was split by the median (4.33 pg/ml) and accordingly subjects were stratiﬁed into 
those with high and low values.
Results: Patients with high relaxin (n=41) compared to those with low relaxin (n=39) 
values did not differ with respect to age, sex, 24 hour ambulatory BP parameters and 
metabolic proﬁle while they exhibited greater ofﬁce diastolic BP (102.1±8 vs. 97±7 mmHg, 
p=0.005) and lower plasma glucose levels (93±11 vs. 99±13 mg/dl, p<0.05). Regarding 
echocardiographic parameters, left ventricular mass index and relative wall thickness 
were not different between the two groups, as well as transmitral ﬂow E/A ratio and tissue 
Doppler imaging derived Em, Em/Am and E/Em ratios (p=NS for all cases). Hypertensives 
with high relaxin compared to those with low relaxin had decreased left atrial (LA) volume 
(33.8±11 vs 41.4±11 ml, p<0.05), LA volume index (18±6 vs. 21.5±5.4 ml/m2, p<0.05) 
and lower PWV (8.7±1.2 vs 9.45±1.6 m/sec, p<0.05). In the total population relaxin was 
negatively correlated with LA volume (r=-0.310, p=0.048) and PWV (r=-0.251, p=0.044) 
and positively with ofﬁce diastolic BP (r=0.240, p=0.032).
Conclusions: In hypertensive subjects, increased relaxin levels are associated with 
favourable cardiovascular phenotype, as reﬂected by decreased aortic stiffening and LA 
dimensions. This ﬁnding further supports the potential role of relaxin as a factor with 
cardioprotective properties, with future therapeutic implications.
9:30 a.m.
1030-77 N-Terminal Pro-Brain Natriuretic Peptide as a Biomarker 
for Hypertensive Disorders of Pregnancy
Nazanin Moghbeli, Sindhu Srinivas, Jamie Bastek, Yun Lu, Mary Putt, Thomas Cappola, 
Michal Elovitz, University of Pennsylvania, Philadelphia, PA
Background: Hypertensive disorders of pregnancy contribute to signiﬁcant maternal 
morbidity. These disorders encompass a broad spectrum of clinical phenotypes, ranging from 
asymptomatic hypertension to severe preeclampsia with multi-organ dysfunction. We tested 
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1030-82 The Central Systolic Loading Response to Light 
Exercise Is Signiﬁcantly Impaired in Patients With Type 
2 Diabetes and Remains Unchanged After Four Weeks 
of Exercise Training
Matthew D. Hordern, Thomas H. Marwick, David J. Holland, Jeff S. Coombes, James E. 
Sharman, The University of Queensland, Brisbane, Australia
Background: Patients with type 2 diabetes (T2DM) often have a hypertensive response 
to maximal exercise, but little is known on the response to light exercise similar to daily 
living. This study aimed to compare light exercise central hemodynamics in patients with 
T2DM, with matched controls and to examine the effects of exercise training.
Methods: Brachial BP and central BP (radial tonometry) was measured during light 
cycle exercise (60% of max heart rate) in 42 T2DM patients and 21 controls. Systolic 
loading was estimated by radial and central augmentation index (AIx). Exercise variables 
were also assessed in T2DM patients following randomisation to four weeks of moderate 
intensity exercise training (n=28) or usual care (n=14).
Results: Despite no signiﬁcant differences between T2DM patients and controls in 
heart rate or brachial BP during exercise, the central and peripheral AIx response to 
light exercise in T2DM patients was signiﬁcantly impaired compared to controls (table). 
Exercise training had no signiﬁcant effect on resting or exercise hemodynamic indices, 
despite signiﬁcantly (p=0.03) increasing cardiorespiratory ﬁtness (data not shown).
Conclusions: Patients with T2DM have an impaired central systolic loading response 
to light exercise. The ineffectiveness of 4 weeks of exercise training in accordance with 
guidelines for reversing these abnormal exercise hemodynamics suggests that these 
changes may be more likely related to arterial structure than function. 
Comparison of haemodynamic variables at rest and light exercise 
between groups
Healthy Controls (n=21) T2DM (n=42) p
Rest Exercise Rest Exercise
Heart rate (bpm) 62 ± 8 101 ± 7 83 ± 11 98 ± 7 0.07
Systolic BP (mmHg) 124 ± 13 159 ± 19 139 ± 21 157 ± 23 0.70
Diastolic BP (mmHg) 78 ± 9 81 ± 9 82 ± 10 81 ± 11 0.98
Mean Pressure (mmHg) 93 ± 10 107 ± 11 101 ± 11 108 ± 14 0.90
Radial AIx (%) 84.5±16.6 64 ± 16 81.3±15.3 76 ± 14.1 0.02
Central AIx (%) 21.2± 13.1 12 ± 14 19.7± 10.5 20 ± 11 0.01
Data are mean ± SD
9:30 a.m.
1030-83 Ofﬁce Blood Pressure Is a Predictor of Subclinical 
Renal Damage in Patients With White Coat 
Hypertension
Konstantinos Aznaouridis, Charalambos Vlachopoulos, Gregory Vyssoulis, Eva 
Karpanou, Nikolaos Alexopoulos, Christodoulos Stefanadis, 1st Cardiology Department, 
Hippokration Hospital, Athens Medical School, Athens, Greece
Background: Renal function and urinary protein excretion are considered as independent 
predictors of cardiovascular outcomes in hypertensive patients. White coat hypertension 
(WCH) has been related to increased target organ damage and cardiovascular risk 
compared with subjects with normal ofﬁce blood pressure (BP). We hypothesized that 
the BP surge during the ofﬁce visits is a better determinant of renal function than the 
ambulatory BP in patients with WCH.
Methods: We studied 440 consecutive untreated non-diabetic patients (172 men, 268 
women, age 52.5±12.3 years old) with WCH (ofﬁce BP >140/90 mmHg, mean daytime 
ambulatory BP <135/85mmHg). All participants were Caucasians and had a serum 
creatinine level < 1.5 mg/dL. In 24-hour urine collection, albumin excretion and albumin/
creatinine ratio (ACR) were measured as markers of glomerular function and urinary A1-
microglobulin was measured as a marker of renal tubular function.
Results: Overall, the mean systolic BP (SBP) /diastolic BP was 158±9/98±7 mmHg 
and the mean daytime ambulatory BP was 124±8/77±5 mmHg. The mean GFR was 
81.7±20.3 ml/min/1.73m2 and the mean urinary albumin, ACR and A1-microglobulin 
were 12.0±8.7 mg/24h, 15.4±10.5 mg/g and 4.8±1.9 mg/24h respectively. In univariate 
analysis, ofﬁce SBP correlated signiﬁcantly with GFR (r= -0.252, P<0.001), albumin (r= 
0.134, P=0.005), ACR (r= 0.199, P<0.001) and A1-microglobulin (r= 0.118, P=0.013). 
In contrast, mean ambulatory SBP did not correlate with any of the above markers of 
urinary protein excretion (all P>0.5). Multivariable analysis including age, gender, BMI 
and smoking status as covariates showed that ofﬁce SBP is an independent determinant 
of albumin (B= 0.155, P=0.001), ACR (B= 0.203, P<0.001) and A1-microglobulin (B=
0.111, P=0.019).
Conclusions: In non-diabetic WCH individuals, ofﬁce SBP is a predictor of subclinical 
glomerular and tubular renal damage. This ﬁnding suggests that the BP surge during the 
ofﬁce visits may be a marker of cardiovascular risk in subjects with WCH
Table 1 - LV remodelling and LV function ( * p<0.01, ** p<0.05 - ANOVA, 
contrast to normals)
LV 
geometry n
age 
(years)
systolic BP 
(mmHg)
diastolic 
BP 
(mmHg)
Mean no. 
of anti-
hypertensives
LAVI 
(ml/
m2)
Sa 
(cm/s)
Ea 
(cm/s) E/Ea
CH 73 62.2 ± 8.0 *
147.6 ± 
20.0 *
86.6 ± 
12.3 0.84
20.8 ± 
7.5*
8.5 ± 
1.6*
7.4 ± 
1.8*
9.5 ± 
2.6*
EH 213 62.2 
±8.3 *
147.6 ± 
18.2 *
85.7 ± 
10.2 0.90 **
22.4 ± 
8.2*
8.7 ± 
1.9*
8.1 ± 
2.0*
9.2 ± 
2.9*
CR 138 62.5 ± 8.5 * 146.5 ± 20.7
86.2 ± 
11.8 0.82
17.3 ± 
5.1
9.1 ± 
1.8
8.0 ± 
1.8**
9.0 ± 
2.4**
Normal 651 58.6 ± 9.2 142.9 ± 16.5 86.2 ± 9.5 0.69 17.0 ± 5.6
9.0 ± 
1.7
8.8 ± 
1.9
8.3 ± 
2.2
9:30 a.m.
1030-80 Effect of Waist Circumference Reduction on Blood 
Pressure in Stage I Hypertensive Normal Weight 
Obeses
Roberto Fogari, Giuseppe Derosa, Annalisa Zoppi, Luca Corradi, Paola Preti, Amedeo 
Mugellini, Pierangelo Lazzari, Department of Internal Medicine, University of Pavia, 
Pavia, Italy
Background: to evaluate the role of waist circumference (WC) reduction on blood 
pressure (BP) in normal weight obese stage 1 hypertensive patients.
Methods: we studied 295 normal weight obese [BMI < 25 Kg/m2, and WC q 94 cm in 
men and q 80 cm in women] stage 1 hypertensive outpatients (SBP > 140 < 160 mmHg 
and DBP > 90 < 100 mmHg) never treated for hypertension. They were given appropriate 
dietary advice and standardized physical activity with the aim to achieve a WC < 94 cm in 
men and < 80 cm in women in 6 months. The patients who achieved this reduction were 
followed for further 6 months and BP, body weight (BW) and WC were measured every 
month. At baseline and after 6 and 12 months of the treatment 24-h ambulatory BP was 
evaluated and venous blood sample was drown to evaluate plasma leptin, active renin 
and aldosterone.
Results: a WC normalization (< 94 cm in men and < 80 cm in women) was achieved 
by 156 (54.4 %) of the enrolled patients, with a mean WC reduction of 5.2 ± 1.3 cm. In 
these 156 patients, SBP and DBP signiﬁcantly lowered (-6.7 ± 2.5/.4.2 ± 1.2 mmHg, 
respectively, p< 0.01 for both) and their changes showed a linear relationship (p< 0.01) 
with WC changes. There was also a signiﬁcant reduction in plasma leptin (from 9.2 ± 4.1 
to 6.9 ± 3.2 ng/ml, p< 0.05), active renin (from 7.2 ± 4.6 to 5.7 ± 2.8 ng/l, p< 0.05), and 
aldosterone (from 0.7 ± 0.3 to 0.4 ± 0.1 ng/l, p< 0.01). Ninety nine (48%) of the subjects 
with WC normalization showed a BP normalization (< 140/90 mmHg). Plasma leptin, 
active renin, and aldosterone decreases were not different from those of the 105 patients 
who did not achieve the BP normalization despite the same WC reduction.
Conclusions: in normal weight obese stage 1 hypertensive patients the WC 
normalization induced a signiﬁcantly decreases in BP as well in plasma leptin, active 
renin, and aldosterone with a signiﬁcant relationship between BP and WC changes. BP 
normalized in 48% of the patients achieving a WC normalization, despite a reduction in 
plasma leptin, active renin, and aldosterone similar to that of patients whose BP did not 
normalize. These data suggest that hypertension in this type of patients should not be 
always considered as “essential”, because in half of them it seems to be “secondary to 
central obesity”.
9:30 a.m.
1030-81 Noninvasive Flow-Indexed Blood Pressure Is Superior 
to Stand-Alone Blood Pressure in Predicting Heart 
Failure: Data From the Heart and Soul Study
Robert Morlend, Ramin Farzaneh-Far, Bee Ya Na, Nelson B. Schiller, Mary A. Whooley, 
Department of Medicine, University of California, San Francisco, San Francisco, CA
Background: Blood pressure is a prototypical noninvasive hemodynamic measurement 
that has been pivotal in guiding therapy and estimating prognosis among patients with 
coronary artery disease. Since, at any given systemic arterial resistance, the magnitude 
of blood pressure is ﬂow-mediated, we hypothesized that its prognostic value may be 
improved by a correction that reﬂects cardiac output at the time of measurement. We 
sought to compare mean arterial pressure (MAP) with the ratio of MAP to left ventricular 
outﬂow tract (LVOT) velocity time integral (VTI) as predictors of heart failure (HF).
Methods: A total of 1014 patients with stable coronary disease completed Doppler 
echocardiography as part of the Heart and Soul Study. We measured resting MAP using 
a brachial cuff and estimated ﬂow-indexed blood pressure as the ratio of resting MAP to 
VTILVOT. Cox proportional hazards models were used to estimate the risk of subsequent 
hospitalization for HF. C-statistics were obtained to compare MAP to MAP/VTILVOT as 
continuous predictors of HF.
Results: Of the 1014 participants, 131 (13%) developed HF during 4.8 years of follow-up. 
The age- and sex- adjusted C-statistic for MAP/VTILVOT as a predictor of hospitalization 
for HF was 0.70, compared with 0.63 for MAP (p=.003). Each standard deviation (SD 
= 115-points) increase in MAP/VTILVOT was associated with a 40% increased rate of 
developing HF (HR per SD 1.4, 95% conﬁdence interval 1.1-1.7; p=.001), adjusting for 
age, sex, race, body mass index, smoking, history of diabetes, hyperlipidemia, stroke or 
HF, systolic and diastolic blood pressure, LV ejection fraction, diastolic function and NT-
proBNP. In contrast, MAP was not associated with subsequent risk of HF (HR per SD 1.0, 
95% conﬁdence interval 0.9-1.2; p=.82).
Conclusions: A noninvasive measurement of ﬂow-indexed blood pressure provides 
better prognostic information for HF hospitalization than MAP alone.
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10 males) with angina, who received elective coronary angiography, were enrolled. 
Central aortic pressure obtained with a ﬂuid-ﬁlled catheter placed in the aortic root. We 
simultaneously measured right brachial pressure, and carotid arterial pulse wave non-
invasively using automated vascular testing device (VP-2000). In a subset (n=15), we 
immediately measured radial arterial pulse waves by an applanation tonometry-based 
automated device (HEM-9000AI). Estimated central arterial pressure (c-SBPca) was 
calculated using carotid augmentation index (c-AI) and brachial pressure (c-SBPca = 
1.06*{(0.0065c-AI + 0.53)*brachial pulse pressure + brachial diastolic pressure}+7.4). In 
addition, nineteen patients were prospectively analysed.
Results:The a-SBP correlated well with c-SBPca, central arterial pressure calculated with 
radial pulses (c-SBPra), early and late estimated radial pressure (r-SBP and r-SBP2), and 
brachial pressure (br-SBP) (Table 1).
Conclusions: Non-invasively automatic carotid arterial pressure waveform analysis with 
ordinary measurement of brachial blood pressure may be more accurately applied method 
to assess invasively measure systolic blood pressure and augmentation in the aorta .
Initail (n=26) Prospective (n=19) Total (n=45)
Mean ± SD r Mean ± SD r Mean ± SD r
a-SBP 135±20 - 138±24 - 137±22 -
c-SBPca 127±19 0.882 128±21 0.884 128±20 0.882
c-AI 23±15 - 20±20 - 22±17 -
a-AI 27±12 0.843 25±16 0.948 26±14 0.902
r-AI 68±20 0.536 76±23 0.813 71±21 0.693
9:30 a.m.
1030-87 Exercise Capacity Is Inversely Associated With 
Mortality Risk in Prehypertensive Men
Andreas Pittaras, Puneet Narayan, Jonathan Myers, Charles Faselis, Joshua Abella, 
Athanasios Manolis, Steven Singh, Peter Kokkinos, VAMC, Washington, DC, Mediton, 
Athens, Greece
Background: Epidemiologic evidence supports an inverse and strong association 
between ﬁtness status, and mortality in healthy individuals. Pre-hypertensive individuals 
are at increased risk for cardiovascular events compared to those with normal blood 
pressure. However, there is no information on the association between exercise capacity 
and mortality in pre-hypertensive individuals.
Methods: We assessed the association between peak exercise capacity (METs) and 
all-cause mortality in pre-hypertensive men (n=4,735; age=56±12) at twoVeterans 
Affairs Medical Centers. We established four ﬁtness categories based on the MET level 
achieved. Those who achieved <5 METs (n=674); 5-7 METs (n=1,170); 7.1 to 10 METs 
(1,784); and > 10 METs (n= n=1,107). There were 943 deaths over 22 years of follow-up 
(mean=8.0±5.5).
Results: After adjusting for age, BMI, diabetes and dyslipidemia, exercise capacity was 
the strongest predictor of risk for mortality. The adjusted risk was reduced by 14% for 
every 1-MET increase in exercise capacity (Hazard Ratio= 0.86; CI: 0.84-0.88; p<0.001). 
When compared to those who achieved a5 METs, the mortality risk in those who achieved 
5.1-7 METs was 25% lower (hazard ratio= 0.75; CI: 0.64-0.87; p<0.001); 60% lower for 
those who achieved 7.1-10 METs (hazard ratio= 0.40; CI: 0.33-0.48; p<0.001), and 75% 
lower for those achieving >10 METs (Hazard Ratio= 0.25; CI: 0.19-0.33; p<0.001).
Conclusions: The association between exercise capacity and mortality in pre-
hypertensive individuals was strong, inverse and graded. The mortality risk was lowered 
by 14% for each 1-MET increase in exercise capacity. The overall reduction in mortality 
was 25% to 75% for those with an exercise capacity of >7 METs compared to those who 
achieved <5 METs.
9:30 a.m.
1030-88 The Determination of Local Pulse Wave Velocity and 
Wave Intensity in the Human Carotid Artery: A New 
Noninvasive Technique
Ashraf W. Khir, Nearchos Hadjiloizou, Justin E. Davies, Jamil Mayet, Darrel P. Francis, 
Alun D. Hughes, Brunel University, Uxbridge, United Kingdom, Imperial College, 
London, United Kingdom
Background: Local Pulse Wave Velocity (PWVL) and Wave Intensity (WI) are used 
to assess arterial stiffness and the arrival time of reﬂected waves; indices of clinical 
importance. We present a new non-invasive analysis which directly uses ﬂow velocity (U) 
and arterial diameter (D) measurements for the determination of PWVL and WI.
Methods: From the water hammer equation it can be shown that
PWVL=(D/2)(dU±/dD±) where dU and dD are the changes in U and D, and ± indicates 
the forward and backward directions. Plotting U against D produces the DU-loop whose 
slope in the absence of reﬂection during the early part of systole is related to PWVL. The 
separation of WI can also be determined using WI
±
=dD
±
dU
±
=±(c/2D)(dD±DdU/2c)2 where 
c is PWVL. We studied 28 patients (58±15 years, 21 male) with good systolic function 
(EF>55%) and no valve disease. We measured U and D in the left carotid artery using 
Doppler ultrasound and a wall tracking system (Aloka, SSD-5500). ECG was recorded 
and data were sampled at 1kHz. Measurements were taken before and 6 weeks after 
Percutaneous Coronary Intervention (PCI). Statistics were made using paired t-test and 
p<0.05 was considered statistically signiﬁcant.
Results: Results of the new technique are in agreement with other approaches for 
determining PWVL and WI. PWVL in patients > 50 years (n=11) was higher than in patients 
< 50 years by 20% (7.3±3.8 vs. 6.1±2.5 m/s, p<0.05). PWVL was higher before than 
after PCI by 21% (5.98±2.2 vs. 4.7±1.8 m/s, p< 0.05). WI pattern determined by the 
new non-invasive technique using D and U, closely resembles that measured by invasive 
techniques using P and U. Reﬂected waves in patients > 50 years arrived earlier than 
in patients <50 years by 35% (0.06±0.01 vs. 0.04±0.008 s, p<0.05). Neither the size of 
9:30 a.m.
1030-84 A Point System Table to Estimate the Risk of 
Cardiovascular Events in Patients With Hypertension 
and Left Ventricular Hypertrophy. The Losartan 
Intervention For Endpoint Reduction in Hypertension 
(LIFE) Study
Darcy Hille, Sverre E. Kjeldsen, Björn Dahlöf, Jonathan M. Edelman, Richard B. 
Devereux, Merck & Co., Inc., North Wales, PA
Background: We assessed readily available patient characteristics, including albuminuria 
(not included in traditional cardiovascular risk scores), as predictors of cardiovascular 
events in patients with hypertension and left ventricular hypertrophy (LVH) and to develop 
risk algorithms for outcomes.
Methods: A Cox proportional hazards model identiﬁed baseline variables that had a 
signiﬁcant impact on the occurrence of the primary composite endpoint (cardiovascular 
death, stroke, and myocardial infarction) in 9193 patients with hypertension and LVH 
enrolled in the LIFE study. A point table was developed which assigned points to various 
levels of the risk factors, including interaction terms, by adapting the point system 
algorithm developed by Sullivan (2004).
Results: The Cox model identiﬁed age, sex, smoking, log urinary albumin:creatinine ratio, 
total cholesterol, history of stroke, diabetes, atrial ﬁbrillation, ischemic heart disease, 
degree of LVH, exercise, and age-sex interaction to be signiﬁcant predictors of the risk 
for the composite endpoint. Points for age were calculated separately for females and 
males due to interaction. Points for age (55 to 80 years) ranged from -2 to 10 for females 
and from 5 to 11 for males, compared to 4 points for elevated abuminuria. Risk estimates 
deﬁned by point totals were compared to risk estimates deﬁned by the Cox model; the 
weighted kappa for agreement was 0.89.
Conclusions: A number of patient characteristics predicted cardiovascular events in patients 
with hypertension and LVH, with age, gender and albuminuria the most important. The point 
table represents an intuitive method to compare the relative contribution of the risk predictors 
and to communicate a complicated statistical model to clinicians and patients.
9:30 a.m.
1030-85 Readmission in Patients With Acute Severe 
Hypertension Is Common and Predictable: The 
Studying the Treatment of Acute hyperTension Registry
Joel M. Gore, Jason Katz, Kurt Kleinschmidt, Allison Wyman, Frank Peacock, Frederick 
A. Anderson, Christopher B. Granger, on behalf of the STAT Investigators, University 
of Massachussetts Medical School, Worcester, MA, Duke Clinical Research Institute, 
Durham, NC
Background: Few studies have evaluated predictors of hospital readmission in acute 
hypertension.
Methods: The Studying the Treatment of Acute hyperTension (STAT) registry enrolled 
consecutive patients with blood pressure >180/110 mmHg, or >140/90 mmHg for 
subarachnoid hemorrhage, who received IV antihypertensive therapy in critical care 
settings.
Results: Of the 1588 patients enrolled from 25 US hospitals, 7% died in hospital. Of the 
1415 patients alive at discharge who had 90-day follow-up, 5% died during follow-up and 
37% were readmitted. Median age (57 v 58 y), female sex (49% v 49%) and Black race 
(63% vs 57%) were similar between patients with and without readmission, respectively. 
Of the patients readmitted, 18% were within 1 week of index admission, 53% from 1-8 
weeks, and 28% from 8 weeks to 90 days. Medication nonadherence contributing to the 
index admission did not differ in readmitted vs nonreadmitted patients (30 vs 26%, p=.07). 
The 2 strongest independent predictors of readmission were history of chronic kidney 
disease and prior hospitalization for HTN (Table). One-quarter of readmissions were for 
recurrent severe HTN; for these patients, prior hospitalization for HTN, admitting diagnosis 
of HTN, and history of drug abuse were the strongest predictors of rehospitalization. 
Multivariable predictors of readmission
Index hospitalization p-value Odds ratio 95% conﬁdence interval
History of chronic kidney disease <0.0001 1.75 1.32 - 2.32
Prior hospitalization for hypertension <0.001 1.76 1.32 - 2.34
History of cardiac disease 0.001 1.57 1.20 - 2.05
Presented with seizures 0.003 3.06 1.47 - 6.37
Admitted with hemorrhagic stroke 0.01 0.37 0.17 - 0.82
Admitted with subarachnoid hemorrhage 0.03 0.52 0.29 - 0.95
History of drug abuse 0.04 1.43 1.01 - 2.01
Conclusions: STAT provides a contemporary view of acute severe HTN, including high 
rates of readmission, particularly among patients with renal disease, prior hospitalization 
for HTN, and cardiac disease.
9:30 a.m.
1030-86 Estimation of Central Aortic Pressure Using Automated 
Carotid Arterial Tonometry
Un-Jung Choi, Jung-Won Hwang, Hyoung-Mo Yang, Jin-Sun Park, Hong-Seok Lim, 
Soo-Jin Kang, Byung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, 
Seung-Jea Tahk, Joon-Han Shin, Department of Cardiology, Ajou University Medical 
Center, Suwon-si, South Korea
Background:The aim of this study was to evaluate whether automated carotid pressure 
wave analysis can provide information comparable with central aortic and radial arterial 
pulse wave analyses.Methods:Twenty-six patients (mean age: 63 ± 11 years-old, 
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9:30 a.m.
1030-91 Cardiovascular Comorbidities and Blood Pressure 
Control in Stroke Survivors
Manoj Kesarwani, Alejandro Perez, Victor A. Lopez, Nathan D. Wong, Stanley S. 
Franklin, University of California, Irvine, CA
Background: Hypertension (HTN) is the most important modiﬁable risk factor for 
secondary stroke prevention. However, there is uncertainty as to the relationship between 
cardiovascular comorbidities and optimal control of HTN in stroke survivors.
Methods: In the National Health and Nutrition Examination Survey from 1999 to 2004, 495 
stroke survivors (projected to 4.98 million in the United States), aged 20 years or older, 
were characterized by cardiovascular risk factors and comorbidities. HTN prevalence, 
treatment, and control rates were determined, and logistic regression was performed to 
examine the likelihood of stroke, according to the presence of comorbidities.
Results: Stroke survivors were 59.4% women, 57.1% age 65 years or older, 66.2% 
overweight/obese, 25.1% current smokers, 75.1% hypertensive, and 79.3% were with 
additional comorbidities, including diabetes mellitus (24.7%), coronary artery disease 
(28.8%), chronic kidney disease (25.3%), heart failure (16.5%), and peripheral arterial 
disease (10.9%). The odds (and 95% conﬁdence intervals) of prevalent stroke were 2.2 
(1.5-3.2), 5.0 (3.2-7.8), 4.1 (2.1-7.8), and 10.0 (4.8-20.9) with 1, 2, 3, and 4 or more 
comorbidities, respectively. Of these high-risk stroke survivors with comorbidities and 
HTN, 18% were not receiving antihypertensive therapy; of those receiving therapy, 75% 
did not meet a systolic blood pressure goal of <130 mm Hg and, on average, were 25 
mm Hg above this target.
Conclusion: A high percentage of stroke survivors have multiple cardiovascular risk 
factors, numerous comorbidities, and poor control of HTN, placing them at increased 
risk for further complications. Therefore, greater efforts must be made to reduce elevated 
blood pressure in these high-risk persons.
ACC.ORAL CONTRIBUTIONS
904
Arterial Function: Pulse Wave Velocity 
and Stiffness
Monday, March 30, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W308A
10:30 a.m.
0904-3 Wave Reﬂection Remains Important to Age-Related 
Aortic Blood Pressure Elevation Across the Human 
Lifespan
Mayooran Namasivayam, Barry J. McDonnell, Carmel M. McEniery, Michael F. 
O’Rourke, University of New South Wales, Sydney, Australia, University of Cambridge, 
Cambridge, United Kingdom
Background: Aortic systolic and pulse pressure (ASP and APP respectively) rise with 
age due to aortic stiffening. Two factors are responsible: 1) premature wave reﬂection 
and 2) larger incident wave due to increased aortic characteristic impedance. This study 
aimed to identify the relative contribution of each factor before and after age 60.
Methods: Aortic pressure waveforms were generated for 3682 healthy subjects using 
a generalized transfer function applied to radial pressure waveforms recorded by 
applanation tonometry. Product of coefﬁcient mediation analysis was performed in the 
cross-sectional cohort in order to determine the change in ASP and APP per year of 
life due to the reﬂected and incident waves (waves measured as augmented pressure 
and 1st systolic peak, respectively). This was done separately for subjects a60 and >60 
years (n=2311 and 1371 respectively). Analyses were repeated with correction for height, 
weight, heart rate and mean arterial pressure.
Results: The reﬂected wave (RW) was the key contributor to age-mediated ASP and 
APP elevation a60 years, with no signiﬁcant contribution of the incident wave (IW) in this 
age group. After age 60, both RW and IW were signiﬁcant and comparable contributors 
(Figure). This pattern persisted after correction for confounders.
Conclusions: Up to age 60, RW is the key contributor to age-related ASP and APP 
elevation. After age 60, the contribution of RW and IW is similar. Drugs targeting RW 
(widely available) are logical across the human lifespan. 
reﬂected waves nor the forward compression and expansion wave differed signiﬁcantly 
between the two age groups.
Conclusions: The DU-loop offers a graphical and a mathematically solid basis for the 
determination of PWVL. The new technique offers the possibility of studying arterial sites 
that are not accessible by applanation tonometery (more versatile), and does not assume 
a linear relationship between arterial diameter and arterial pressure (more valid).
9:30 a.m.
1030-89 Increased Uric Acid Levels Are Associated With 
Arterial Stiffness and Elevated Peripheral and Central 
Pressures in Healthy, Normotensive Individuals
Panagiotis Xaplanteris, Charalambos Vlachopoulos, Katerina Baou, Ioanna Dima, 
Nikolaos Ioakeimidis, Konstantinos Aznaouridis, Dimitrios Terentes-Printzios, 
Christodoulos Stefanadis, 1st Department of Cardiology, Athens Medical School, 
Hippokration Hospital, Athens, Greece
Background: Uric acid (UA) is the end-product of purine catabolism. Hyperuricemia 
has been associated with increased risk for cardiovascular disease and mortality, 
hypertension and endothelial dysfunction. The relationship between UA and arterial 
stiffness, peripheral and central pressures in healthy, normotensive individuals has not 
been addressed yet.
Methods: The study included 120 healthy normotensive, euglycemic,normolipidemic 
individuals (79 males, mean age 40.9 years). UA levels were determined from blood samples; 
peripheral pressures were measured by an electronic sphygmomanometer; aortic pressures 
were measured using a validated device, while carotid-femoral pulse wave velocity (PWV) 
was measured as an index of aortic stiffness. The distribution of serum uric acid (UA) was 
split by the median (4.5 mg/dL) and subjects were divided in a low (n=59) and high (n=61) UA 
group. Comparisons were performed using the independent samples t-test.
Results: UA levels were positively correlated with both peripheral systolic (pSP, r=0.373, 
p<0.001) and diastolic (pDP, r=0.362, p<0.001) blood pressures, as well as central 
systolic (cSP, r=0.296, p<0.001), and diastolic (cDP, r=0.359, p<0.001) pressures. 
When compared to low UA subjects, high UA subjects demonstrated signiﬁcantly higher 
levels of pSP (110.9±12.3 vs 118.5±8.7 mmHg, p<0.001), pDP (66.5±11 vs 74.05±7 
mmHg, p<0.001), cSP (100.6±12.4 vs 107.2±8.9 mmHg, p=0.001) and cDP(67.6±10.9 
vs 75.1±7.3 mmHg, p<0.001). As regards to PWV, it was positively correlated with UA 
levels (r=0.242, p<0.01), with signiﬁcantly higher levels observed in the high UA group 
(6.03±1.06 vs 6.55±1.18 m/sec, p=0.01).
Conclusions: Increased levels of UA are associated with higher levels of peripheral, as 
well as central pressures and herald arterial stiffening, as estimated by PWV, even in 
healthy, normotensive individuals. Our ﬁndings further elucidate the interplay of UA and 
arterial function.
9:30 a.m.
1030-90 Impact of Lifestyle Changes During Five Years of 
Drug Treatment in the Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT)
David J. Collier, Timothy J. Stride, Sophie He, Sarah L. Wilson, Julian I. Shiel, Mark J. 
Caulﬁeld, Barts and The London School of Medicine and Dentistry, London, United Kingdom
Background: Healthy diet and exercise have been shown to reduce blood pressure, but it 
is not known if changing your lifestyle during an intensive drug-treatment trial is worthwhile.
This study looked at the effect of lifestyle changes on blood pressure during ASCOT.
Methods: In a single, large, study centre, patients annually graded their changes from 
pre-study in four lifestyle areas (salt intake, fat intake, general diet and exercise). The ﬁve 
options (1=lot worse to 5=lot better) were averaged over ﬁve-years, and the cohort divided 
into change and no change groups. Group characteristics were compared, focusing on 
blood pressure reduction. A matching analysis of participants taking 1-2 medications 
before the study, and again at 5 years, was used to compare percentage change in blood 
pressure in the change and no change groups.
Results: Of 1056 participants, over 40% consistently reported a changed diet, salt and 
fat intake. Those making changes tended to be younger (2 yrs average). Women were 
more likely to change their salt and fat intake than men, and participants changing their fat 
intake and general diet were heavier at the start (3kg average). Patients on the amlodipine 
arm put on less weight than those on atenolol (0.76kg over 5 yrs), matching that seen 
in the ASCOT study as a whole (0.79kg). More of those on amlodipine-based treatment 
made lifestyle changes (52-54% vs. 46-48% on atenolol-based therapy), signiﬁcantly so 
for fat intake (53.1% vs. 46.6%; p=0.04). General diet change had a signiﬁcant effect on 
reducing systolic blood pressure for those on 1-2 medications before the study (n=775) 
and at 5 years (n=284), equating to a 1.5% reduction (2.0mmHg; p<0.05 t-test). This 
was backed (in the 1056 patient cohort) by a trend for requiring fewer medications (on 
average) when salt, fat and overall changes were made.
Conclusions: Even in a drug study setting, general diet changes signiﬁcantly reduced 
systolic blood pressure. Those on amlodipine-based therapy were more likely to make 
changes to fat intake and general diet, and also tended to put on less weight than those 
taking beta-blockers by an amount that matched the signiﬁcant weight difference found in 
the whole cohort at the end of ASCOT-BPLA.
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treatments were separated by a 2 week washout period. Half of the patients began 
with atenolol, the other half began with metoprolol succinate. AASI was derived from 
hourly 24-hour BP recordings. Finger arterial tonometry was used to calculate AIx from 
peripheral pulse waves and taken as a measure of wave reﬂection magnitude. These 
vascular measurements were made at baseline, at week 4 (following ﬁrst 4-wk drug 
intervention), and at week 10 (following second 4-wk drug intervention).
Results: There were similar reductions in mean arterial pressure following treatment with 
atenolol (-9 %) and metoprolol (-7 %; p for interaction =NS). There was a 12% reduction 
in AASI following atenolol vs. a 12% increase following metoprolol (p for interaction 
<0.05). There was a 15% increase in AIx following atenolol vs. an 82% reduction following 
metoprolol (p for interaction < 0.05).
Conclusion: Although having similar effects on blood pressure reduction, atenonol and 
metoprolol succinate have distinct and diverging effects on the vasculature. Atenolol 
reduces arterial stiffness and increases arterial wave reﬂection. Conversely, metoprolol 
succinate increases arterial stiffness while reducing arterial wave reﬂection. These data 
suggest that these two beta-blockers lower arterial pressure via a different vascular 
mechanism which might have clinical implications depending on the indication for 
treatment in an individual patient. 
11:30 a.m.
0904-7 Peripheral Pulse Pressure, Aortic Diameter, and Left 
Ventricular Mass in Patients With Hypertension: 
A Substudy of the ALiskiren in Left VentriculAr 
HypertrophY (ALLAY) Trial
Akshay S. Desai, Anil Verma, Evan Applebaum, Tommy Berglund, Valentina 
Lukashevich, Bjorn Dahlof, Scott Solomon, Brigham and Women’s Hospital, Boston, 
MA, Ochsner Heart and Vascular Institute, New Orleans, LA
Background: Left ventricular hypertrophy (LVH) is common in patients with hypertension 
(HTN), but the hemodynamic factors that determine LV mass are not clear. Abnormal 
pressure-ﬂow relationships in the central aorta may play a role.
Methods: The ALLAY trial randomized 465 overweight patients with HTN and LVH 
to 36 weeks of treatment with aliskiren 300 mg, losartan 100 mg, or the combination. 
The primary endpoint was change in LV mass indexed to body surface area (LVMI) as 
assessed by cardiovascular magnetic resonance (CMR). We examined the relationship 
between baseline blood pressure (BP) parameters, aortic dimensions, aortic compliance, 
and LV mass at baseline. Brachial systolic and diastolic BP were measured using a 
standard sphygmomanometer. Ascending aortic diameter and regional aortic compliance 
were measured by CMR.
Results: LVMI was associated directly with increased height, weight, mean arterial 
pressure, systolic and diastolic BP, pulse pressure, and aortic diameter and inversely with 
female gender and age. Baseline aortic compliance was inversely associated with age, 
systolic BP, and pulse pressure, but was not associated with LVMI. After multivariable 
adjustment, only age, gender, pulse pressure, and aortic diameter remained important 
predictors of LVMI. Pulse pressure was inversely associated with aortic diameter, but no 
interaction was noted with regard to LVMI.
Conclusion: Peripheral pulse pressure and aortic diameter are inversely associated and 
independently predict increased LV mass. This data supports the hypothesis that smaller 
effective aortic diameter and increased aortic stiffness associated with HTN and aging 
may contribute to a mismatch between pressure and ﬂow in the proximal aorta, fueling the 
generation of increased pulse pressure and the development of LVH.
ACC.POSTER CONTRIBUTIONS
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Hypertension; Risk Reduction and 
Rehabilitation
Monday, March 30, 2009, 1:30 p.m.-4:30 p.m.
Orange County Convention Center, West Hall D
3:30 p.m.
1039-67 Pulse Wave Velocity Correlates With Left Ventricular 
Systolic Function in Never-Treated Essential 
Hypertensives
Dimitrios Terentes-Printzios, Charalambos Vlachopoulos, Nikolaos Ioakeimidis, 
Konstantinos Aznaouridis, Katerina Baou, Nikolaos Alexopoulos, Athanasios Bratsas, 
Panagiota Pietri, Georgios Lazaros, Christodoulos Stefanadis, 1st Department of 
Cardiology, Athens Medical School, Hippokration General Hospital, Athens, Greece
Background: Arterial stiffness is involved in the pathogenesis of hypertension and is 
a predictor of cardiovascular risk. Furthermore, arterial stiffness has been shown to 
correlate with diastolic dysfunction of left ventricle in hypertensive patients. We assessed 
the hypothesis that arterial stiffness is associated with left ventricular systolic function in 
never-treated hypertensive patients.
Methods: We enrolled 409 consecutive essential hypertensives (mean age 52±12 
years) with preserved left ventricular ejection fraction (LVEF>45%). Arterial stiffness 
was determined with carotid-femoral pulse wave velocity (PWV). LVEF was measured 
echocardiographically and calculated using the Teichholz method.
Results: Subjects were divided into tertiles according to PWV. There was a correlation 
of PWV tertiles with age (46±12 vs 52±11 vs 58±10 years at the 1st, 2nd and 3rd tertile, 
respectively). Mean blood pressure was similar across the tertiles (p=NS). We observed 
a stepwise decrease of LVEF with increasing PWV.(Figure) Multivariable regression 
10:45 a.m.
0904-4 Aortic Stiffness Is Correlated With Albuminuria and 
Glomerular Filtration Rate in Essential Hypertension: 
The Hippokration Hellenic Hypertension (3H) Study
Costas Tsiouﬁs, Kyriakos Dimitriadis, Alexandros Kasiakogias, Costas Thomopoulos, 
Dimitris Syrseloudis, Vicky Katsi, Ioannis Kallikazaros, Christodoulos Stefanadis, First 
Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
Background: Arterial stiffness, albuminuria and impaired renal function are associated 
with atherosclerosis progression. The aim of the study was to investigate the relationships 
of arterial stiffness with urinary albumin excretion, expressed as the albumin to creatinine 
ratio (ACR) and estimated glomerular ﬁltration rate (eGFR) in hypertensives.
Methods: A total of 893 consecutive essential hypertensive subjects [482 men, mean 
age=56 years, ofﬁce blood pressure (BP)=145/90mm Hg] that were included in the 
Hippokration Hellenic Hypertension (3H) Study, an ongoing greek registry of hypertension-
related target organ damage, were considered for analysis. In all participants, ACR values 
were determined as the mean of two non-consecutive morning spot urine and eGFR was 
calculated using the Modiﬁcation of Diet in Renal Disease equation. Moreover, aortic 
stiffness was evaluated on the basis of carotid to femoral pulse wave velocity (PWV), by 
means of a computerized method (Complior SP). The distribution of PWV was split by 
the median (8m/sec) and accordingly subjects were stratiﬁed into those with high and 
low values.
Results: Hypertensive patients with high PWV (n=414) compared to those with low PWV 
values (n=479) were older (61±10 vs 51±years, p<0.0001), had higher ofﬁce systolic BP 
(150±9 vs 142±6mmHg, p<0.0001) and increased left ventricular mass index (107.7±16 
vs 99±13 g/m2, p<0.0001). Moreover, hypertensives with high PWV compared to those 
with low PWV exhibited higher ACR (18.7±9.5 vs 14.8±7.5 mg/g, p<0.05), whereas had 
lower eGFR (76±17 vs 82±17 ml/min/1.73m2, p=0.006), independently of confounders. 
In the total population, PWV was related to age (r=0.525, p<0.0001), ofﬁce systolic BP 
(r=0.242, p<0.0001), left ventricular mass index (r=0.188, p<0.0001), ACR (r=0.012, 
p=0.001) and negatively associated with eGFR (r=-0.221, p<0.0001). Regarding eGFR, it 
was correlated to ofﬁce systolic BP (r=0.113, p=0.001).
Conclusions: In essential hypertension, heightened PWV values are associated with 
pronounced albuminuria and impaired kidney function. These ﬁndings further support that 
aortic stiffening is a hallmark of diffuse renal and vascular atherosclerotic disease.
11:00 a.m.
0904-5 Brachial and Central Blood Pressure Is Associated With 
Obesity: Relation to Large Artery Stiffness
Oluwaseun Kolade, Trisha O’Moore-Sullivan, Michael Stowasser, Thomas H. Marwick, 
James E. Sharman, University of Queensland, Brisbane, Australia
Background: Increasing body weight is associated with elevations in brachial blood 
pressure (BP) as well as aortic stiffness. Both these factors may contribute to the rise in 
cardiovascular risk associated with obesity. The ﬁrst aim of this study was to determine if 
central BP (a stronger risk factor than brachial BP) follows the same pattern of association 
with obesity as brachial BP. Secondly, the relation between body weight and aortic 
stiffness may be confounded by BP, and this study also aimed to examine associations 
between these variables.
Methods: Cross sectional analysis was performed in 75 non-diabetic healthy subjects 
(aged 51 ± 12 years; 57% males) with a wide range of body mass index (BMI; 18.7 to 
38.0 kg/m2; mean 25.3 ± 3.6 kg/m2) and waist measures (69 to 112 cm; 88 ± 10 cm), but 
who were normocholesterolemic, normoglycemic and free from coronary artery disease. 
Brachial BP was measured by standard mercury sphygmomanometer and central BP 
estimated by radial tonometry. Aortic and brachial pulse wave velocity (PWV) were 
recorded as measures of regional arterial stiffness, whereas augmentation index (AIx) 
was recorded as a marker of systemic arterial stiffness.
Results: BMI was signiﬁcantly associated with mean arterial pressure (r=0.42; P<0.001), 
aortic PWV (r=0.24; P=0.05), insulin (r=0.38; P<0.01), brachial and central systolic BP 
(SBP; r=0.37; P<0.01 for both), but not AIx (r=0.10; P=0.38) or brachial PWV (r=0.22; 
P=0.08). Both brachial and central SBP increased with each tertile of increasing BMI, 
as did mean arterial pressure and aortic PWV (P<0.001 for all) but not AIx (P=0.40). On 
multiple regression analysis, age (B=0.51; P<0.001) and mean arterial pressure (B=0.37; 
P<0.001), but not any of the used measures of body fatness, were independent predictors 
of aortic PWV (model R2=0.44; P<0.001).
Conclusions: There are parallel increases in central and brachial BP as body weight 
increases. However, the increase in aortic stiffness associated with body weight is 
probably related to the concomitant rise in mean arterial pressure. 
11:15 a.m.
0904-6 The Effect of Beta-Blockers on Ambulatory Arterial 
Stiffness Index and Wave Reﬂection in Patients With 
Hypertension
Kevin S. Heffernan, Ramya Suryadevara, Paula Mooney, Richard H. Karas, Jeffrey T. 
Kuvin, Tufts Medical Center, Boston, MA
Background: Beta-blockers are frequently prescribed anti-hypertensive medications 
with variable and unclear effects on vascular function. Ambulatory arterial stiffness index 
(AASI) and augmentation index (AIx) are measures of vasomotor function and novel 
predictors of cardiovascular risk. In the present study, we evaluated the ability of atenonol 
versus metoprolol succinate to alter AASI and AIx.
Methods: 24 patients (age 56 ± 2 yrs; 8 female; BMI 28 ± 1) with hypertension completed 
this randomized, double-blind, cross-over design. Each beta-blocker (atenolol or 
metoprolol succinate) was taken by patients once daily for a 4 week period. The two 
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ARBs was examined in Pgp or BCRP-overexpressing cell lines. Moreover, the effect of 
ARBs on ABC transporter activity was studied using ATPase-activity assays.
Results: Telmisartan was identiﬁed to be among the most potent inhibitors of Pgp 
currently available (IC50=0.38±0.15 μmol/L - corresponding to plasma concentrations in 
the low therapeutic range) and inhibited BCRP (IC50=16.9±8.12 μmol/L), whereas none 
of the other ARBs potently inhibited the function of these ABC transporters. However, 
the prodrug candesartan-cilexitil, which is rapidly converted into candesartan in vivo,
inhibited Pgp activity (IC50=0.93±0.13 μmol/L). Moreover, telmisartan also inhibited MRP2 
activity (IC50=25.4±0.6 μmol/L). Further in vitro analysis revealed that telmisartan may 
itself serve as a weak substrate of Pgp and BCRP.
Conclusions: In conclusion, we identiﬁed telmisartan as an inhibitor of Pgp, BCRP, and 
MRP2. These ﬁndings are of clinical relevance as telmisartan may increase the risk of 
drug interactions and adverse drug reactions when used concomitantly with drugs which 
are eliminated via these ABC transporters.
3:30 p.m.
1039-70 J-Curve Revisited: An Analysis of the Treating to New 
Targets (TNT) Trial
Sripal Bangalore, Franz H. Messerli, Chuan-Chuan Wun, Andrea L. Zuckerman, David 
DeMicco, John B. Kostis, John C. LaRosa, Treating to New Targets Steering Committee 
and Investigators, Brigham and Women’s Hospital, Boston, MA
Background: In patients with coronary artery disease (CAD), J-curve relationship has 
been proposed between blood pressure and future cardiovascular events. However, this 
is controversial.
Methods: We evaluated 10,001 CAD patients enrolled in Treating to New Targets (TNT) 
trial (randomized study of Atorvastatin 80 mg vs. 10 mg). The primary endpoint was a 
composite of death from coronary disease, nonfatal myocardial infarction, resuscitated 
cardiac arrest or stroke.The average post baseline blood pressures [systolic (SBP) and 
diastolic (DBP)] were categorized into 10mm Hg increments. The risk of outcomes were 
evaluated for each BP category using a reference HR=1 for SBP 130-140 and DBP 70-
80 mm Hg.
Results: Among the 10,001 patients, 982(9.82%) reached the primary endpoint at the 
end of 4.9 years of follow-up. The relationship between SBP or DBP and primary endpoint 
followed a J-curve with increased event rates above and below the reference BP range, 
both unadjusted and adjusted (Figure). A non-linear cox model identiﬁed a nadir of 139.9 
mm Hg for SBP and 79.2 mm Hg for DBP where the event rate was lowest. Similar J-curve 
relationship was found for the endpoints of all-cause mortality, CV mortality, nonfatal MI 
or nonfatal stroke.
Conclusions: In this cohort of patients with CAD, despite substantial lowering of LDL-
cholesterol in both the treatment groups, J-curve relationship persists between blood 
pressure and cardiovascular events, suggesting that excessive lowering of BP maybe 
harmful.
3:30 p.m.
1039-71 Renin-Angiotensin-System and Bradykinin Pathway 
Genes Are Strongly Associated With Hypertension in 
10.060 Patients With Stable Coronary Artery Disease
Jasper J. Brugts, Moniek de Maat, Eric Boersma, Jacqueline Witteman, Cock van Duijn, 
Andre Uitterlinden, Jan Danser, Maarten L. Simoons, Erasmus MC, Rotterdam, The 
Netherlands
Background: The renin-angiotensin system modulates blood pressure and water balance. 
Genetic defects in the RAAS may be related to an increased risk of hypertension.
Objective: We investigated whether genetic polymorphisms in renin-angiotensin-system 
and bradykinin genes are related to hypertension in a large group of patients.
Methods: DNA was available in 10.060 patients with stable CAD. We selected 60 SNP’s 
in 10 genes of the RAAS and BK pathways based on haplotype-tagging and functionality. 
Hypertension was classiﬁed as 160/90 mmHg or the use of antihypertensives. Logistic 
regression analysis was used to calculate odds ratios adjusted for age,gender, 
hypertension, hypercholesterolemia,diabetes, use of beta-blockers, statins, ACE-
inhibitors and anti-platelet-inhibitors. Conﬁrmation was sought in haplotype analyses.
Results: In the study population, mean age was 60 and 85% were male. Several genes 
indicated a strong relation with hypertension. The strongest effect was seen in the 
analysis showed that the inverse correlation of LVEF with PWV was independent of age, 
sex and mean blood pressure (p=0.005, adjusted R2 of model=0.175).
Conclusions: Higher PWV is an independent predictor of a lower LVEF in never-treated 
essential hypertensives. This ﬁnding provides further insights into the role of arterial 
stiffness in left ventricular function. 
3:30 p.m.
1039-68 Redeﬁning the Cardiovascular Impact of New-
Onset Diabetes Mellitus in Essential Hypertension: 
Experience of a Six Year Follow-Up
Dimitris Tsiachris, Costas Tsiouﬁs, Elena Vezali, Dimitris Chatzis, Dimitris Syrseloudis, 
Eirini Andrikou, Kostas Toutouzas, Dimitris Tousoulis, Ioannis Kallikazaros, 
Christodoulos Stefanadis, First Cardiology Clinic, University of Athens, Hippokration 
Hospital, Athens, Greece
Background: There is still controversy over the impact of new-onset Diabetes mellitus 
(DM) on cardiovascular outcome in hypertensive. We sought to determine the effect of 
new onset DM on major cardiovascular events, such as coronary artery disease (CAD) 
and stroke, in a large cohort of non-diabetic hypertensives
Methods: We followed up 1446 non-diabetic hypertensives (aged 54.2 years, body mass 
index 28.4 kg/m2, ofﬁce BP 146/93 mmHg, duration of hypertension 6.1 years) for a mean 
period of 6 years. Based on the development of new cases of DM (deﬁned as fasting 
plasma glucose q 126 mg/dl) the cohort was divided into two subgroups and examined 
for the presence of CAD (presence of at least one of the following: myocardial infarction, 
coronary revascularization procedure, signiﬁcant stenosis at angiography), and stroke 
(deﬁned as rapid onset of a new neurological deﬁcit persisting at least 24 hours unless 
death supervened).
Results: During follow-up period, the incidence of new-onset DM was 11.5% while new or 
recurrent cases of CAD and stroke were 7.3% and 6.2%. The independent predictors for 
new-onset DM were plasma glucose levels (OR 1.033, 95% CI: 1.019 to 1.047, p<0.001), 
waist circumference (OR 1.035, 95% CI: 1.018 to 1.053, p<0.001), family history of DM 
(OR 2.189, 95% CI: 1.358 to 3.529, p=0.001) and baseline use of b-blockers (OR 1.626, 
95% CI: 1.010 to 2.618, p=0.046). Hypertensive subjects with new onset DM compared 
to those who did not develop DM, exhibited higher incidence of stroke (10.2% vs 4.4%, 
p=0.001, OR 2.48, 95% CI: 1.41 to 4.38), especially of the ischemic type (7.2% vs 1.6%, 
p<0.001, OR 4.88, 95% CI: 2.34 to 10.17) but did not differ regarding the incidence of 
CAD (6.6% vs 5.2%, p=0.46).
Conclusion: Our ﬁndings support the high incidence and the non benign nature of 
new-onset DM in hypertensives as reﬂected by the accompanied increased incidence 
of stroke. The fact that body size along with antihypertensive treatment emerged as 
potent predictors of new-onset DM, suggest that a network of lifestyle modiﬁcations and 
appropriate drug intervention is warranted.
3:30 p.m.
1039-69 Identiﬁcation of Angiotensin Receptor Antagonist 
Telmisartan as a Potent Inhibitor of ATP-Binding 
Cassette Transporters Pgp, BCRP and MRP2
Ralf A. Benndorf, Alexandra Sauer, Caroline H. Storch, Rainer H. Böger, Walter E. 
Haefeli, Johanna Weiss
Hamburg, Germany
Background: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (Pgp), 
the breast cancer resistance protein (BCRP), and the multidrug resistance-related 
proteins (MRPs) are membrane-spanning efﬂux pumps which transport a wide variety of 
drugs thus regulating their absorption and distribution. Pgp and BCRP are also expressed 
in the healthy and failing human heart, where they may function as a protective barrier 
against cardiotoxic agents and drugs, such as anthracyclines. Angiotensin receptor 
blockers (ARBs) are routinely used in the treatment of hypertension and are increasingly 
prescribed for the treatment of heart failure. However, the effect of ARBs on ABC 
transporter functionality remains elusive. Thus, we assessed the hypothesis that ARBs 
may inhibit ABC transporter activity.
Methods: We analysed the effect of various ARBs (telmisartan, candesartan, irbesartan, 
losartan, olmesartan, eprosartan) on ABC transporter activity in vitro. For this purpose, 
accumulation of ﬂuorescent transporter-speciﬁc substrates in presence or absence of 
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Cox analyses, but was not signiﬁcantly associated with a risk of cardiovascular mortality, 
stroke or the LIFE composite endpoint of these two events and MI. In Cox multivariable 
analyses adjusting for in-treatment ECG LVH, systolic and diastolic pressure, randomized 
treatment, HCTZ use and other risk factors, higher in-treatment glucose remained 
associated with a 9.3% greater risk of all-cause mortality only. 
Outcome Variable
Univariate Multivariate
Hazard
Ratio* 95% CI p value
Hazard
Ratio* 95% CI p value
All-Cause Mortality (n=604) 1.077 1.005 - 1.155 0.035 1.093
1.009 - 
1.184 0.029
Cardiovascular Mortality 
(n=316) 1.028
0.929 - 
1.139 0.590 1.053
0.937 - 
1.183 0.384
Myocardial Infarction (n=264) 0.852 0.750 - 0.968 0.014 0.874
0.758 - 
1.007 0.062
Stroke (n=380) 0.933 0.842 - 1.033 0.933 1.001
0.896 - 
1.119 0.983
Composite Endpoint (n=776) 0.939 0.875 - 1.008 0.082 0.975
0.902 - 
1.055 0.534
* per 1 mmol higher serum glucose level
Conclusion: Higher in-treatment serum glucose levels are associated with a higher 
likelihood of all-cause mortality in hypertensive patients without known diabetes.
3:30 p.m.
1039-74 A Multi-site Examination of Age Differences in Cardiac 
Rehabilitation Barriers
Sherry L. Grace, Shannon Gravely-Witte, Shamila Shanmugasegaram, Janette Brual, 
Neville Suskin, Lyall Higginson, Donna E. Stewart, York University, Toronto, ON, Canada
Background: Despite its beneﬁts and need, older patients are signiﬁcantly less likely to 
participate in cardiac rehabilitation (CR). The purpose of this study was to quantitatively 
investigate age differences in CR barriers.
Methods: 1273 cardiac outpatients (mean age 65.9±11.2) of 97 cardiologists completed 
a mailed survey to discern CR participation. Both enrollees and non-enrollees were asked 
to rate 18 investigator-generated and piloted CR barriers on a 5-point Likert scale.
Results: 535 (43%) respondents self-reported participating in CR at one of 40 sites, with 
younger patients being more likely to participate (p=.002). Total CR barriers to enrolment 
and participation were signiﬁcantly related to age, with older patients endorsing more 
barriers than younger patients (p<.001). Pearson’s correlations revealed that older patients 
more strongly endorsed the following CR barriers: already exercising at home (p=.001),
conﬁdence in ability to self-manage their condition (p=.003), perception of exercise as 
tiring or painful (p=.001), not knowing about CR (p=.001), lack of physician encouragement 
(p<.001), perceptions that other patients do not attend CR (p<.001), comorbidities 
(p<.001), and perception that CR will not improve their health (p<.001). Younger patients 
more strongly endorsed work responsibilities (p<.001) and time constraints (p<.001) as 
CR barriers than older patients, with a trend for family responsibilities (p=.01).
Conclusion: While previous research has established that older patients are signiﬁcantly 
less likely to participate in CR, this study has tested and identiﬁed health system and 
patient-level age differences in CR barriers. Given that the beneﬁts of CR are achieved in 
older patients as well as the young, interventions to overcome these modiﬁable barriers 
are needed.
3:30 p.m.
1039-75 Bridging the Interruption of Chronic Oral 
Anticoagulation in Patients With Atrial Fibrillation 
using Enoxaparin: Results With 722 Patients From the 
Prospective BRAVE- Registry
Christoph Hammerstingl, Heyder Omran, Universitiy of Bonn, Department of Cardiology, 
Bonn, Germany, St. Marien Hospital Bonn, Department of Cardiology
Background: Current guidelines on the perioperative management of oral anticoagulation 
(OAC) suggest bridging therapy with low molecular weight heparin in patients with 
atrial ﬁbrillation (AF) at moderate or high thromboembolic risk. In patients with low 
thromboembolic risk low dose LMWH is recommended. The aim of this study was to 
assess the efﬁcacy and safety of bridging OAC therapy in patients with AF using LMWH 
(enoxaparin) according to the ACCP guidelines.
Patients and methods: Patients with AF and need for bridging therapy were consecutively 
enrolled. Thromboembolic (TE) risk and renal function was assessed following a speciﬁed 
stratiﬁcation scheme. Patients with high or moderate TE- risk and preserved renal function 
were treated with therapeutic LMWH doses, all other patients (low thromboembolic risk) 
received low dose LMWH. Follow-up time was 30days.
Main outcome measures were the incidence of hemorrhagic or thromboembolic events.
Results: 722 patients were included, thereof 425 (58.9%) categorized as high TE- risk 
and 297 (42.1%) as non- high TE- risk; renal impairment was detected in 322 patients 
(44.6%). 225 patients (31.2%) were treated with therapeutic and 497 (68.8%) with reduced 
LMWH- doses. TE- complications were not observed after bridging therapy (0%; 95% 
conﬁdence interval [CI] 0.0 - 0.51%). 3 major bleedings (0.4%; 95% CI 0.09% - 1.2%) 
and 39 minor bleeds occurred (5.4%; 95% CI 3.8% - 7.3%). Haemorrhages occured more 
frequently in patients with high TE risk (7.056% vs. 3.497%, p = 0.046), but independent 
of the type of conducted intervention.
Conclusions: This study supports the current ACCP guidelines on bridging 
anticoagulation in patients with AF according to the individual thromboembolic risk. The 
patients’ co- morbidities and not the type of conducted interventions was the strongest 
predictor for bleeding complications.
angiotensinogen gene (Table 1), especially for rs4762 (T174M) in the angiotensinogen 
gene with a 47% increased risk of hypertension in homozygous 174TT subjects. Strong 
relations were also seen in other genes, especially the angiotensin-converting enzyme 
gene, prorenin receptor and kallikrein gene (data not shown). Haplotype analyses 
conﬁrmed these results.
Conclusion: This large genetic study identiﬁes several important genetic factors 
signiﬁcantly and independently associated with hypertension.
Angiotensinogen gene polymorphisms and hypertension in 10.060 
patients with coronary artery disease
SNP Location Freq 1/1 1/2 2/2 OR 1/1 OR 1/2 OR 2/2
P for 
trend
rs5046 promotor 77.3 21.0 1.6 1.00(ref)
1.18 (1.05-
1.31)
1.17 (0.84-
1.66) 0.004
rs5049 promotor 77.1 21.3 1.6 1.00(ref)
1.20(1.07-
1.34)
1.16 (0.81-
1.66) 0.002
rs5051 promotor 30.9 48.8 20.3 1.00(ref)
1.11 (1.00-
1.24)
1.24 (1.10-
1.42) 0.001
Rs2478545 intron 56.6 37.7 5.7 1.00(ref)
1.06 (0.97-
1.17)
1.22 (1.01-
1.49) 0.034
rs4762 exon 74.4 23.8 1.8 1.00(ref)
1.11 (1.00-
1.23)
1.47 (1.07-
2.03) 0.007
rs943580 3’UTR 30.9 49.1 20.0 1.00(ref)
1.31 (1.15-
1.49)
1.12 (1.00-
1.24) 0.001
3:30 p.m.
1039-72 Exaggerated Blood Pressure Response Is 
Accompanied by a State of Pronounced Albuminuria, 
Hypoadiponectinemia and Increased Asymmetric 
Dimethylarginine Levels in Essential Hypertension
Kyriakos Dimitriadis, Costas Tsiouﬁs, Dimitris Syrseloudis, Ioannis Andrikou, Panagiotis 
Tolis, Vanessa Tzamou, Alexandros Kasiakogias, Dimitris Tousoulis, Christodoulos 
Stefanadis, First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, 
Greece
Background: A hypertensive response to exercise (HRE) is associated with high 
cardiovascular risk, whereas there are scarce data regarding its relation to markers of 
atherosclerosis progression. In this study we sought to determine the relationships of HRE 
with asymmetric dimethylarginine (ADMA), adiponectin and urinary albumin excretion, 
expressed as the albumin to creatinine ratio (ACR), in essential hypertensives.
Methods: 109 newly diagnosed untreated non-diabetics with stage I to II essential 
hypertension [76 men, mean age=52 years, ofﬁce blood pressure (BP)=146/94 mmHg] 
with a negative treadmill exercise test (Bruce protocol) were divided into those with HRE 
(n=34) (peak exercise systolic BP q210mmHg in men and q190 mmHg in women) and to 
those without HRE (n=75). Moreover, in all subjects ACR values were determined as the 
mean of two non-consecutive morning spot urine samples.
Results: Patients with HRE compared to those without HRE were older (55±9 vs 51±9 
years, p<0.05), had greater 24-h systolic BP (141±13 vs 132±12 mmHg, p<0.05), 
while did not differ regarding metabolic proﬁle and left ventricular mass index (p=NS). 
Furthermore, patients with HRE compared to those without HRE exhibited greater 
levels of ADMA (0.62±0.05 vs 0.54±0.04 μmol/l, p<0.0001) and ACR (61.4±12 vs 
15.2±2.2 mg/g, p<0.0001), whereas had lower adiponectin values (6.1±1.4 vs 9.3±2.1 
μg/ml, p<0.0001), independently of confounders. In the total population, peak exercise 
systolic BP was positively related to 24-h systolic BP (r=0.239, p<0.05), ACR (r=0.432, 
p<0.0001) and ADMA (r=0.260, p=0.007), while negatively correlated with adiponectin 
(r=-0.216, p<0.05). Multiple regression analysis revealed that apart from 24-h systolic BP 
(b=0.232, p=0.023) and male sex (b=0.240, p=0.029), ACR (b=0.450, p<0.0001) was an 
independent predictor of peak exercise systolic BP.
Conclusion: In hypertension, a HRE is associated with hypoadiponectinemia, augmented 
ADMA and ACR values, reﬂecting activation of diverse pro-atherosclerotic pathways. 
These ﬁndings suggest that treadmill exercise testing could be an additional tool to 
identify hypertensive patients with pronounced cardiorenal vascular dysfunction.
3:30 p.m.
1039-73 Relationship of In-Treatment Serum Glucose to All-
Cause Mortality and Cardiovascular Morbidity and 
Mortality In Hypertensive Patients Without Known 
Diabetes During Treatment: The LIFE Study
Peter M. Okin, Richard B. Devereux, Darcy A. Hille, Sverre E. Kjeldsen, Lars H. Lindholm, 
Jonathan M. Edelman, Björn Dahlöf, Weill Cornell Medical College, New York, NY
Background: The association of elevated serum glucose with morbidity and mortality in 
diabetic patients is well-established. In contrast, evidence is mixed whether new dysglycemia 
during antihypertensive treatment is associated with adverse outcomes and may be 
confounded by treatment of hyperglycemia in patients with existing or new diabetes.
Methods: Outcomes were assessed in 7,436 hypertensive patients who were free of 
diabetes at baseline and throughout follow-up, treated in a blinded fashion with losartan 
or atenolol and additional open-label hydrochlorothiazide (HCTZ) as needed according 
to study protocol.
Results: During 4.6±1.1 years follow-up, each 1 mmol higher in-treatment serum glucose 
treated as a time-varying covariate was signiﬁcantly associated with a 7.7% increased 
risk of all-cause mortality and a 14.8% lower risk of myocardial infarction (MI) in univariate 
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ages 30-65. An optimal risk factor proﬁle was deﬁned using measured traditional risk 
factors (BP < 120/80 mmHg; total cholesterol <200 mg/dl; no diabetes; and non-smoking 
status). Coronary artery calcium (CAC) and abdominal aortic plaque (AAP) prevalence 
were assessed by CT and MRI, respectively.
Results: Of the 3072 participants (mean age 44 ± 9 yrs, 48% black, 55% women), 546 
(18%) had an optimal risk factor proﬁle, with differing prevalence between racial groups 
(18% white, 13% black, 31% Hispanic, 27% other, p<0.01). The number of optimal risk 
factors was inversely associated with the prevalence of CAC, ranging from 55% in those 
with no optimal risk factors to 3.1% among those with all 4; similar associations were 
observed for AAP (p-trend < 0.01). After adjusting for age, sex, and race, individuals with 
an optimal risk factor proﬁle had >90% lower odds of CAC and >75% lower odds of AAP 
compared with those with no optimal risk factors (Figure).
Conclusions: An optimal risk factor proﬁle is associated with a markedly lower prevalence 
of subclinical atherosclerosis. Broader achievement of this proﬁle may dramatically reduce 
the burden of atherosclerosis in the population. 
3:30 p.m.
1039-79 Glycemic Control and Cardiovascular Events in Type 
2 Diabetes Mellitus: A Meta-Analysis of Randomized 
Controlled Trials
Ahmad Khraisat, Amol Bahekar, Bassel Artin, Rohit Bhuriya, Eshraq Al-Jaghbeer, 
Sarabjeet Singh, Janos Molnar, Sandeep Khosla, Rohit Arora, Mount Sinai Hospital, 
Chicago, IL, Rosalind Franklin University, North Chicago, IL
Background: Earlier meta-analysis addressing the effects of intensive glycemic control 
on cardiovascular events in type 2 diabetes mellitus (DM-2) didn’t include 2 large scale 
randomized control trials (Action to Control Cardiovascular Risk in Diabetes [ACCORD], 
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modiﬁed Release 
Controlled Evaluation [ADVANCE]).
Methods: A systemic literature search found 10 randomized controlled trials (N=42,198) 
comparing the effects of intensive glycemic control versus conventional treatment for DM-
2. Heterogeneity was assessed by Cochran’s Q test. Mantel-Haenszel ﬁxed-effect model 
was used to calculate combined relative risks (RR) when studies were homogenous and 
the random effect model was used when the studies were heterogenic.
Results: Myocardial infarction (MI) was signiﬁcantly decreased in the intensive treatment 
group, as compared to the control group (RR 0.9; CI: 0.83 - 0.96; P= 0.002). The RR for 
all cause mortality, heart failure, stroke/transient ischemic attack (TIA), and peripheral 
vascular events was 0.97 (0.9 - 1.03), 1.03 (0.7 - 1.51), 0.97 (0.87 - 1.1), 0.97 (0.86 - 
1.07); respectively in the intensive treatment group, as compared to the control group 
(ﬁgure 1).
Conclusions: Intensive glycemic control of DM-2 was associated with a signiﬁcant 
decrease in the risk of MI. A trend towards decrease in all cause mortality and stroke/TIA 
was observed in the intensive glycemic control group but the results were not signiﬁcant. 
3:30 p.m.
1039-76 Native LDL-Cholesterol Mediated Monocyte Adhesion 
Molecule Overexpression Is Blocked by Simvastatin
Carlos V. Serrano, Jr., Antonio E. Pesaro, James De Lemos, Fabiana Rached, Fernando 
Gomes, Adriano F. Ribeiro, Jose C. Nicolau, Vanda M. Yoshida, Hugo P. Monteiro, Heart 
Institute (InCor), School of Medicine, University of Sao Paulo, Sao Paulo, SP, Brazil
Background: It is recognized that an early event of atherosclerosis is the increased 
uptake of monocytes into the intima where they differentiate into macrophages and, 
ultimately, into foam cells. This study sought to evaluate the effect of nLDL concentrations 
on monocyte adhesion molecule expression in hypercholesterolemic patients with stable 
coronary artery disease (CAD) and to determine whether lipid-lowering therapy with 
simvastatin would change this effect.
Methods: Blood samples from patients with hypercholesterolemia (mean LDL 152 mg/
dL) and CAD (HC, n=23) were collected before and after a 12-week treatment with 40 
mg of simvastatin. Healthy individuals (mean LDL 111 mg/dL) were used as controls (CT, 
n=15). Isolated nLDL, at a ﬁxed concentration of 100 mg/dL, was added to monocyte 
suspensions obtained before and after the simvastatin treatment. Monocyte activation 
was determined by changes in cellular adhesion molecule expression.
Results: In response to nLDL, CD11b and CD14 adhesion molecule expression was higher 
in HC patients than CT before treatment (174.2 ± 8.4 vs 102.2 ± 6.3, P<0.03 and 140.4 
± 5.0 vs 90.4 ± 6.7, P<0.04). After simvastatin treatment, CD11b expression decreased 
to 116.9 ± 12.5 (P<0.03) and CD14 expression to 107.5 ± 6.2 (P<0.04). Alternatively, 
L-selectin expression was lower in HC patients than CT before therapy (46.0 ± 3.5 vs 62.1 
± 5.5, P<0.04), and it increased markedly after lipid reduction to 58.7 ± 5.0 (P<0.04 vs 
baseline). After simvastatin treatment, LDL was reduced to mean 101.5 mg/dL.
Conclusions: These data demonstrate that monocytes from HC patients are more prone 
to marked nLDL-mediated changes of adhesion molecule expression than monocytes 
from controls. Simvastatin is capable of inhibiting such nLDL effects. This proinﬂammatory 
response to nLDL may have a role in the early onset of atherosclerosis.
3:30 p.m.
1039-77 Evaluation of the AHA Cardiovascular Disease 
Prevention Guideline in the Women’s Health Initiative
Judith A. Hsia, Rebecca J. Rodabough, JoAnn Manson, William Graettinger, Simin Liu, 
Milagros Rosal, Matthew S. Frieberg, Jennifer G. Robinson, Barb Cochrane, Barbara 
V. Howard, George Washington University, Washington, DC, Fred Hutchinson Cancer 
Research Center, Seattle, WA
Background: The 2007 AHA Guideline for Cardiovascular Disease Prevention in Women 
recommended categorization as high risk, at-risk or optimal risk. We evaluated the 
proposed stratiﬁcation scheme in the Women’s Health Initiative.
Methods: We followed 161,808 women aged 50-79y for 7.8y, categorized them according 
to the AHA guideline and evaluated clinical event rates by ANOVA and chi square. 
Subgroups were compared by likelihood ratio testing (generalized linear models with 
Poisson distribution and log link function).
Results 11% of women were high risk, 72% at-risk, 4% optimal risk and 13% did not 
fall into any category. The latter lacked risk factors, but did not adhere to a healthy 
lifestyle. Annualized event rates demonstrated a strong, graded relationship across 
risk categories (Table). Women who could not be categorized had event rates similar to 
optimal risk women. Although event rates increased across risk categories among white, 
black, Hispanic and Asian women, absolute event rates differed among ethnic groups 
(p for interaction <0.01). In a random subsample (n=5022) with measured lipids, risk 
stratiﬁcation was generally consistent with Framingham categories, but the AHA guideline 
identiﬁed 3695 at-risk women, 92% with Framingham risk <10% (p<.0001 for comparison 
of risk strata).
Conclusion: The AHA guideline provides a simple, accessible and accurate approach to 
risk stratiﬁcation. Not all women could be categorized, suggesting a need for additional 
reﬁnement.
N (%/year) of women with cardiovascular events by AHA risk category
High risk
n=17578
At-risk
n=116626
Optimal risk
n=6784 p value
MI 1141 (0.91) 2224 (0.25) 47 (0.09) <.0001
CHD death 631 (0.49) 747 (0.08) 14 (0.03) <.0001
Stroke 936 (0.74) 2366 (0.26) 63 (0.12) <.0001
MI/CHD death 1568 (1.25) 2749 (0.31) 59 (0.11) <.0001
MI/CHD death/stroke 2342 (1.90) 4922 (0.55) 119 (0.22) <.0001
3:30 p.m.
1039-78 Optimal Cardiovascular Risk Factor Proﬁle and 
Subclinical Atherosclerosis: Results From the Dallas 
Heart Study
Kamakki Banks, Jarett Berry, Darren McGuire, James DeLemos, Scott Grundy, Amit 
Khera, Donald W. Reynolds Cardiovascular Clinical Research Center, Dallas, TX, 
Division of Cardiology, the University of Texas Southwestern Medical Center, Dallas, TX
Background: An optimal risk factor proﬁle is associated with a marked decrease in CV 
events. We sought to determine the prevalence of an optimal risk factor proﬁle and its 
association with subclinical atherosclerosis in the general population.
Methods: The Dallas Heart Study is a multiethnic, population-based study of subjects 
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METHODS Baseline clinical and laboratory data from the multi-center, international, 
BARI 2D trial (n=2321) were examined to compare differences in risk factors across 
ﬁve geographic regions: United States [US], Canada [CA], Mexico City [MC], Sao Paolo 
[SP] and Europe [EU]. Participants in the BARI 2D trial had DM and angiographically 
documented stable CAD. 
RESULTS Mean age at enrollment was 62 ± 9y with 70% male participants and a mean 
duration of DM=10 years, HbA1C=7.8% and 6.6 medications for achieving treatment 
goals. Over 90% of trial participants were overweight/obese, with the greatest proportion 
of obese men (61%) and women (72%) from the US, and the lowest proportion from MC 
(16% and 14%, respectively; p<0.0001). Smoking varied signiﬁcantly by region with fewer 
current smokers in SP (7%) as compared with the US (13%, p=0.005) and EU (19%, 
p=0.006). Sedentary lifestyle was more common amongst patients enrolled in MC (65%) 
relative to SP (32%), US (19%), CA 18%) and EU (4%). BP>130/80mmHg was present in 
53% of all trial participants, with the highest mean SBP in SP (141mmHg) and the lowest 
in MC (119mmHg, p<0.0001). Similarly, mean LDL cholesterol varied by region with the 
lowest values in CA (2.4mmol/L) and highest in SP (2.9mmol/L, p<0.0001).
CONCLUSIONS Despite an average of greater than 6 medications for achieving 
treatment goals in DM patients with CAD, the co-existence of sub-optimally controlled 
CAD risk factors is universally high. Important differences exist in LDL cholesterol levels, 
BP, BMI and smoking rates amongst geographic regions. While a population-based study 
is required to conﬁrm our results, this observation emphasizes the pressing need for 
global strategies in achieving treatment targets.
3:30 p.m.
1039-83 Comparative Efﬁcacy of Strategies for Risk Screening 
and Prevention for Cardiovascular Disease
Anthony N. DeMaria, James A. De Lemos, George A. Diamond, Philip Greenland, 
Vilmundur Gudnason, Rory Hachamovitch, Mitchell K. Higashi, Barbara R. Peskin, Julia 
R. Dziuba, Sanjay Kaul, University of California, San Diego, San Diego, CA, Cedars 
Sinai Medical Center, Los Angeles, CA
Background: We used computer modeling (Archimedes) to simulate a clinical trial 
comparing several strategies for risk screening and prevention of cardiovascular (CV) 
disease. The Archimedes Model is a large scale simulation model of physiological 
pathways, clinical events, and health care systems pertinent to CV diseases and their 
complications, and has been validated against more than 50 clinical trials.
Methods: The simulated population was based on a representative sample of the U.S. 
population without CV disease, age 40-75, followed for 35 years. We compared a strategy 
of do nothing (NONE), ATP-III guidelines (STD), SHAPE 1 and 2 screening with coronary 
calciﬁcation (CACS) or carotid intima medial thickness (CIMT) respectively, and treatment 
of everyone with simvastatin 20mg and 81 mg aspirin (UNCONDL). We assumed an 
adherence of 50% for protocols. Endpoints were composite of MI, stroke, or CV death; 
cost-effectiveness was assessed. Results are shown in Table. All screening strategies 
were superior to NONE, while only UNCONDL was superior to STD. The average cost/
quality adjusted life-year (QALY) was low for all arms compared to NONE. UNCONDL was 
cost saving compared to STD.
Conclusions: Using a validated model, these simulations indicate that the tested 
strategies reduce hard CV events at a low cost/QALY. Unconditional treatment with statin 
and aspirin is cost saving and is the only strategy signiﬁcantly superior to ATP-III.
3:30 p.m.
1039-84 Risk of Cardiovascular Morbidity and Mortality 
Associated With the Use of Nonsteroidal Anti-
inﬂammatory Drugs (NSAIDs) Among Healthy 
Individuals: A Nationwide Study
Emil L. Fosbøl, Gunnar H. Gislason, Fredrik Folke, Søren Jacobsen, Lars Køber, 
Christian Torp-Pedersen, Department of Cardiology, Gentofte University Hospital, 
Copenhagen, Denmark
Background: Studies have raised concern on the cardiovascular risk proﬁle of non-
steroidal anti-inﬂammatory drugs (NSAIDs).
Methods: By individual-level-linkage of nationwide registers; we identiﬁed a study-
population consisting of individuals without hospitalizations ﬁve years prior to ﬁrst 
prescription claim of NSAID and no claimed drug prescriptions for selected concomitant 
medication two years previously. Risk of coronary death and non-fatal myocardial 
infarction and fatal and non-fatal stroke associated with use of NSAIDs was estimated by 
Cox proportional-hazard and case-crossover analyses.
3:30 p.m.
1039-80 Signiﬁcant Relationships of Daily Sleep With Arterial 
Stiffness, Blood Pressure and the Other Metabolic 
Measures in a Population of Male Workers
Yu Misao, Jun Misao, Tomiyo Ohmura, Yoko Murase, Rie Yoneyama, Chika Fujita, Naomi 
Kondo, Yasuyuki Kato, Chu Misao, MISAO Health clinic, Gifu, Japan
Background: It remains controversial whether daily sleep actually affects the occurrence 
of cardiovascular diseases (CVD). The objective of this study was to analyze the 
relationships of self-reported daily sleep with cardiovascular risk factors including blood 
pressure (BP), the other metabolic measures, and arterial stiffness evaluated based on 
brachial-ankle pulse wave velocity (baPWV), an integrated index of vascular status and 
CVD risk, in a population of male workers.
Methods and Results: Participating in this study were 251 consecutive male workers, 
aged less than 60 years, who underwent baPWV measurement in addition to an annual 
check-up in which age, physical proﬁle such as body weight (BW), body mass index 
(BMI) and waist circumference, systolic BP, diastolic BP, and metabolic measures, 
such as fasting blood glucose and hemoglobin A1c as glucose metabolism; triglyceride 
(TG), HDL-, and LDL-cholesterol as lipid metabolism were documented. The subjects’ 
information on daily sleep, not only sleep duration but also bedtime, was obtained by 
a questionnaire. We observed, using a multivariable analysis, that sleep duration had 
signiﬁcant correlations with systolic BP, diastolic BP, BMI, waist circumference, and 
TG, respectively (all Ps<0.05), but not with baPWV. The population was, subsequently, 
categorized four subgroups by sleep duration: <5.99, 6-6.99, 7-7.99, or 8< hrs. In each 
subgroup, the subjects with an early bedtime (bedtime before midnight) had signiﬁcantly 
lower baPWV than those with a late bedtime (bedtime after midnight) (P <0.05 in each 
subgroup).
Conclusions: Our ﬁndings support an importance of daily sleep, which affects CVD risk 
factors, such as hypertension and arterial stiffness, in this population of male workers. In 
addition to the concept, previously reported, that daily sleep duration signiﬁcantly affects 
hypertension and the other metabolic measures, bedtime also might be considered as 
educational issues to prevent CVD and the risk factors.
3:30 p.m.
1039-81 Cardiovascular Event Risk in Relation to Water-Intake in 
Patients Wiith Coronary Endothelial Dysfunction: Effect 
on Inﬂammatory Stress
Keishi Saihara, Shuichi Hamasaki, Sanemasa Ishida, Akiko Yoshikawa, Tetsuro 
Kataoka, Masakazu Ogawa, Naoya Oketani, Takuro Shinsato, Hideki Okui, Takuro 
Kubozono, So Kuwahata, Takuro Takumi, Hitoshi Ichiki, Shoji Fujita, Yuichi Ninomiya, 
Satoshi Yoshino, Yasuhisa Iriki, Kaai Tomita, Chuwa Tei, Kagoshima University, 
Kagoshima City, Japan
Background: There is increasing evidence that mild dehydration plays a role in the 
development of various morbidities. However, there was no reliable evidence that 
estimated the appropriate rehydration volume to prevent cardiovascular disorders. 
Therefore, we investigated whether moderate amount of water-intake had an effect on 
reducing cardiovascular events. Methods: Consecutive 121 patients without coronary 
artery disease underwent Doppler ﬂow study of the left anterior descending coronary 
artery. Vascular reactivity was examined by intra-coronary administration of acetylcholine 
(Ach) and nitroglycerin using a Doppler guidewire. Out of 121 patients, 105 patients 
(63±12 years, 43 women) who revealed coronary endothelial dysfunction (the percent 
change in coronary blood ﬂow induced by Acha50% or the percent change in coronary 
artery diameter induced by Acha30%) were enrolled in this study. According to the 
amount of water which the questionnaire responders drink per day, they were divided 
into two groups: Hydrate group (n=80) who intentionally drink water more than 1L/day 
(mean 1.52±0.57 L/day) and Non-hydrate group (n=25) who drink water less than 1L/day 
(mean 0.42±0.18 L/day). Serum high-sensitive C-reactive protein (hs-CRP) level, serum 
level of blood urea nitrogen (BUN) and creatinine were also measured. Cardiovascular 
outcomes were assessed at long-term follow-up using questionnaire surveys for major 
adverse cardiovascular events (MACE). Results: The average follow-up period was 
894±508 days. There were no signiﬁcant differences in cardiac function assessed by 
ejection fraction or Tei index in the two groups. Serum hs-CRP level and BUN/creatinine 
ratio in Non-hydrate group were signiﬁcantly greater than Hydrate group (0.34±0.49 mg/
dl vs. 0.12±0.16 mg/dl, P<0.01; 20.7±10.5 vs. 16.9±5.1, P<0.05, respectively). MACE free 
ratio in Non-hydrate group was signiﬁcantly lower than that in Hydrate group (84% vs. 
96%, P<0.05). Conclusion: In patients with coronary endothelial dysfunction, intentional 
water-intake more than 1L/day may reduce cardiovascular events when compared with 
water-intake less than 1L/day, which may be associated with inﬂammation stress.
3:30 p.m.
1039-82 Distribution and Prevalence of Traditional Risk Factors 
in Diabetics With Coronary Artery Disease Around the 
Globe: An Analysis From the BARI 2D Trial
Carolyn M. Taylor, Manuel S. Lombardero, Ashok Krishnaswami, Petr Neuzil, Felipe D. 
Paulitsch, Michael E. Farkouh, Krishnan Ramanathan, University of British Columbia, 
Vancouver, Canada
BACKGROUND The global prevalence of type 2 diabetes mellitus (DM) is reaching 
epidemic proportions. While DM and other CAD risk factors frequently co-exist, geographic 
differences in risk factor prevalence in those with DM and CAD are unknown. We examined 
risk factor distribution by region in the Bypass Angioplasty Revascularization Investigation 
2 Diabetes (BARI 2D) trial, the largest clinical trial to date of diabetics with CAD. 
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questionnaire. Results: After adjusting for age, gender, physical activity, education status, 
clinical diagnosis (i.e., myocardial infarction or unstable angina), previous history of 
ACS, smoking habits, presence of obesity, hypercholesterolemia and diabetes mellitus, 
multi-adjusted analysis revealed that in normotensive patients coffee consumption of 0-1 
cups/day was associated with 92% (95%CI: 0.01-0.56) lower likelihood of developing 
LVSD, consumption of 1-2 cups/day was associated with 88% (95%CI: 0.02-0.74) lower 
likelihood of developing LVSD and consumption of 3-5 cups/day with 93% (95%CI: 0.009-
0.50) lower likelihood for LVSD, compared with rare consumption of coffee. On the other 
hand in hypertensive patients coffee consumption of 0-1 cups/day was associated with 
4-fold higher likelihood for developing LVSD (95%CI: 1.16-10.64) as compared with rare 
coffee consumption and consumption of 3-5 cups/day was associated with 5-fold higher 
likelihood for developing LVSD (95%CI: 0.95-21.50). Conclusion: Coffee consumption has 
opposite effects on the likelihood of developing LVSD in post ACS patients depending on 
their blood pressure levels.
3:30 p.m.
1039-87 High Dose Atorvastatin Provides Sustained Beneﬁt 
in Reducing Risk of Cardiovascular Disease Among 
Stable Coronary Heart Disease Patients Sixty-Five 
Years and Older
Nanette Kass Wenger, John C. LaRosa, James Shepherd, on behalf of the Treat to New 
Target (TNT) Investigators, Emory University School of Medicine, Atlanta, GA, Grady 
Memorial Hospital, Atlanta, GA
Background: In TNT, intensive lipid lowering with atorvastatin (ATV) 80 mg signiﬁcantly 
reduced the risk of CVD compared with ATV 10 mg among stable CHD patients q65 yrs. 
As with most randomized clinical trials, analysis of TNT was restricted to analyses of time 
to ﬁrst event. Since many patients experience multiple events, this approach precludes 
displaying much useful clinical and economic data. Here, we evaluated the effect of 
treatment with ATV 80 mg vs 10 mg among patients q65 yrs for the duration of the trial 
after occurrence of a ﬁrst CV event.
Methods: In TNT, 3809 patients q65 yrs were randomized to receive ATV 10 or 80 
mg and followed for 4.9 yrs. Post hoc time-to-event analysis was used to estimate the 
treatment hazard ratio separately for time to ﬁrst through ﬁfth occurrences of any CV 
event (deﬁned as: any coronary event [CHD death, nonfatal MI, resuscitated cardiac 
arrest, revascularization procedure, procedure-related MI or documented angina]; a 
cerebrovascular event [fatal or nonfatal stroke, TIA]; PAD; hospitalization with primary 
diagnosis of CHF.
Results: Among patients q65 yrs receiving ATV 80 mg the relative risk of a ﬁrst CV event 
was signiﬁcantly reduced compared with those receiving ATV 10 mg (Fig). Similar ﬁndings 
were evident for the occurrence of second, third, fourth and ﬁfth events.
Conclusions: Treatment with ATV 80 mg continued to signiﬁcantly reduce the risk of 
any CV event over time compared with ATV 10mg among patients aged q65 yrs who had 
survived previous CV events. 
3:30 p.m.
1039-88 Sex-Speciﬁc Role of Abdominal Obesity in 
Hypertension-Induced Cardiac Adaptations
Dimitris Tsiachris, Costas Tsiouﬁs, Dimitris Syrseloudis, Panagiotis Tolis, Anastasia 
Mazaraki, Ioannis Andrikou, Giorgos Metallinos, Panagiotis Agelopoulos, Ioannis 
Kallikazaros, Christodoulos Stefanadis, First Cardiology Clinic, University of Athens, 
Hippokration Hospital, Athens, Greece
Background: Obesity and hypertension deteriorate left ventricular (LV) structure and 
function in an additive manner increasing the risk of congestive heart failure. Our aim 
was to assess the differential effect of waist circumference on LV cardiac adaptations, in 
hypertensive males and females.
Methods: A total of 1789 non-diabetic, essential hypertensives (aged 55.8±13.5 years, 
966 females), that were included in the 3H Study, were classiﬁed to obese and non-
obese according to ATP III criteria regarding waist circumference value (>88 cm for 
obese women and >102 cm for obese men). In all participants, LV mass index (LVMI) 
and relative wall thickness were determined, while LV diastolic function was evaluated 
by means of transmitral ﬂow and tissue Doppler imaging (TDI), averaging early and late 
Results: The Danish population aged 10 years or more consisted of 4,614,807 individuals 
on January 1, 1997, of which 1,028,437 were included in the study. A total of 44.7% 
claimed at least one prescription for NSAID from 1997-2005. Results from the case-
crossover analysis are shown in the ﬁgure. Compared to no NSAID use, diclofenac and 
the selective COX-2 inhibitors rofecoxib and celecoxib were associated with increased 
risk of coronary death. Diclofenac was also associated with increased risk of stroke. A 
dose-dependent increase in risk was also seen for these drugs. Use of naproxen and 
ibuprofen was neutral for all examined endpoints. Conclusions: Use of diclofenac and 
selective COX-2 inhibitors among healthy individuals was signiﬁcantly associated with 
increased cardiovascular risk. This study raises concern about the cardiovascular safety 
of diclofenac in the general population. 
3:30 p.m.
1039-85 Free Fatty Acid Released From Visceral fat May 
Deteriolate Endothelial Function and Blood Rheology 
Partly via Renin-Angiotensin System in Leukocytes
Takanori Yasu, Mayumi KObayashi, Daichi Iwasaki, Ken Yamakawa, Hidenori Urata, Shinichiro 
Ueda, University of Ryukyus, Nishihara, Japan, Fukuoka University, Fukuoka, Japan
Background: Elevated serum free fatty acids (FFAs) originated from expanded visceral 
adipose tissue may develop endothelial dysfunction and insulin resistance in metabolic 
syndrome. We have reported that FFA-induced endothelial dysfunction was prevented by 
inhibition of renin-angiotensin system (RAS), although there were no detectable changes 
in circulating RAS. Aim is to extend our investigation to explore effects of elevated FFAs 
on microcirculation and its link to activity of local RAS in mononuclear cells.
Methods: We measured forearm blood ﬂow (FBF), skin perfusion pressure reﬂecting 
pre-capillary arteriolar pressure and whole blood transit time through 8700-parallel, 
7-μm equivalent diameter microchannels, ex vivo capillary model, as parameters for 
microcirculation, plasma level of derivatives of reactive oxygen metabolites (d-ROMs) as 
an oxidative stress marker, plasma myeloperoxidase level and adhered leukocyte number 
on the terrace as markers for leukocyte activation and angiotensin (Ang) II forming activity 
in the mononuclear cell fraction before and during systemic infusion of lipid/heparin or 
saline/heparin in 10 healthy men. We repeated the experiments in the same subjects 
administered candesartan (12 mg/day) or perindpril (4 mg/day) for 2 days in a randomized 
cross-over design.
Results: Elevated serum FFAs by Lipid/heparin infusion for 2 h signiﬁcantly increased 
vascular resistance around small arterioles and capillaries, whole blood transit time through 
micro-channels, leukocyte adhesiveness and dROMs test values (P<0.05 vs. saline/
heparin), and signiﬁcantly enhanced Ang II forming activity in mononuclear cell fraction by 
130%. Candesartan but not perindopril signiﬁcantly prevented FFA-induced increases in 
whole blood transit time and adhered leukocyte numbers, but not in d-ROMs test.
Conclusions: Elevated serum FFA levels cause microcirculatory deterioration and 
leukocyte activation which are partly regulated by local RAS in mononuclear cells. 
Preventive effects of Ang II receptor blocker on these FFA-induced events may be 
beneﬁcial for patients with metabolic syndrome.
3:30 p.m.
1039-86 Moderate Coffee Consumption Lowers the Likelihood of 
Developing Left Ventricular Systolic Dysfunction After 
an Acute Coronary Event in Normotensive, but Not in 
Hypertensive Patients
Christina Chrysohoou, Christina Castorini, Panagiotis Aggelopoulos, Demosthenes 
Panagiotakos, George Metallinos, John Skoumas, Christos Pitsavos, Christodoulos 
Stefanadis, 1st Cardiology Clinic University of Athens, Athens, Greece
Background: The aim of the present work was to evaluate the association between 
coffee consumption and the development of left ventricular systolic dysfunction (LVSD) in 
patients who had had an acute coronary syndrome (ACS). Methods: During 2006-2007, 
288 male (64±13 years) and 75 female (71±11 years) post-ACS patients who developed 
LVSD (ejection fraction <40%) after the cardiac event and 221 male (62±11 years) and 
69 female (66±11 years) post-ACS patients without LVSD (ejection fraction >50%), 
were included in the study. Detailed information regarding their medical records, socio-
demographic, anthropometric data, and various psychological, and lifestyle characteristics 
(physical activity, smoking habits etc) were recorded. Particularly, nutritional habits, 
including coffee consumption, were evaluated using a semi-quantitative food-frequency 
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1039-91 Does A Twelve Week Community Based Cardiac 
Rehabilation Program Lead To Better Glycemic And 
LDL Controll for Patients With Type 2 Diabetes?
Peggy Hulan, Janice Macisaac, Darlene Cooley - Warnell, Annette Love, Sarah 
Manley, Joyce McCormack, Daneille Aldous, Wanda Firth, Jennifer Crafer, Nicholas 
Giacomantonio, QEII health Science Center, halifax, Canada
Background:The explosive increase in diabetes in the 21st century has made it a real 
health threat. Diabetes affects 151 million people worldwide, with 90- 95% presenting as 
Type 2 diabetics. It is estimated that by 2010, 221 million people will develop diabetes. 
Vascular disease is the leading cause of death in patients with Type 2 diabetes. Evidence 
indicates that lifestyle modiﬁcations can prevent or delay the occurrence of diabetes by 
up to 58%.The Community Cardiovascular Hearts in Motion (CCHIM) Rehabilitation 
program is a pilot program aimed at delivering cardiovascular care to patients at high risk 
for vascular disease and established vascular disease in the community. The purpose 
of this analysis was to compare the difference in HgbA1c, fasting glucose and LDL at 
study entry, 12 weeks and 6 months. Our hypothesis is that the 12 week CCHIM Program 
will lead to a reduction in HgbA1c, fasting glucose and LDL, and that this effect will be 
sustained.
Methods: Of the 332 patients enrolled in CCHIM from Jan 2007 to Aug 2008, a total 
of 174 patients had Type 2 diabetes and were analyzed for this study, (73 males101 
females). The glycemic parameters for analysis included; fasting glucose, Hgb A1c levels 
and LDL levels. These levels were compared at program entry, program graduation (3 
months) and 6 months.
Results: The CCHIM group results on program effect for Hgb A1c at 3 months (n=133) 
and 6 months (n=75) were -4.7% (p = 0.0001), without medication changes and -5.6 % 
(p = 0.0004) respectively. The CCHIM program effect on fasting AC Glucose at 3 and 6 
months (n=170 at 3 months) was -3.7 %( (p= 0.03) and (n=145 at 6 months) was -4.6 % 
(p=0.01). LDL levels were reduced by 9% (p=0.0001) at 3 months due to program effect. 
This reduction was sustained and further reduced to -10.6% (p=0.0001) at 6 months.
Conclusions: The inclusion of a cardiac rehab program for patients with Type 2 diabetes 
has a signiﬁcant impact on lowering Hgb A1c, fasting glucose and LDL cholesterol which 
has potential to reduce the number of vascular events. All patients with Type 2 diabetes 
should be encouraged by health professions to attend a Prevention/Rehab program as 
part of a primary prevention program.
3:30 p.m.
1039-92 Changes in Cardiac Output Follow Weight Loss and 
Regain at 2 and 5 Years After Gastric Bypass Surgery: 
Clinical Implications
Zachary R. Williams, Theophilus Owan, Travis Ault, Richard Gress, Ted Adams, Steven 
Hunt, Sheldon E. Litwin, University of Utah, Salt Lake City, UT
Background: Increased cardiac output (CO) in severe obesity may contribute to the 
development of LVH and the increased risk of heart failure. We tested the hypothesis that 
resting CO follows weight changes after gastric bypass surgery (GBS).
Methods: 881 severely obese patients (BMI 46±7) enrolled in a prospective registry and 
then had GBS (n=239) or nonsurgical therapy (NonSurg, n=652). We calculated resting 
stroke volume (SV), and CO using quantitative echo-Doppler measurements at baseline, 
2 years and 5 years after enrollment. Ex Cap was determined by treadmill testing 
(modiﬁed Bruce protocol).
Results: GBS subjects lost 46±1 kg (* p < 0.001 vs. baseline) vs. 3±1 in the NonSurg 
group at 2 years. The GBS group regained 9±1* kg vs. no change in the NonSurg group 
at 5 years. CO decreased in the GBS group by 24% at 2 years (5.8±1.5 to 4.2±0.1* L/min). 
The reduction in CO resulted from a 21 % decrease in heart rate (73±11 to 59±9*) and 
a 4% decrease in SV (79±17 to 76±7*) relative to baseline. CO then increased by 4.3% 
(4.2±0.1 to 4.4±0.1) in the GBS group at 5 year follow up (vs. the 2 year time point) due to 
a 2% increase in SV as well as a 1.5 % increase in HR. At 2 years, Ex Cap improved by 
40 %* in GBS subjects, but then declined by 8% compared at 5 years. Ex Cap negatively 
correlated with resting CO (r = -0.35, p < 0.0001) at 2 years and also at 5 years (r = -.31, 
p < 0.0001) independent of age, sex, blood pressure, diabetes and smoking.
Conclusion: GBS results in dramatic weight loss at 2 years with modest weight gain 
between 2 and 5 years. Resting CO was decreased at 2 years with a corresponding 
improvement in Ex Cap. However, there is a trend towards increased CO with weight regain 
that correlates with decreased Ex Cap at 5 years. These ﬁndings support the idea that 
chronically elevated CO may contribute to cardiovascular pathophysiology in obesity.
diastolic mitral annular peak velocities (Em, Am) from four separate sites of measurement 
(septal, lateral, anterior and inferior walls).
Results: Hypertensive obese women (n=599) compared with non-obese (n=367) 
exhibited signiﬁcantly greater LVMI and a higher prevalence of LV hypertrophy (by 5.5gr/
m2 and 8.8%, p=0.003 and 0.005, respectively), while such differences were not present 
between hypertensive obese (n=415) and non-obese (n=408) men. Among hypertensive 
women, obese compared to non-obese were accompanied by signiﬁcantly lower ratios 
of transmitral E/A (by 0.08 p<0.001), TDI derived Em/Am (by 0.12, p<0.001) and higher 
ratio of E/Em (by 0.8, p=0.016). In contrast, hypertensive obese men compared to non-
obese exhibited only lower E and Em (by 0.04m/s and 0.6cm/s, both p<0.05). A signiﬁcant 
interaction between sex and abdominal obesity was observed only regarding TDI-derived 
Am and Em/Am (p<0.05 for both). Waist circumference along with age and hemodynamic 
variables was a predictor of E/A (B=-0.097, p=0.002) and Em/Am (B=-0.116, p=0.001), 
independently of body size, in females but not in males.
Conclusions: The adverse effect of abdominal obesity on LV structural and functional 
alterations is more pronounced among hypertensives of the female gender suggesting 
that routine measurement of waist circumference provides additional information on 
cardiac phenotype especially in women.
3:30 p.m.
1039-89 Association of Framingham Risk Score With Chronic 
Kidney Disease: Insight From National Health and 
Nutrition Examination Survey 2003-2006
Jou-Wei Lin, Lian-Yu Lin, Chien-Yu Lin, Hsu-Ko Kuo, National Taiwan University Hospital 
Yun-Lin Branch, Dou-Liou City, Taiwan,ROC, National Taiwan University Hospital, Taipei, 
Taiwan,ROC
Background: The objective of this study was to illustrate the association between 
cardiovascular risk factors and CKD.
Methods: Subjects aged between 30 and 74 who participated in the National Health and 
Nutrition Examination Survey (2003-2006) were included for analysis, and Framingham 
risk score was calculated. Glomerular ﬁltration rate was estimated (eGFR) by the 
Modiﬁcation of Diet in Renal Disease (MDRD) Equation, and eGFR less than 60 ml/
min/1.73m2 was deﬁned as CKD.
Results: A total of 2,524 men (mean age: 51±13) and 2,516 women (mean age: 50±13) 
completed both cardiovascular risk assessment and renal function evaluation. The 
proportion of Mexican Hispanics, other Hispanics, whites, blacks, and other races was 
20.4%, 3.1%, 51.9%, 20.4%, and 4.2%, respectively. The 10-year coronary risk, deﬁned 
as high (>=20%), intermediate (10~20%), and low (< 10%) was assigned to 434 (17.2%), 
650 (25.8%), and 1440 (57.0%) male subjects, and to 73 (2.9%), 406 (16.1%), and 
2037 (81.0) female subjects. The crude prevalence of CKD was 5.7% in men and 7.2% 
in women. Male subjects in the high- and intermediate-CHD-risk group was positively 
associated with the risk of CKD (odds ratio: 7.20, 95% CI: 4.62~11.2, p < 0.001, and OR: 
3.67, 95% CI: 2.33~5.77, p < 0.001) as compared to those in the low-CHD-risk group. 
In the female, the odds ratio was 8.64 (high risk vs. low risk, 95% CI: 4.99~14.9, p < 
0.001) and 4.30 (intermediate risk vs. low risk: 95% CI: 3.08~6.01, p < 0.001). Receiver-
operating-characteristic (ROC) analysis showed that Framingham risk score could 
discriminate the subjects with and without CKD with area under curve 0.75 (95% CI: 
0.72~0.79) in men and 0.79 (95% CI: 0.76~0.81) in women.
Conclusion: The result of this study has demonstrated that Framingham risk score could 
be used as a potential predictor not only for future CHD but also for concurrent CKD. 
3:30 p.m.
1039-90 Resting Diastolic Blood Pressure Is a Strong Predictor 
of Exercise Metabolic Rate
Mark Kroll, Ryan M. Kroll, James A. Levine, E. Andrew Wood, Gabriel Koepp, Gary 
Stein, Marc Seaburg, University of Minnesota, Minneapolis, MN
Background: There is a need to estimate the increase in metabolic rate during exercise 
(EMR) to optimize activity monitoring obesity control programs. Classic resting metabolic 
rate estimation formulae have used height, weight, body mass index (BMI), gender, and 
age although 2 recent reports have suggested a role for blood pressure. We thus sought 
to evaluate the utility of using systolic and diastolic blood pressure (SBP and DBP) as 
independent predictors of EMR.
Methods: We recruited 93 participants in an industrial weight monitoring program. We 
excluded 5 for DBP q 110 or SBP q 170 mmHg leaving 88 (39M/49F, age 43.4 ± 10.8). 
Clinical variables were: BMI = 28.4 ± 6.2, body fat = 31.5 ± 10.7%, height = 1.70 ± 
0.1 m, weight = 82.8 ± 18.6 kg, SBP = 127.3 ± 14.0 mmHg, and DBP = 79.2 ± 9.1 
mmHg. Subjects were instrumented with a gas exchange system and metabolic rate was 
calculated with Weir’s equation. Subjects also wore an Actical® activity monitor on the hip 
and walked on a treadmill at speeds of 1.5, 2.9, and 4.4 m/s (1, 2, and 3 mph).
2ESULTS ! TOTAL OF    s 	 DATA WERE GATHERED AND  READINGS WERE EXCLUDED AS 
Tukey outliers. EMR was predicted by treadmill speed with r2 = .59 ( p < .0001). Stepwise 
regression then added DBP (increasing r2 to .68, p < .0001). No other clinical variables 
were signiﬁcant predictors. During normal daily activity a walking speed is not available 
so the EMR was then regressed with the activity monitor score ( r2 = .50, p < .0001). 
Stepwise regression then added DBP (r2 = .64, p < .0001) and height (r2 = .64, p = .003). 
No other variables were signiﬁcant.
Conclusions: Diastolic blood pressure was the strongest clinical predictor of exercise 
metabolic rate in this preliminary study. Further studies should be done to explore the 
mechanism. Activity based obesity control programs should consider the use of blood 
pressure to improve the accuracy of caloric expenditure estimates.
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0910-5 Differential Effects of Extended Release Carvedilol 
and Extended-Release Metoprolol on Lipid Proﬁles in 
Patients With Hypertension: Results of the Carvedilol 
CR Lipid Trial
Mary Ann E. Lukas, Gregg C. Fonarow, Prakash Deedwania, Vivian Fonseca, Richard 
W. Nesto, Karol Watson, Elizabeth Tarka, Anuradha Madan, Mayadah Shabbout, 
Carvedilol CR Lipid Study Investigators, UCLA School of Medicine, Los Angeles, CA, 
GlaxoSmithKline Pharmaceuticals, Philadelphia, PA
Background: Hypertension (HTN) and dyslipidemia are modiﬁable risk factors for CV 
morbidity and mortality. Beta blockers treat HTN, but some may adversely affect lipids 
and increase insulin resistance. Beta blockers without adverse metabolic effects may be 
preferred in long-term HTN therapy.
Methods: Patients with HTN but without diabetes and not on lipid altering therapy were 
randomized to once daily carvedilol phosphate CR (C) or metoprolol succinate (M), 
and titrated to target BP (<140/<90 mm Hg) with 20, 40, 80mg C or 50, 100, 200mg M. 
Co-primary endpoints were comparison between groups of % change from baseline to 
24 weeks in HDL or triglycerides (analysis alpha = 0.025). Treatment differences were 
assessed using ANCOVA adjusted for treatment, center, gender and baseline values. 
Additional endpoints were lipid (TC, LDL, HDL subfractions, LDL relative ﬂotation) and 
glycemic parameters (FPG, HbA1c, fasting insulin [I], c-peptide [CP], HOMA-%S).
Results: 568 pts were randomized (C n=290, M n=278); 48% female; mean age 52 yrs. 
At baseline, mean BP was 147.9/93.9 mm Hg, BMI 32 kg/m2; triglycerides 190 mg/dL; 
HDL 45.4 mg/dL. SBP and DBP were signiﬁcantly reduced at endpoint in both groups (C 
-15.90/-10.89 mm Hg; M -16.23/-11.06 mm Hg). C was superior to M in median % change 
in triglycerides -8.03% (p=0.0141; 97.5%CI, -15.35, -0.67) from baseline to endpoint. 
Triglycerides increased signiﬁcantly from baseline to endpoint in M (10.39%, p<0.0001; 
97.5%CI, 5.17, 16.00). There was no signiﬁcant difference in effect on HDL. There were 
signiﬁcant decreases with C vs M in I [-2.56 mciu/mL (p=0.0213; 95%CI, -4.74, -0.38)] 
and CP [-0.43 ng/mL (p=0.0007; 95%CI, -0.68, -0.18)]. Additional analyses of C vs M 
in pts with low baseline HDL (C n=149, M n=144) showed signiﬁcant positive effects 
on triglycerides, I, CP and HOMA-%S, and in pts with high BMI (C n=175, M n=167), 
signiﬁcant positive effects on triglycerides, I, and CP.
Conclusion: In patients with HTN, extended-release carvedilol resulted in signiﬁcantly 
lower levels of triglycerides, I and CP vs metoprolol succinate, including in high-risk 
subgroups. This differential metabolic proﬁle could be useful in determining treatment 
options in pts with HTN.
5:15 p.m.
0910-6 Calcium Channel Blockers and Cardiovascular 
Outcomes: A Meta-Analysis
Pierluigi Costanzo, Pasquale Perrone-Filardi, Mario Petretta, Caterina Marciano, 
Paola Gargiulo, Giuseppina Guerra, Andrea Petretta, Antonio Marzano, Gianluca 
Caiazzo, Massimo Chiariello, Department of Internal Medicine, Cardiovascular and 
Immunological Science, Naples, Italy
Background: The aim of this study was to update the previous meta-analyses with the 
results of the recent trials, assessing the effect of CCBs treatment, compared to other 
drugs or placebo/top of therapy, on all cause mortality, cardiovascular death, major 
cardiovascular events, heart failure, myocardial infarction and stroke.
Methods: We performed a meta-analysis of randomized controlled trials that compared 
a long acting calcium channel blocker with another drug or placebo/top of therapy and 
that assessed all cause mortality and cardiovascular events. Overall estimates of effect 
were calculated with a ﬁxed-effects, random effects model or Peto method. We performed 
also random effects meta-regression analysis to assess the inﬂuence of blood pressure 
reduction on the outcomes.
Results: We included 27 trials (175,634 patients). The risk of all cause death was reduced 
by dihydropyridine CCBs (OR 0.96, 95% CI 0.93 to 0.99, p=0.03; heterogeneity (h) 
p=0.87) without inﬂuence of placebo trials and blood pressure reduction. The risk of heart 
failure was increased by CCBs compared to active treatment (OR 1.17, 95% CI 1.11 to 
1.24, p=0.0001; h p=0.0001) and it was decreased when compared to placebo (OR 0.72, 
95% CI 0.59 to 0.87, p=0.001; h p=0.77), also in the subgroup of coronary artery disease 
patients (OR 0.76, 95% CI 0.61 to 0.95, p=0.01; h p=0.29). CCBs did not increase the risk 
of myocardial infarction (OR 1, 95% CI 0.95 to 1.04, p=0.83; h p=0.004), cardiovascular 
death (OR 0.97, 95% CI 0.93 to 1.02, p=0.24; h p=0.16), major cardiovascular events 
(OR 0.97, 95% CI 0.90 to 1.06, p=0.53; h p=0.0001). CCBs decreased the risk of fatal 
or nonfatal stroke (OR 0.86, 95% CI 0.82 to 0.90, comparison p=0.0001; h p=0.12), also 
when compared to ACE inhibitors (OR 0.87, 95% CI 0.78 to 0.97, p=0.016; h p=0.48)
Conclusions: Our study demonstrates that calcium antagonists reduce the risk of 
all cause mortality compared to active therapy, and prevent heart failure compared to 
placebo. Furthermore, with the inclusion of recent trials, we conﬁrm that they reduce 
the risk of stroke, also in comparison to ace inhibitors and do not increase the risk of 
cardiovascular death, myocardial infarction and major cardiovascular events
ACC.ORAL CONTRIBUTIONS
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Issues with Antihypertension Therapy
Monday, March 30, 2009, 4:30 p.m.-6:00 p.m.
Orange County Convention Center, Room W308A
4:30 p.m.
0910-3 Hyperkalemia During Treatment of Hypertension With 
Aliskiren, Losartan, or the Combination: An Analysis of 
the Aliskiren in Left Ventricular Hypertrophy (ALLAY) 
Trial
Akshay S. Desai, Valentina Lukashevich, Evan Applebaum, Beverly Smith, Bjorn Dahlof, 
Scott Solomon, Brigham and Women’s Hospital, Boston, MA
Background: Hyperkalemia (HK) is a known and potentially life-threatening complication 
of treating hypertension (HTN) with inhibitors of the renin angiotensin system (RAS). Dual 
RAS inhibition with aliskiren and losartan may enhance the risk of HK.
Methods: ALLAY randomized 465 overweight patients with HTN and left ventricular 
hypertrophy (LVH) to 36 weeks of treatment with aliskiren, losartan, or the combination. 
Key exclusion criteria included potassium (K) q 5.2 mmol/L, renal dysfunction, and use 
of K-sparing diuretics. The primary endpoint was LVH regression by magnetic resonance 
imaging. Periodic measurement of K and creatinine was conducted by a central laboratory. 
We examined the rates of HK according to treatment assignment.
Results: Enrolled subjects were largely non-diabetic (75.9%) with mean age 58.8 ± 10.4 
years, potassium 4.2 ± 0.4 mmol/L, and estimated glomerular ﬁltration rate (eGFR) 85 
± 17 cc/min/1.73 m2. 452 subjects had at least one post-baseline K assessment. One 
subject, randomized to losartan, discontinued study drug for HK. There were no HK-
related deaths. Rates of HK were higher in patients with baseline diabetes, eGFR<60 cc/
min/1.73 m2, or K >= 5.0, but did not vary with treatment group.
Conclusions: Relative to either agent alone, combination therapy of HTN with aliskiren/
losartan in ALLAY did not increase the risk of HK. Still, surveillance for HK is important 
when using RAS inhibitors to treat HTN, particularly amongst those with diabetes, low 
eGFR, or high K. 
Serum 
Potassium
Aliskiren 300 mg 
(n=149)
Losartan 100 mg 
(n=151)
Combination
(n=152)
Total 
(n=452)
> 5.5 mmol/L 4 (2.7%) 5 (3.3%) 5 (3.3%) 14 (3.1%)
q 6.0 mmol/L 3 (2.0%) 1 (0.7%) 1 (0.7%) 5 (1.1%)
4:45 p.m.
0910-4 The Cyclooxygenase Inhibiting Nitric Oxide Donator 
Naproxcinod Lacks the Hypertensive Effects Seen With 
Naproxen in Patients With Osteoarthritis
William B. White, Thomas Schnitzer, University of Connecticut School of Medicine, 
Farmington, CT, Northwestern University School of Medicine, Chicago, IL
Nonsteroidal anti-inﬂammatory drugs are associated with destabilization of systolic BP control 
in hypertensive (HTN) patients with osteoarthritis (OA), especially when treated with renin-
angiotensin system (RAS) blockers. To mitigate against the HTN effects of COX inhibition, 
the cyclooxygenase-inhibiting NO donator (CINOD) naproxcinod is being developed for the 
treatment of OA. We studied the effects of naproxcinod on systolic BP (SBP) vs. naproxen and 
placebo in a 13-week double-blind, randomized trial with 916 treated OA patients, of which 
457 had HTN and 207 were treated with a RAS blocker. At baseline, patients were 61 ± 9 
years, 70% female, and 86% non-black. As shown in the Table, baseline SBPs were slightly 
higher for HTN on RAS blockers. Reductions from baseline in SBP were larger in patients on 
naproxcinod 750 mg compared to naproxen (p < 0.02) and similar to placebo (p = 0.505). In 
the RAS blocker group, changes from baseline in SBP were 6.5 mmHg higher on naproxen 
compared to naproxcinod 750 mg (p < 0.02) and 4.2 mmHg higher compared to the 375 mg 
dose (p = 0.10). In all HTN patients, the proportion whose SBP rose by > 10 mmHg was lower 
on naproxcinod and placebo than on naproxen. These data show that naproxcinod induces 
less destabilization of BP compared to naproxen - particularly in HTN on RAS blockers - 
and behaves similarly to placebo in patients with OA. These ﬁndings have important clinical 
implications for HTN patients with arthritis.
EFFECTS OF TWICE DAILY NAPROXCINOD, NAPROXEN , AND 
PLACEBO ON SBP (13 WEEKS)
Naproxcinod 
750 mg 
Naproxcinod 
375 mg
Naproxen 
500 mg Placebo
All Patients
Baseline SBP
Mean ± SD (mmHg)
N = 229
125 ± 14
N = 240
127 ± 13
N = 225
126 ± 15
N = 222
126 ± 
13
$ in SBP ± SE (mmHg) -3.9 ± 0.8* -2.8 ± 0.8 -1.0 ± 0.8 -3.1 ± 1.0
RAS blocker group
Baseline SBP
Mean ± SD (mmHg)
N = 53
129 ± 12
N = 56
129 ± 15
N = 44
128 ± 12
N = 54
128 ± 
13
$ in SBP ± SE (mmHg) -5.0 ± 1.7* -2.7 ± 1.7 1.5 ± 1.9**
-4.6 ± 
1.9
All Hypertensives at 13 weeks
Proportion with > 10 mmHg 
increase in SBP
N = 96
11.5 %†
N = 94
16.0%
N = 90
23.3%
N = 72
15.3%
* p < 0.02 vs naproxen; ** p < 0.05 vs placebo; †p < 0.04 vs naproxen
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day). CO-conﬁrmed CAR in the last 4 weeks of treatment (weeks 9-12) was higher for 
VAR than PLA (47.3% versus 14.3%; odds ratio [OR]: 6.05; 95% conﬁdence interval [CI]: 
4.13, 8.86 P<0.0001). The superiority of VAR over PLA persisted through 40 weeks of 
follow-up (CAR Weeks 9-52: 19.8% versus 7.4%;OR: 3.19; 95% CI: 1.97, 5.18; P<0.0001). 
The most frequent adverse events (AE) in the VAR group (occurring more than in the 
placebo group) were nausea (29.5%), headache (12.7%), insomnia (11.9%), vomiting 
(8.2%) and abnormal dreams (7.9%). Discontinuations due to AEs occurred in 2.3% of 
VAR and 1.4% of PLA subjects. Serious AEs occurred in 6.5% of VAR and 6.0% of PLA 
subjects; 0.6% of VAR and 1.4% of PLA subjects died. Conclusion: In CVD patients, VAR 
is effective for smoking cessation after 12 weeks of treatment and through 52 weeks of 
follow-up, and it has an acceptable safety proﬁle. Varenicline is an effective treatment to 
aid quitting in smokers with CVD.
9:30 a.m.
1048-68 The Obesity Paradox in Acute Coronary Syndrome 
Patients in Israel
Michael Shechter, Haim Hammerman, Valentina Boyko, Hanoch Hod, Solomon Behar, 
Shlomi Matetzky, The Heart Institute, Sheba Medical Center, Tel Hashomer, Israel, 
Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel
Background: While obesity is a coronary disease risk factor, its effect on acute coronary 
syndrome (ACS) outcome is inconsistent.
Methods: To explore the impact of body mass index (BMI) on short (30-day) and long (1-year)-
term clinical oucome, we retrospectively analyzed data of 5,751 patients [4,400 (77%) males, 
2,754 (48%) with and 2,994 (52%) without ST-segment elevation ACS] from the Acute 
Coronary Syndrome Israel Survey (ACSIS), comprising data from ACS patients hospitalized 
in 2002, 2004 and 2006 during a 2-month period in all coronary care units in Israel.
Results: Patients were divided into National Institutes of Health BMI-based 4 categories: 
Underweight (BMI<18.5 kg/m2), normal (18.5-24.9), overweight (25.0-29.9), and obese (q30 
kg/m2) (Table). Mean BMI increased signiﬁcantly during 2002, 2004 and 2006 (27.0±4.0, 
27.2±4.3 and 27.7±4.5 kg/m2, p<0.0001; respectively). Time from chest pain onset to 
hospitalization and invasive procedure, Killip class on admission, left ventricular ejection 
fraction, creatinine clearance and in-hospital therapy were the same in all 4 groups.
Conclusion: Overweight and obese BMI-based categories were associated with younger 
age and better survival than normal and underweight ACS patients. Our obserevation of 
a U-shaped relationship between increaseing BMI and mortality in ACS patients warrants 
careful propsective evaluation.
Values are expressed as mean±SD; *p for trend<0.0001; †OR=odds ratio adjusted for 
CAD risk factors.
Underweight 
(n=43)
Normal 
(n=1709)
Overweight 
(n=2700)
Obese
(n=1299)
Age (yrs) 69.9±17.7 65.3±13.7 63.3±12.6 61.4±12.4*
30-day 
mortality 9.3% 5.6% 3.3% 4.7%
OR†(95% C.I.) 0.91(0.24-2.69) 1.0 0.50(0.38-0.67) 0.88(0.62-1.22)
1-year 
mortality 20.7% 12.3% 8.2% 9.4%
OR† (95% 
C.I.) 1.0(0.34-2.96) 1.0 0.63(0.49-0.80) 0.78(0.57-1.06)
9:30 a.m.
1048-69 Cardiovascular Risk Modiﬁcation in Chronic Kidney 
Disease Patients with Coronary Disease: Results From 
the Kidney Early Evaluation Program (KEEP)
Peter A. McCullough, Adam Whaley-Connell, Wendy W. Brown, Allan J. Collins, Shu-
Cheng Chen, Suying Li, Keith C. Norris, Bruce Johnson, David Calhoun, Claudine 
Jurkovitz, Samy McFarlane, Chamberlain Obialo, Michael Shlipak, James Sowers, 
Lesley Stevens, Joseph A. Vassalotti, George L. Bakris, KEEP Investigators, William 
Beaumont Hospital, Royal Oak, University of Chicago School of Medicine, Chicago, IL
Background. Coronary artery disease (CAD) identiﬁed by prior myocardial infarction 
(MI), percutaneous coronary intervention (PCI) or coronary artery bypass surgery 
(CABG) identiﬁes a patient in need of intensive cardiovascular risk modiﬁcation. Chronic 
kidney disease (CKD) may complicate the long-term management of cardiovascular risk 
factors.
Methods. Volunteers at risk for CKD by history, from 47 US sites, completed surveys 
regarding past medical events and underwent blood pressure, and laboratory testing. 
Estimated glomerular ﬁltration rate (eGFR) was computed and the urine albumin:creatinine 
ratio (ACR) was measured. CKD was deﬁned as eGFR<60 ml/min/1.73 m2 or ACRq30
mg/g. CAD was deﬁned as prior MI, PCI, or CABG.
Results. Of 70,454 the mean age was 53.5±15.7 years, 68.3% were female, 27.9% had 
diabetes. A total of 5,410 (7.7%) had a self-reported history of CAD and 15,968 (27.1%) 
had CKD; 1,295 (1.8%) had prior PCI; and 1,124 (1.6%) had a previous CABG. Rates of 
blood pressure control, deﬁned as a systolic blood pressure<130 mm Hg, among those 
with CKD were: no CAD history 34.4%; prior CAD without revascularization (no PCI or 
CABG) 30.9%; and CAD with revascularization, 34.5%. Likewise, glycemic control rates, 
deﬁned as fasting glucose<125 mg/dl for diabetics were 70.3, 55.5, and 57.1%; total 
cholesterol<200 mg/dl 48.9, 57.2, and 72.1%; and current smoking 10.2, 10.6, and 8.2%. 
Multivariate analysis for the outcome of suboptimal cardiovascular risk management 
which occurred in 38,746/53,403 (72.6%) deﬁned as the composite of SBPq130 mm Hg, 
glucoseq125 mg/dl for diabetics, cholesterolq200 mg/dl, or current smoking); revealed 
that older age (per year) OR=1.04; male OR=1.40; ACRq30 OR=1.66; one unit increase 
of BMI OR=1.06; family history of CKD OR=0.74; having insurance OR=0.73; high school 
education or more OR=0.77 (all p<0.0001); and CAD without revascularization OR=1.14, 
p=0.019; were all independently associated variables.
5:30 p.m.
0910-7 Long-Term Mortality Associated With New Onset 
Diabetes in Hypertensive CAD Patients Following 
Exposure to Antihypertensive Medications: Findings 
from the INternational VErapamail SR-Trandolapril 
STudy (INVEST)
Rhonda M. Cooper-DeHoff, Yan Gong, Jessica Marin, Adam Rosen, Eileen M. 
Handberg, Julie A. Johnson, Carl J. Pepine, University of Florida, Gainesville, FL
Background: There has not been uniform agreement regarding the impact of 
antihypertensive medication associated new onset diabetes, which has led many to 
believe that it may not be associated with the same adverse outcomes as diabetes of 
other etiologies.
Methods: The INternational VErapamail SR-Trandolapril STudy (INVEST) enrolled 22,576 
hypertensive CAD patients who were randomized to either a verapamil SR-based or an 
atenolol-based treatment strategy. At baseline, 6,400 patients were diabetic and 1,234 
developed diabetes during a mean 2.7 years of follow-up. This study reports cumulative 
all-cause mortality, including deaths reported during the study and deaths during the 5 
years post study end, determined by searching the social security death index. Findings 
are reported according to diabetes status, for the 17,131 patients enrolled in the US.
Results: There were a total of 2,351 deaths; 913 (17.98%) in the baseline diabetics, 186 
(17.82%) in the new onset diabetics and 1,252 (11.37%) in the nondiabetics. Cumulative 
incidence of death is shown in the Figure. After approximately 3 years, mortality in those 
with new onset diabetes is similar to mortality in those with diabetes at baseline.
Conclusions: These data indicate that mortality in patients with hypertension, CAD and 
diabetes, whether diabetes develops during exposure to antihypertensive medications or 
as a result of other etiologies, is signiﬁcantly higher than in patients with hypertension and 
CAD but without diabetes. 
ACC.POSTER CONTRIBUTIONS
1048
Risk Reduction and Rehabilitation
Tuesday, March 31, 2009, 9:30 a.m.-12:30 p.m.
Orange County Convention Center, West Hall D
9:30 a.m.
1048-67 Efﬁcacy and Safety of Varenicline for Smoking 
Cessation in Patients With Cardiovascular Disease: 
A Randomized Trial
Nancy A. Rigotti, Andrew Pipe, Dahlia Garza, Carmen Arteaga, Neal L. Benowitz, 
Serena Tonstad, Massachusetts General Hospital & Harvard Medical School, Boston, 
MA, University of Ottawa Heart Institute Minto Prevention and Rehabilitation Centre, 
Ottawa, ON, Canada
Background: Smoking cessation is a cornerstone of secondary cardiovascular disease 
(CVD) prevention. Varenicline (VAR), a partial agonist of the A4B2 nicotinic cholinergic 
receptor, is effective for smoking cessation in healthy smokers, but its safety and efﬁcacy 
in smokers with CVD has not been tested. Methods: A randomized, double-blind, 
placebo-controlled, multicenter trial tested the efﬁcacy and safety of VAR versus placebo 
(PLA) for smoking cessation in smokers aged 35-75 years who smoked q10 cigarettes/
day and had stable documented cerebrovascular, cardiovascular (other than hypertension 
alone), or peripheral vascular disease diagnosed >2 months before screening. Subjects 
received either VAR 1 mg BID or PLA for 12 weeks along with motivational support and 
were followed for 40 weeks off drug treatment (total 52 weeks). The primary endpoint 
was the carbon monoxide (CO)-conﬁrmed continuous abstinence rate (CAR) for Weeks 
9-12 (last 4 weeks of treatment). A key secondary endpoint was CO-conﬁrmed CAR for 
Weeks 9-52. Safety was also evaluated. Results: 703 subjects (353 VAR; 350 PLA) were 
randomized and treated with >1 dose of study drug. Subject demographics were similar 
between groups (mean age, 56.5 years; 78.7% male; 80.5% white; mean, 23 cigarettes/
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studied. All underwent cardiovascular risk assessment by phlebotomy, anthromorphmetry 
and blood pressure measurement. Patients with renal dysfunction were subsequently 
excluded from analysis. Those remaining patients with hypercalcaemia had parathyroid 
hormone (PTH) levels assayed.
Results: 33,314 (23,587 males) were studied. Mean age was 52 years (50.5 for 
females). 341 patients (224 males, mean age 50.8 yrs; 117 females, mean age 57.3 yrs) 
had elevated PTH (>65 pg/ml) in the presence of hypercalcaemia and were therefore 
considered to have primary hyperparathyroidism. These patients overall had signiﬁcantly 
elevated Diastolic BP (p=0.03), BMI (p=0.001), WC (p=0.014) and Glucose (p=0.009) 
when compared to the normocalcaemic group. 55 (16.2%) of these patients had 
metabolic syndrome (MetS) as diagnosed by ATPIII criteria with IDF criteria identifying 80 
(35.9%) subjects as having MetS. Linear regression determined hyperparathyroidism as 
independently predictive of ATPIII deﬁned MetS and Framingham Risk Score. 
Males Females
Age
(years)
No. (prevalence) 
with
hyperparathyroidism
Signiﬁcant*
correlates v 
background cohort
No. (prevalence) 
with
hyperparathyroidism
Signiﬁcant*
correlates v 
background 
cohort
<50 89 (0.9%) Chol., TG, LDL, HDL 23 (0.5%) Chol., TG,
50-59 79 (0.9%) HDL 46 (1.6%) Diastolic BP,Chol.,HDL,WC
>60 47 (0.7%) HDL 49 (2.2%) BMI
Chol..=cholesterol; TG=triglycerides; LDL=low density lipoprotein; HDL=high 
density lipoprotein; BMI=Body mass index; WC=Waist Circumference; BP=Blood 
pressure;*p<0.05.
Conclusion: Screen-detected primary hyperparathyroidism is a signiﬁcant marker for 
considerable concomitant cardiovascular risk. Whether directed therapy can alleviate this 
risk correlates demands investigation.
9:30 a.m.
1048-73 A Simple and Effective Approach to Improving Cardiac 
Rehabilitation (CR) Referrals: Improving Clinical 
Practice Through Mandatory Computerized Physician 
Order Entry (CPOE)
Mahesh J. Patel, Daniel R. Bensimhon, Bradi B. Granger, Phil Mendys, Karen P. Craig, 
Bernie McCants, Jr., William E. Kraus, James A. Heinsimer, Duke University, Durham, NC
Background: CR is associated with numerous clinical beneﬁts, including reduced 
mortality in patients (pts) post-MI. However, referral to CR and attendance at CR if 
referred has been poor: ~ 15-30% in most studies. Furthermore, with passage of the 
Pulmonary and Cardiac Rehabilitation Act which mandates CR as a Medicare beneﬁt in 
2010, CR referral may become a quality metric for hospitals. Thus, strategies to enhance 
referrals and attendance at CR are needed.
Methods: Discharge data were used to identify pts eligible for CR at Duke Hospital 
from 8/1/07 - 8/1/08, per 6 payable Medicare indications for CR - stable angina, surgical 
or percutaneous revascularization, cardiac transplant, valve surgery and myocardial 
infarction. The Duke cardiovascular database and CR referral information was used to 
stratify these pts by readmission, region of residence and CR attendance. In August of 
2008, a strategy to enhance CR referral was initiated - implementing a mandatory CPOE 
response for CR referral in Duke Hospital admission order sets for cardiology services.
Results: Over 1 year, 5718 discharges met Medicare criteria for CR referral at Duke 
Hospital; 664 pts had multiple entries with 37 pts having 20 or more entries, leaving 3303 
unique pts. Of these 3303 CR eligible pts, only 839 (25%) were referred from Duke to 
CR and 1295 (39.2%) lived within 30 miles of Duke. Only 217 pts in the tri-county area 
surrounding Duke (17% of local pts) were referred to CR. Of 128 pts whose primary site 
of care is Duke Medical Center, 55 pts (43%) were referred and attended CR, 34 (27%) 
were referred but did not attend and 39 (30%) were never referred. Post-operative pts had 
better referral rates than non-operative pts. In a pilot program, response to CR referral 
within CPOE became mandatory for all Duke CCU admissions, doubling the number of 
referrals from pts admitted to the CCU within the ﬁrst month.
Conclusions: Referral rates and attendance at CR are low despite Medicare 
reimbursement and the known beneﬁts of CR. A pilot strategy involving mandatory 
response for CR referral via CPOE upon admission may be a simple and effective way to 
increase CR referrals. A broader strategy to enhance CR referrals and attendance is now 
being undertaken at Duke.
9:30 a.m.
1048-74 Genetic Polymorphisms in the Renin-Angiotensin System 
and Bradykinin Pathway Determine the Treatment Beneﬁt 
of ACE-Inhibitor Use in 10.060 Patients With Stable CAD: 
Feasibility of Pharmacogenetic Proﬁling.
Jasper J. Brugts, Moniek de Maat, Eric Boersma, Cock van Duijn, Jacqueline Witteman, 
Andre Uitterlinden, Jan Danser, Maarten L. Simoons, Erasmus MC Thoraxcenter, 
Rotterdam, The Netherlands
Background: Cost-effectiveness of ACE-inhibitors in stable CAD could be signiﬁcantly 
increased by targeting therapy to those patients who are most likely to beneﬁt. Genetic 
proﬁling could be a new way to select patients in advance.
Objective: We investigated whether genetic polymorphisms in renin-angiotensin-system 
and bradykinin genes determine the treatment beneﬁt of ACE-inhibitors.
Methods: In the EUROPA-trial, DNA was available in 10.060 patients with stable CAD 
randomized perindopril versus placebo. We selected 60 SNP’s in 10 genes of the RAAS 
Conclusions: CKD is associated with suboptimal cardiovascular risk management in 
CAD patients with or without prior revascularization. Major modiﬁable risk factors require 
intensiﬁed management in the CKD population.
9:30 a.m.
1048-70 High Density Lipoprotein Cholesterol Levels Contribute 
Signiﬁcantly to Residual Coronary Heart Disease Risk 
in Statin-Treated Patients
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas, Tufts Medical Center, Boston, MA
Background: Reducing low-density lipoprotein cholesterol (LDL-C) with statins 
signiﬁcantly lowers the risk of coronary heart disease (CHD). However, the rate of CHD 
events in statin-treated patients with well optimized LDL-C levels remains unacceptably 
high. We examined the extent to which high-density lipoprotein cholesterol (HDL-C) levels 
contribute to this residual risk in large, randomized controlled trials (RCTs) of statins.
Methods: A MEDLINE search identiﬁed statin RCTs with q 1,000 years of follow-up. 
Weighted meta-regressions (inverse of variance) evaluated the association of HDL-C and 
the risk of myocardial infarction (MI), in statin-treated and control cohorts.
Results: A total of 16 eligible statin RCTs were identiﬁed (with 476,917 person-years of 
follow-up and 7157 MIs). The rate of MI was signiﬁcantly and inversely correlated with 
HDL-C levels in both statin-treated and control arms, such that there were 6.9 and 8.9 
fewer MIs per 1000 person years for every 10mg/dl increment in HDL-C in the statin and 
control groups respectively (p = 0.001 for both; FIGURE). In contrast, statin treatment 
reduced MIs by a median of 4.4/1000 person years. The signiﬁcant inverse relationship 
between HDL-C and MI persisted after adjusting for LDL-C and age (p < 0.001).
Conclusion: Baseline HDL-C levels contribute importantly to risk of MI in statin-treated 
patients. These data support that low HDL-C levels contribute to the residual CHD risk 
observed in statin-treated patients. 
9:30 a.m.
1048-71 Elderly Patients with Congestive Heart Failure and 
Cheyne-Stokes Respiration: Adaptive Servoventilation 
Leads to Improvement in Symptoms and Cardiac 
Function
Olaf Oldenburg, Thomas Bitter, Roman Lehmann, Stefan Korte, Anke Schmidt, Birgit 
Wellmann, Dieter Horstkotte, Department of Cardiology, Heart and Diabetes Center 
North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany, Cardiac 
Research Unit, Bad Oeynhausen, Germany
Background: Nocturnal Cheyne - Stokes respiration (CSR) is associated with an impaired 
prognosis in patients (pts) with congestive heart failure (CHF). Adaptive servoventilation 
(ASV) was recently introduced to treat CSR in CHF. Aim of this study was the investigation 
of ASV effects in elderly patients (age q 65 years) with moderate to severe CSR (apnea-
hypopnea-index [AHI] q 15/h) and symptomatic CHF (NYHA q II, LV-EF a 40%).
Methods: In 33 pts with CHF treated according to current guidelines (32 male; 72±5years, 
BMI 26.7±4 kg/m2) cardiorespiratory polygraphy (PG), cardiopulmonary exercise (CPX) 
testing and echocardiography was performed before and after 3.6±1.6 months of ASV 
treatment (AutoSet CS™2, ResMed).
Results: In this cohort of elderly patients, mean duration of ASV usage during night was 
6:30±1:0 hrs, while the device was used in 83±18% of nights possible. AHI was reduced 
from 35.6±13/h to 6.0±8/h (p<0.001). Minimum oxygen saturation rose from 82.9±5.1% 
to 86.0±7.7% (p=0.01) while mean oxygen desaturation was reduced from 6.3±2.6% 
to 4.4±1.5% (p<0.001). Peak oxygen consumption (VO2) during CPX testing increased 
from 14.0±4.7ml/kg/min to 16.7±5.1ml/kg/min and predicted peak VO2 from 60.9±20% to 
73.7±21% (both p<0.05). LV-EF increased from 29.4±6.4% to 33.5±10.5% (p=0.01).
Conclusions: In selected elderly pts with CHF and CSR, addition of nocturnal ASV 
therapy to standard heart failure therapy is able to abolish CSR and improve cardiac 
function. Whether this improvement in CSR and CHF parameters is accompanied by an 
improved prognosis needs to be proven.
9:30 a.m.
1048-72 Cardiovascular Risk and Screen-Detected Primary 
Hyperparathyroidism
Deirdre F. Waterhouse, Ronan A. Cahill, Frances Sheehan, Blackrock Clinic, Dublin, 
Ireland
Introduction: The cardiovascular signiﬁcance of primary hyperparathyroidism in those 
not presenting for speciﬁc medical attention in contemporary Ireland is unclear.
Methods: Consecutive patients attending health screening over a ten year period were 
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1048-77 Comprehensive Cardiometabolic Risk Assessment: A 
Simple Count of the Total Number of Traditional and 
Novel Risk Factors Is Associated With an Increased 
Risk of Cardiovascular Events
Subroto Acharjee, Jie Qin, Sabina A. Murphy, Carolyn McCabe, Christopher P. Cannon, 
Beth Israel Deaconess Medical Center, Boston, MA, Brigham and Women’s Hospital, 
Boston, MA
Background: Despite emergence of novel cardiometabolic risk factors, risk stratiﬁcation 
is still largely derived from traditional risk factors. We examined if evaluating newer 
markers is helpful.
Methods: We studied the distribution of 12 risk markers (age q65, male sex, family 
history of premature CHD, LDL q 70 mg/dl, HDL < 40 mg/dl in men and < 50 mg/dl in 
women, SBP > 130 mmHg, diabetes, smoking status, CRP q 2 mg/L, TG > 150 mg/dl, 
prediabetes [fasting glucose 100-125 mg/dl or HbA1c > 6] and obesity [BMI q 30 kg/m2])
in 3675 patients from the PROVE IT-TIMI 22 trial at 4 months and evaluated the risk of CV 
events stratiﬁed by the number of risk factors, using Log-rank testing for trend.
Results: The median number of risk factors was 5. In individual risk factor subgroups, 
men, smokers, hypertensives and patients with raised LDL had just that added risk factor 
compared to their counterparts (median no. 5 vs 4). In contrast, patients with diabetes, 
pre-diabetes, and elevated TG, CRP or BMI had not only that, but also another added risk 
factor (median no. 6 vs 4). A higher risk factor count was strongly related with increased 
rates for the primary endpoint* and death/MI/stroke (Figure).
Conclusions: Rates of CV events increase directly with number of cardiometabolic risk 
factors. Some factors cluster together thus adding to the incremental risk factor burden. 
These data suggest that when treating patients for one risk factor, a comprehensive 
review of all traditional and novel risk factors is important to fully assess CV risk.
9:30 a.m.
1048-78 Serum Matrix Metalloproteinase-8 Concentrations 
Are Associated With All-Cause Mortality Among 
Overweight Men
Sudhir Kurl, Timo Mäkikallio, Jari A. Laukkanen, Research Institute of Public Health, 
School of Public Health and Clinical Nutrition, Kuopio, Finland
Background: Matrix metalloproteinase-8 (MMP-8) thins the protecting ﬁbrous cap of the 
atherosclerotic plaque thereby increasing its vulnerability to unexpected rupture. However, 
results on the association of serum MMP-8 concentrations and mortality from all causes 
and coronary heart disease (CHD) death are very limited among over-weight men.
Methods: We analysed the association of serum MMP-8 and tissue inhibitor of 
metalloproteinase-1 (TIMP-1) concentrations in a population-based prospective sample 
of 1018 men (aged 46-64 years) of the Kuopio Ischemic Heart Disease risk factor study 
with the follow-up time of 10 years.
Results: During the follow-up, a total 192 deaths occurred and 69 were due to CHD 
occurred. MMP-8 concentrations were higher in men with body-mass index of > 25 at 
and BK pathways based on haplotype-tagging and functionality. Primary outcome measure 
was the reduction in cardiovascular mortality, non-fatal MI and resuscitated cardiac arrest. 
In the main study, perindopril was associated with a 20% reduction (HR 0.80 (0.71-0.91)) 
of the primary endpoint. The selected SNP’s were tested for heterogeneity in the treatment 
effect. Haplotype analysis was corrected for multiple testing by permutation analysis.
Results: In the study population, mean age was 60 and 85% were male. The primary 
outcome occurred in 382(8.1) patients using perindopril and 472(10.0) using placebo 
during 4 years. Four polymorphisms were identiﬁed that showed a clear heterogeneity in the 
treatment effect. The strongest effect was seen for rs4762 (T174M) in the angiotensinogen 
gene :(174TT;74%) HR 0.70 (0.60-0.87); (174TM;24%) HR 1.00 (0.81-1.26) and (174TT 
rare allele,2%) HR 1.36 (0.89-3.06), with P for interaction 0.02. Haplotype analysis 
conﬁrmed this result (P 0.04). The overall pharmacogenetic proﬁle consisting of 4 SNP’s 
in the angiotensinogen, angiotensinogen receptor type 1 and bradykinin genes deﬁned 
a group of patients not beneﬁting from treatment at all (24.4%), and a group with a more 
pronounced effect who should deﬁnitely be treated (75.6%).
Conclusion:. This large pharmacogenetic analysis demonstrates the feasibility of 
pharmacogenetic proﬁling in stable CAD for the ﬁrst time. This pharmacogenetic proﬁle could 
be used to guide ACE-inhibitor therapy to those patients most likely to beneﬁt. Such “tailored-
therapy” can increase cost-effectiveness of this prolonged prophylactic therapy signiﬁcantly.
9:30 a.m.
1048-75 Mediterranean Diet Is Associated With Lower Incidence of 
CVD Events: A Five-Year Follow-up of the ATTICA Study
Demosthenes B. Panagiotakos, Christina Chrysohoou, Christos Pitsavos, John 
Skoumas, John Lentzas, Dina Masoura, Akis Zeibekis, Christodoulos Stefanadis, 1st 
Cardiology Clinic University of Athens, Athens, Greece
BACKGROUND: The role of Mediterranean diet in the primary prevention of cardiovascular 
disease (CVD) has been investigated through several observational studies. We evaluated 
whether adherence to this traditional diet is associated with 5-year incidence of CVD 
events, in a random sample of CVD-free adults from Greece. METHODS: From May 2001 
to December 2002, 1514 men and 1528 women (>18 y) without any clinical evidence of 
CVD, living in Attica area, Greece, were enrolled in the ATTICA study. In 2006, a group 
of experts performed the 5-year follow-up. Development of CVD (coronary heart disease, 
acute coronary syndromes, stroke, or other CVD) during the follow-up period was deﬁned 
according to WHO-ICD-10 criteria. Adherence to the Mediterranean diet was assessed 
through a special diet score (MedDietScore, ranged 0-55). RESULTS: The 5-year 
incidence of CVD was 11.0% in men and 6.1% in women (p < 0.001); the case fatality 
rate was 1.6%. MedDietScore was inversely associated with the development of CVD 
(relative risk per 1 unit = 0.92, 95% CI 0.89-0.94, after adjustment for sex, physical activity 
status, smoking habits and other bio-clinical characteristics of the participants). Age-
speciﬁc analysis revealed that only among people between 35-65 yrs, greater adherence 
to Mediterranean diet was inversely associated with CVD incidence (relative risk per 1 
unit = 0.94, 95% CI 0.90-0.97, after several adjustments were made). CONCLUSION: Our 
study conﬁrmed that adherence to this traditional dietary pattern is associated with lower 
risk of developing CVD events. The signiﬁcant ﬁndings observed only among middle aged 
people needs further investigation, and may explained by the level of adherence in the 
other age categories, or the burden of CVD risk factors.
9:30 a.m.
1048-76 Longterm Survival After Cardiac Rehabilitation: 
Prognostic Value of the Six Minute Walk Test
Vera Bittner, Todd M. Brown, Bonnie K. Sanderson, University of Alabama at 
Birmingham, Birmingham, AL
Background: Six Minute Walk Distance (6MWD) predicts survival in heart failure patients. 
It is unknown, whether it is similarly prognostic in the cardiac rehabilitation (CR) setting and 
whether changes in 6MWD (c6MWD) after CR exercise training also predict survival.
Methods: We analyzed 728 CHD patients completing CR (1/96- 2/08) with 6MWD and 
c6MWD data (98% of completers). Vital status was assessed with the Social Security 
Death Index; follow-up was complete to 3/31/08. Patients were grouped by 6MWD: both 
6MWD and c6MWD below the median (Gr1; n=157); 6MWD below, c6MWD above 
(Gr2; n=208); 6MWD above, c6MWD below (Gr3; n=209), and both above (Gr4; n=154). 
Survival for Gr1-4 was plotted using Kaplan Meier (KM) curves. Cox proportional hazards 
modeling was used to determine hazard ratios (HR) and 95% CI using Gr 4 as the referent 
group after adjusting for age, sex, race; clinical risk and co-morbidities assessed at CR 
entry; and number of CR sessions attended.
Results: Mean age was 61.7±10.6 yrs; 28% were women, 31% non-white, 37% high clinical risk; 
22% had a co-morbidity score >2. Mean 6MWD was 1305±378 ft; mean c6MWD was 237±251 ft. 
After a mean of 5.1±3.2 yrs, 100 patients had died (13.7%): 50 in Gr1 (31.8%), 11 in Gr2 (5.3%), 
36 in Gr3 (17.2%), 3 in Gr4 (1.9%). KM plots and adjusted HR are shown in the Figure.
Conclusions: Among patients completing CR, both 6MWD and c6MWD after exercise 
training independently predict longterm survival. Performance below the median on both 
indicators identiﬁes a very high risk group.
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1048-81 Association of Rheumatoid Factor Seropositive 
Status and Cardiovascular Events in Patients With 
Rheumatoid Arthritis
Matthew Kaminski, Mehdi H. Shishehbor, Antonio Gutierrez, Mohammad Amini, Walter 
Coats, Meisam Moghbelli, Arman T. Askari, Cleveland Clinic, Cleveland, OH
Background: Patients with rheumatoid arthritis (RA) have increased cardiovascular 
morbidity and mortality, possibly due to the inﬂammatory nature of the disease. While 
serum biomarkers in RA have been linked to atherosclerosis, the relationship between 
rheumatoid factor (RF) and cardiovascular events is less well-deﬁned.
Methods: Medical records at our institution were reviewed for patients with diagnosis 
of RA between January 2000 and July 2006. Demographic, clinical, and medication 
data were then extracted. We collected data on major adverse cardiac events (MACE), 
including MI, unstable angina, hospitalization for congestive heart failure, stroke, and 
TIA. All-cause mortality was obtained by using the Social Security Death Index. We 
used multivariable logistic regression analysis to assess the association between RF 
seropositivity and MACE, including all-cause mortality.
Results: A total of 1723 consecutive patients with RA were identiﬁed. These patients 
experienced 250 MACE, including 58 deaths, over 6 year period. We found a signiﬁcant 
univariate association between RF seropositivity and MACE. After adjustment for several 
confounders including history of coronary artery disease, hypertension, hyperlipidemia, 
current smoking, obesity, and concomitant medications (statins, aspirin, disease-
modifying anti-rheumatic drugs), RF seropositivity remained independently associated 
with MACE (OR 1.61; 95% CI 1.13-2.28).
Conclusions: In patients with RA, RF seropositivity was strongly associated with MACE. 
RF seropositivity may identify individuals with RA that are at increased risk of MACE, 
including death.
9:30 a.m.
1048-82 Prevalence of Coronary Artery Disease Across the 
Ramingham Risk Categories: Coronary Artery Calcium 
Scoring and MSCT Coronary Angiography
Gaetano Nucifora, Joanne D. Schuijf, Jacob M. van Werkhoven, J. Wouter Jukema, 
Roxana Djaberi, Arthur J. Scholte, Martin J. Schalij, Ernst E. van der Wall, Jeroen J. Bax, 
Leiden University Medical Center, Leiden, The Netherlands
Background:Non-invasive assessment of subclinical atherosclerosis by means of 
coronary artery calcium scoring (CACS) and multi-slice computed tomography (MSCT) 
coronary angiography could improve patients’ risk stratiﬁcation. However, data relating 
observations on CACS and MSCT coronary angiography to traditional risk assessment 
are scarce.
Methods:In 314 consecutive outpatients (54±13 years, 56% males) without known CAD, 
CACS and 64-slice MSCT coronary angiography were performed. Accordingly to the 
Framingham risk score (FRS), 51% of patients were at low, 24% at intermediate and 25% 
at high risk, respectively. MSCT angiograms showing atherosclerosis were classiﬁed as 
showing obstructive (q50% luminal narrowing) CAD or not.
Results:Both CACS and MSCT coronary angiography showed a high prevalence of 
normal coronary arteries in low FRS patients (70% and 61%, respectively). An increase in 
the prevalence of CACS>400 (4% low vs. 19% intermediate vs. 36% high), CAD (39% low 
vs. 79% intermediate vs. 91% high) and obstructive CAD (15% low vs. 43% intermediate 
vs. 58% high) was observed across the FRS categories (p<0.0001 for all comparisons).
Conclusions:A strong positive relationship exists between FRS and the prevalence 
and extent of atherosclerosis. Especially in intermediate FRS patients, CACS and 
MSCT coronary angiography provide useful information on the presence of subclinical 
atherosclerosis.
9:30 a.m.
1048-83 Increased High-Sensitivity C-reactive Protein Levels 
Preceding the Occurrence of Metabolic Syndrome
Naomi Tominaga, Yasuhiko Sakata, Masahiko Shimizu, Shinichiro Suna, Masaya Usami, 
Sen Matsumoto, Hiroshi Sato, Health Care Center, Osaka Prefectural Police, Osaka, 
Japan, Department of Cardiovascular Medicine, Osaka University Graduate School of 
Medicine, Suita, Japan
Background: Metabolic Syndrome (MetS), a novel risk factor for cardiovascular diseases 
is considered to be associated with vascular and systemic inﬂammation. However, little 
evidence is available regarding whether inﬂammation precedes or accelerates the 
development of MetS. The aim of our study is to evaluate the relationship between 
transitions in MetS status and the levels of an inﬂammatory biomarker, high sensitivity 
C-reactive protein (hs-CRP), in the preceding year. 
Methods: We examined working 14,122 men (aged 20-61 years, mean age 39.3±11.1 
years) who underwent the annual health check-ups in the consecutive two years of 2006 
and 2007. The deﬁnition of NCEP-ATP[[Unsupported Character - &#1064;]] was employed 
to diagnose MetS. After the health check-up of 2006, we advised those with MetS to 
reduce their waist circumference by lifestyle modiﬁcation. The subjects were divided into 
4 groups according to the transitions in the MetS status; 10,499 men without MetS in both 
years (Group A, mean age 37.0±10.8 years), 901 men who did not have MetS in 2006 
but developed MetS by 2007 (Group B, mean age 43.8±9.9 years), 1,129 men who had 
MetS in 2006 but overcame MetS by 2007 (Group C, mean age 45.5±9.2 years), and 
1,593 men who had MetS in both 2006 and 2007 (Group D, mean age 47.5±8.3 years). 
We compared the hs-CRP levels in 2006 among the groups. 
Results: The prevalence of MetS in 2007 (17.7%) decreased signiﬁcantly compared 
baseline than those without. MMP-8 concentrations were associated with the risk of all-
cause deaths (RR 1.31, 95% CI 1.06 to 1.61, p=0.011), among those with high C-reactive 
protein from all causes (RR=1.12, 95 % CI 1.04-1.22, p=0.004) per one standard 
deviation (SD) increase, after adjustment for age, history of CHD, systolic blood pressure, 
smoking and serum LDL and HDL cholesterol. Serum TIMP-1 concentrations alone had 
no independent predictive value for CHD death.
Conclusions: The results indicate that serum elevated MMP-8 concentrations predict 
the risk of all-causes mortality and coronary heart disease and cardiovascular disease 
death in normal weight men.
9:30 a.m.
1048-79 The Obesity Paradox in Coronary Heart Disease -- Does 
Body Fat Complete the Puzzle?
Carl J. Lavie, Jr., Richard V. Milani, Surya M. Artham, Dharmendrakumar A. Patel, 
Hector O. Ventura, Ochsner Health System, New Orleans, LA
Background: Although obesity is a risk factor for CV disease we and others have 
demonstrated a strong “obesity paradox,” where obese with CV disease have better 
prognosis compared with lean patients. Part of this “obesity paradox” has been attributed 
to the fact that BMI is generally used to deﬁne overweightness/obesity, but this lacks 
sensitivity and speciﬁcity for at risk body fatness. Methods: We assessed 529 CHD 
patients before and after cardiac rehabilitation (CR) and classiﬁed patients as overweight/
obese by both standard BMI criteria (q 25 kg/m2) as well as by the WHO gold standard for 
obesity (% body fat > 25% in men and > 35% in women). Total mortality by the National 
Death Index was assessed (mean 1,295 ± 550 days). Results: Besides having higher 
% fat by design, 315 patients with high fat also had statistically higher BMI, triglycerides, 
fasting glucose and hostility scores and lower HDL-C and peak oxygen consumption than 
214 patients with low % fat. Despite having a higher CV risk proﬁle, similar to the results 
with high vs low BMI (p<0.001), patients with high % fat also had considerably lower 
3-year mortality (4% vs 11%; p<0.01; Figure). Conclusions: These results conﬁrm the 
“obesity paradox” in CHD patients following CR using both BMI and % body fat criteria. 
Despite having more adverse CV risk proﬁles, CHD patients with high % fat have lower 
mortality, supporting data that we previously demonstrated in heart failure. Further studies 
are needed to decipher the mechanisms of this puzzling paradox.
9:30 a.m.
1048-80 Socioeconomic Status and Incident Type 2 Diabetes 
Mellitus: Results From the Women’s Health Study
Timothy C. Lee, Robert J. Glynn, David Conen, Paul M. Ridker, Julie E. Buring, Michelle 
A. Albert, Brigham and Women’s Hospital, Boston, MA
Background: Multiple studies indicate that low socioeconomic status (SES) is associated 
with poor cardiovascular outcome. However, whether low SES also predicts incident 
diabetes is less certain.
Methods: We evaluated the relationship between SES (as measured by education 
and income) and incident diabetes among 23,989 apparently healthy female health 
professionals participating in the Women’s Health Study (WHS) who had baseline HbA1c 
levels less than 6 percent.
Results: Over a median follow-up period of 12.3 years, 1,262 women developed diabetes. 
In age and race adjusted Cox proportional hazard models, the relative risk of incident 
diabetes decreased with increasing levels of education (< 2 years of nursing education, 
2 to < 4 years of nursing education, bachelor’s degree, master’s degree, and doctoral 
degree: 1.0, 0.7, 0.6, 0.5, 0.4, p trend <0.001), and income (< $19, 999, $ 20, 000 to $ 
29, 999, $ 30, 000 to $ 39, 999, $ 40,000 to $ 49, 999, $ 50, 000 to $ 99, 999, and > $ 
100, 000; 1.0, 1.0, 0.9, 0.8, 0.4, p trend < 0.001). These effects, however, were completely 
attenuated in multivariable models that adjusted for traditional and non-traditional risk 
factors (education: p trend =0.97, income: p trend =0.42). In analyses designed to 
understand the mechanism of this attenuation, adjustment for obesity had the largest 
effect on the beta-coefﬁcients, while behavioral factors (alcohol use, exercise frequency, 
smoking history, and hormone use) and metabolic factors (HDL, triglycerides, HbA1c) 
also were signiﬁcant mediators of the relationship between SES and incident diabetes.
Conclusions: Even in this well-educated cohort, we observed an inverse association between 
incident diabetes and increasing levels of education/income, a relationship that was largely 
explained by body mass index and to a lesser extent other modiﬁable CVD risk factors.
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1048-86 Prevalence of Sleep Disordered Breathing in Retired 
NFL Players
Felipe Albuquerque, Fatima Kuniyoshi, Abel Romero-Corral, Justo Sierra-Johnson, 
Daniel Levendowski, David Rapoport, Charles George, Bijoy Khandheria, Arthur 
Roberts, Virend Somers, Mayo Clinic, Rochester, MN, Living Heart Foundation, New 
Jersey, NJ
Background:Sleep disordered breathing (SDB) has been reported to have a high 
prevalence in active National Football League (NFL) players. Our aim was to assess 
prevalence of SDB among retired NFL players and to compare this between linemen and 
other position players.
Methods:We performed an unattended, limited but multichannel SDB diagnostic test in 
167 retired NFL players. We used an apnea-hypopnea index (AHI) cutoff value of 10 
events/hour to deﬁne SDB and divided the players in two groups: lineman (offensive 
and defensive lineman) and nonlineman (every other position). Continuous variables are 
shown as mean ± SD, and binary data as %, an unpaired t -test was used to compare the 
variables between groups.
Results:The mean age was 54.0 ± 12 years, body mass index (BMI) was 32±0.3 kg/
m², and neck circumference was 17.5±1.4 inches. The prevalence of SDB was 51.5%, 
Hypertension(HTN) was 37.4%, Diabetes was 6.1%, Stroke was 1.2%, and Heart 
Disease was 6.1%. In a multivariate logistic regression model, BMI and age were the best 
predictors of the presence of SDB even after adjustment for neck circumference and HTN 
(R2=0.21; BMI B estimate = 0.02± 0.01, p=0.03; age B estimate = 0.017±0.003, pa0.01).
The characteristics of the study population according to the players positions are shown 
on the table below:
Conclusions:SDB was highly prevalent among retired NFL players. SDB was higher in 
linemen compared to nonlinemen. BMI and age were signiﬁcantly associated with SDB, 
independently of neck circumference and HTN.
Linemen(N=61) Nonlinemen(N = 106) p
Age (year) 54.3 ± 1.5 53.9 ± 1.8 0.84
Neck(inches) 18.1 ± 1.2 17.1 ± 1.4 <0.01
Body mass index (kg/m2) 34.2 ± 4.3 30.5 ± 3.6 <0.01
AHI (events/hour) 18.7 ± 1.9 13.4 ± 1.5 0.11
SDB (AHI>10 events/hour) % 60.6 46.2 0.07
Hypertension (%) 45.7 32.7 0.09
Heart disease (%) 8.4 4.8 0.34
Diabetes (%) 10.1 3.8 0.11
Stroke (%) 1.6 1% 0.68
9:30 a.m.
1048-87 Blood Pressure and the Treatment Effect of ACE-
Inhibition by Perindopril in 29463 Patients With 
Vascular Disease
Jasper J. Brugts, Toshiharu Ninomiya, Eric Boersma, Willem Remme, Roberto Ferrari, 
Kim Fox, Stephen MacMahon, John Chalmers, Maarten L. Simoons, Erasmus MC, 
Rotterdam, The Netherlands
Objective: We undertook a combined analysis using individual data from the ADVANCE, 
EUROPA, and PROGRESS trials to determine the consistency of the treatment effect 
of the ACE-inhibitor perindopril with respect to blood pressure levels in patients with 
vascular disease.
Methods: We studied major cardiovascular events during a follow-up of 4 years in 29.463 
patients who participated in these three trials, who were randomly assigned ACE-inhibitor 
perindopril-based treatment or placebo. Major cardiovascular outcomes was deﬁned as 
the incidence of cardiovascular mortality, MI and stroke. Categories of blood pressure 
were>120, 120-139.9,140-159.9 and >160 mmHg systolic and 90 mmHg diastolic. Cox 
regression analysis was used to obtain hazard ratios of treatment effect in strata of blood 
pressure. .
Results: Perindopril-based regimens were associated with a consistent reduction in major 
cardiovascular outcomes across all systolic and diastolic blood pressure strata. A larger 
relative beneﬁt was observed at higher BP levels, especially diastolic (P for interaction 
<0.01) (Figure). Comparable results were observed for blood pressure reduction levels 
during run-in periods or during follow-up.
Conclusion: The cardioprotective effect of ACE-inhibition by perindopril is consistent 
across a wide range of blood pressure strata. These results support the provision of 
ACE-inhibitor based treatment (for secondary preventive purposes), not on the basis of 
arbitrary cut-off points for blood pressure.
to that of 2006 (19.3%) (p<0.001). The values of hs-CRP in Group B (1.66±3.76mg/L) 
was signiﬁcantly higher compared with those in Group A (1.12±3.92mg/L) and were 
comparable with those in Group C (1.57±4.46mg/L) and Group D (1.54±2.92mg/L). 
Conclusion: The levels of hs-CRP seemed to be associated with MetS in the study 
population. Subjects who were newly diagnosed as MetS in 2007 had increased levels of 
hs-CRP in the previous year, which were comparable with those who had been diagnosed 
as MetS. It is suggested that elevated hs-CRP levels might be associated with the future 
development of MetS.
9:30 a.m.
1048-84 Chronic Exposure to Environmental Tobacco Smoke 
Confers to the Development of Left Ventricular 
Systolic Dysfunction in Hospitalized Patients With 
Acute Coronary Syndromes, Through Exaggeration of 
Inﬂammatory Response
Christina Chrysohoou, Panagiotis Aggelopoulos, Christos Pitsavos, Catherine Liontou, 
Dimitris Tsiachris, John Maragiannis, John Skoumas, Eleftherios Tsiamis, Christodoulos 
Stefanadis, 1st Cardiology Clinic University of Athens, Athens, Greece
Background: Several studies have revealed that exposure of non-smokers to 
environmental tobacco smoke (ETS) is associated with a substantial increase in the risk 
of coronary heart disease. The purpose of this work was to investigate the association 
between chronic exposure to ETS and the risk of developing left ventricular systolic 
dysfunction (LVSD) after an acute coronary syndrome (ACS) event. 
Methods: During 2006-2008, 312 male (65±14 years) and 78 female (71±12 years) ACS 
(myocardial infarction or unstable angina) patients who developed LVSD after the cardiac 
event and 355 males (64±12 years) and 89 females (67±10 years) ACS patients who did 
not develop LVSD, were included in this study. Detailed information regarding their medical 
record and other lifestyle habits, were recorded. Exposure to second-hand smoke (>30 
minutes per day and q1 day per week) by non-smokers was recorded. Furthermore blood 
samples were collected during the third day of their hospitalization. Multiple regression 
analysis was used to evaluate the effects of exposure to ETS on the occurrence of LVSD 
and levels of white blood cells count (WBC). 
Results: Exposure to ETS was reported by 55% of those who developed LVSD, and 
53% of those who did not develop. Multi-adjusted analysis revealed that ACS patients 
exposed to ETS were 3-times more likely to develop LVSD (OR= 2.95, 95%CI 1.15-3.62, 
p=0.001), controlling for age, gender, diabetes mellitus, hypercholesterolemia, physical 
activity status, smoking, type of acute coronary syndrome and previous known history 
of coronary heart disease. Furthermore, among patients with LVSD those exposed to 
ETS had higher values of WBC compared to those who were not exposed (10656±3812 
vs. 10310±3618 count, p=0.05); the latter association was not evident among non-heart 
failure patients. 
Conclusions: This work supports the hypothesis that exposure to ETS increases the risk 
of developing LVSD after an ACS. Furthermore, the exposure of ETS seems to increase 
the levels of WBC among ACS patients who developed LVSD. The latter ﬁnding may 
suggest a possible mechanism, by which ETS virtue its adverse effects on myocardial 
function, causing a further increase of inﬂammation response 
9:30 a.m.
1048-85 Components of the Metabolic Syndrome Differ Between 
Young and Old Adults in the Unites States: Results 
From the National Helath and Nutrition Examination 
Survey (1999-2006)
Andrew D. Sumner, Gabriel L. Sardi, James F. Reed, Lehigh Valley Health Network, 
Allentown, PA
Background: The metabolic syndrome (MetSyn) is highly prevalent in the United States 
and is associated with increased cardiovascular disease (CVD) risk. The purpose of this 
study was to determine if the prevalence of the MetSyn and its components differs across 
various age groups in the total US population.
Methods: We analyzed data from four National Health and Nutrition Examination Surveys 
between the years 1999-2006. The prevalence of the MetSyn (ATP III criteria) and the 
prevalence of its components was determined in 41,474 participants age 18 years and 
older with no prior CVD history. Statistical analysis was performed using SPSS V15.0.
Results: The prevalence of the MetSyn among asymptomatic adults was 16.6%, and 
remained stable for the total population over the four survey periods. The prevalence 
of the MetSyn increased with age. It was 4.9 % in young adults (age 18-29 years) and 
was 26.7% in older adults (age greater than 70). The components of the MetSyn differed 
between young and old adults. Compared to older adults, young adults had lower HDL -C, 
less glucose intolerance, and less hypertension.
Prevalence of MetSyn Components Stratiﬁed by Age
HTN low HDL High TG Obesity Glucose Intolerance
Age 18-29 53.9% 93.5% 83.5% 92.2% 15.5%
Age > 70 87.2% 59.7% 81.8% 92.7% 62.7%
p value 0.001 0.001 0.329 0.057 0.001
Conclusions: This study provides a nationally representative estimate of metabolic 
syndrome prevalence in asymptomatic adults in the United States over an eight year 
time period revealing that MetSyn continues to affect a large number of Americans. The 
components of the MetSyn differs between young and old adults and has important 
implications in the general clinical management of these patients.
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1048-90 Changes in Carotid Intima-Media Thickness According 
to the Presence of the Metabolic Syndrome With and 
Without Chronic Inﬂammation
Monica Acevedo, Pilar Arnaiz, Ramón Corbalán, Iván Godoy, Carlos Navarrete, Ximena 
Berríos, Pontiﬁcia Universidad Católica de Chile, Santiago, Chile
Background:Carotid intima-media thikness (CIMT) is a surrogate marker of 
atherosclerosis. Little data exist on the variation of CIMT according to the presence of the 
metabolic syndrome (MetSyn) and systemic inﬂammation. We determined the changes in 
CIMT in subjects with and without MetSyn and inﬂammation determined by ultrasensitive 
C-reactive protein (CRP) levels. 
Methods: Chilean subjects, without CHD or CVD followed in a primary prevention 
program. In all the subjects we performed a survey on demographic and traditional CV 
risk factors and determined blood pressure, BMI, waist and a fasting lipid proﬁle, glycemia 
and CRP levels. We used ATPIII deﬁnition for MetSyn. Mean CIMT was measured with an 
automated software in the far wall of both the right and left common carotid arteries. 
Results: 999 subjects (508 men), mean age 44±11 yo. Hypertension prevalence was 
29.8%, dyslipidemia 68% , current smoking 47% and MetSyn 24%. Mean CIMT was 
0.61±0.1 mm and CRP 2.22±2. mg/L. CIMT increased signiﬁcantly according to increasing 
number of CV risk factors. It also increased signiﬁcantly in subjects with MetSyn. When 
separating the MetSyn subjects in those with and without elevated CRP levels (>2 mg/L 
according to AHA), CIMT was the greatest in those with high CRP (see table). 
Conclusions: Mean CIMT is higher in subjects with MetSyn, and it increases more 
in those with MetSyn and inﬂammation. These ﬁndings suggest that subjects with the 
presence of both inﬂammation and MetSyn might have increased CV risk.
CIMT adjusted by age/sex;*p<0.0001 versus w/o MetSyn;**p<0.001 
versus MetSyn-CRPa2
without MetSyn with MetSyn MetSyn-CRPa 2 mg/L MetSyn-CRP>2 mg/L
CIMT (mm) 0.60±0.10 0.66±0.12* 0.63±0.10 0.69±0.13**
ACC.ORAL CONTRIBUTIONS
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Left Ventricular Hypertrophy
Tuesday, March 31, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W308A
10:30 a.m.
0916-3 Can Severe Left Ventricular Hypertrophy and Its 
Functional Consequences Be Reversed? The LIFE Study
Richard B. Devereux, Eva Gerdts, Kristian Wachtell, Kurt Boman, Markku Nieminen, 
Jonathan Edelman, Bjorn Dahlof, Weill Cornell Medical Center, New York, NY, University 
of Goteborg, Goteborg, Sweden
Background: Hypertensive left ventricular hypertrophy (LVH) is associated with worse LV 
function and clinical outcome. However, the reversibility of severe LVH and its functional 
consequences are unknown.
Methods: A total of 693 hypertensive patients (blood pressure [BP] 174/99 mm Hg, 66 
years old, 57% men) with ECG LVH at screening and echocardiograms at baseline and 
after 4 years of aggressive treatment were classiﬁed by gender speciﬁc quintile (Q) of 
baseline LV mass/body surface area (LVMI); Qs 4 & 5 were older but did not differ in 
BMI or diabetes prevalence from Q1. Standardized methods assessed 4-year change 
and ﬁnal levels of LVMI, LV relative wall thickness (RWT), stress-corrected LV midwall 
shortening (sc-MWS) - an index of myocardial function - and ejection fraction (EF).
Results: At baseline, LVH was moderate-severe in Q4 & Q5 (Table [p:*=<0.05, **=<0.005, 
***=<0.001 vs. quintile 1]). After 4 years, LVMI decreased in all groups, but residual LVH 
prevalence remained high in Q4 & Q5; RWT and concentric LV geometry prevalence 
decreased in all groups. Sc-MWS rose by 9-1-% and EF fell by 2-3% in all groups but both 
remained lower in patients with more severe baseline LVH.
Conclusions: Aggressive antihypertensive therapy substantially reduces moderate and 
severe LVH and decreases concentric LV geometry, but leaves substantial prevalences 
of LVH and lower LV function. Whether treatment targeting LVH regression or achieving 
lower BP in patients with LVH would achieve better results needs to be tested.
Variable Q1 Q2 Q3 Q4 Q5
$BP (mm Hg) -27/16 -30/16 -30/17 -30/17 -30/17
Baseline LVMI (g/m2) 93.5 110.6 120.6 131.5 161.5
$LVMI (g/m2) -10.0 -18.4 -21.1 -24.0 -38.9
Baseline/Year 4 LVH (%) 0/2 52/9* 100/20** 100/39*** 100/71***
$RWT -0.09 -0.09 -0.09 -0.07 -0.09
Year 4 concentric Geometry (%) 2.1 1.4 1.5 2.1 5.3
Year 4 sc-MWS 109.1 108.8 107.3 106.6 101.6***
Year 4 EF 61.9 60.5 59.5 58.3** 55.1***
9:30 a.m.
1048-88 Comparison of the Improvement in Functional Capacity 
With Cardiac Rehabilitation in Patients With and 
Without Diabetes
Christopher Douglas, Todd M. Brown, Bonnie K. Sanderson, Vera Bittner, University of 
Alabama at Birmingham, Birmingham, AL
Background: Cardiac rehabilitation (CR) improves functional capacity and reduces 
mortality in coronary heart disease (CHD) patients. Whether improvements in functional 
capacity are uniform in individuals with and without diabetes (DM) is unknown.
Methods: We analyzed 794 CHD patients completing CR from 1/96 to 4/08. Functional 
capacity (distance on a 6 minute walk test [6MWT]) as well as dyspnea level and relative 
perceived exertion (RPE) on 6MWT were measured at baseline and at CR completion. 
We performed multivariable linear regression to compare changes in these parameters 
with CR in individuals with and without DM, adjusting for demographics, self-reported 
physical activity, beta-blocker use, comorbidities, number of attended sessions, and 
baseline values for these parameters.
Results: Mean age was 61.6 ± 10.6 years, 29% were female, 31% non-white, 38% had 
DM. At enrollment, individuals with DM had signiﬁcantly shorter 6MWT distances and 
increased RPE and dyspnea on 6MWT (see Table; all p<0.01). Following CR, participants 
overall improved their 6MWT distances and experienced less dyspnea during a 6MWT 
(Table). However, after multivariable adjustment, individuals without DM had greater 
improvements in distance achieved (+48 feet, p=0.01), less dyspnea (-0.1, p=0.03), and 
less RPE (-0.5, p<0.01) during a 6MWT than those with DM.
Conclusions: Although functional capacity by 6 MWT among diabetic CHD patients 
improves with CR, the magnitude of this improvement is less than for those without DM.
9:30 a.m.
1048-89 The Impact of Lipid Lowering Treatment on 
Cardiovascular Events Over the Last 30 Years on 
Familial Hypercholesterolemia
Evan A. Stein, Avishay Ellis, Cholesterol Treatment Center, Cincinnati, OH
Background: FH is an inherited condition that results in markedly elevated LDLc from 
birth leading to CAD in early mid life. Long term data on the effects of intensive LDLc 
regimens on LDL-c levels and CVD events is lacking in FH patients. The aims of the study 
were to evaluate the effectivance of long term intensive lipid lowering therapy on LDLc 
levels, and their effect on the natural history of FH.
Methods: Charts of 327 of approximately 1,000 adult heterozygous (He) FH patients, 
treated at our lipid clinic between 1974 and 2008, were randomly selected and reviewed. 
FH was deﬁned according the Simon Broome Registry (http://www.primarycare.ox.ac.
uk/research/vascular/research/simon_broome). The following data was recorded: age, 
gender, and lipid levels at diagnosis, lipid lowering treatments, length of follow up, last 
lipid levels on treatment, CVD events including revascularization procedures, mortality 
and cause.
Results: Of 327 HeFH patient, 60% males, mean (SD) age at diagnosis was 31 (17) 
years, and mean (SD) follow-up was 14.5 (8) years. All lipid assay calibration and 
standardization remained identical throughout the 30 years. CVD events or procedures 
were present in 114 (35%) prior entering the center. Initial untreated (UnRx), most recent 
treated (Rx) lipid levels (mean+SD; mg/dL) and percent changes were as follows; LDLc 
UnRx 256+60, Rx 116+46, -55%; HDLc UnRx 49+14, Rx 54+16, +8%; triglyceride UnRx 
146+86, Rx 123+71, -15%. Of all subjects 37% were treated with statin monotherapy, 
40% with statin plus one other agent, 20 % were on 3 drugs and 3% on 4 or more lipid 
drugs. LDLc levels were <130 mg/dL in 70%, <100 mg/dl in 33% and <70 mg/dL in 11% 
of subjects. During follow up there were 48 CVD events; the interval between CVD events 
prior to being seen in the clinic was 5.3 (4.8) yrs compared to 7.4 (6.7) yrs since.
Conclusions: Long term intensive statin based combination therapy provides the 
opportunity to achieve substantial changes in LDLc in the majority of HeFH patients and 
appears to alter their CVD risk signiﬁcantly.
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hypertension, plasma levels of midregional pro-ADM (MR-proADM) are associated with 
pulse pressure, left ventricular mass (LVM), and albuminuria.
Methods: Participants included 1047 African Americans (65±9 y, 72% women) belonging 
to hypertensive sibships. Plasma MR-proADM was measured by an immunoluminometric 
assay, LVM was assessed by 2-D echocardiography, and albuminuria was assessed 
by urinary albumin:creatinine ratio (UACR). Multivariable regression analyses (using 
generalized estimating equations) were employed to assess whether plasma MR-proADM 
was independently associated with pulse pressure, LVM (indexed to height2.7) and UACR.
Results: Plasma MR-proADM was signiﬁcantly correlated with pulse pressure, LVM 
index, and UACR (Figure). In separate regression models that adjusted for age, sex, BMI, 
estimated GFR, smoking history, diabetes, medication (BP-lowering, statin, and aspirin) 
use, log MR-proADM was signiﬁcantly associated (B ±SE; P -value), with greater pulse 
pressure (5.07±1.59, P =0.001), log LVM index (0.06±0.02, P =0.008), and log (UACR+1) 
(0.54±0.15, P =0.0003).
Conclusion: Plasma MR-proADM is independently associated with arterial stiffness, 
LVM, and albuminuria in African Americans with hypertension and is a potential biomarker 
for target-organ damage in this setting.
11:30 a.m.
0916-7 Concentric Left Ventricular Hypertrophy Brings 
Deterioration of Systolic Longitudinal, Circumferential 
and Radial Myocardial Deformation in Hypertensive 
Patients With Preserved Left Ventricular Pump Function
Yukio Mizuguchi, Yoshifumi oishi, Hirokazu Miyoshi, Arata Iuchi, Norio Nagase, Takashi Oki, 
Higashi Tokushima National Hospital, National Hospital Organization, Tokushima, Japan
Background: It has now been clearly established that heart failure (HF) may occur in 
patients with preserved left ventricular ejection fraction (LVEF). This “isolated” diastolic 
HF is most commonly encountered in patients with hypertension (HT). We hypothesized 
that deterioration of LV myocardial deformation exists as an early sign of diastolic HF in 
patients with HT and LV hypertrophy (LVH).
Methods: Two-dimensional strain echocardiography was performed in 98 treative 
patients with HT and 22 age-matched normal controls. The LV mass index and relative 
wall thickness were used to assign patients into 3 groups with normal geometry (N-LV, 
n=31), concentric hypertrophy (C-LVH, n=25), and eccentric hypertrophy (E-LVH, n=42).
Results: The LVEF was similar between 3 HT groups, whereas was lower in the C-LVH 
group than in the control group. The mean peak systolic longitudinal, circumferential, 
and radial strains in the C-LVH group were lower compared to the control and other 
2 HT groups, and mean peak systolic longitudinal and circumferential strains in the 
E-LVH group and mean peak systolic longitudinal strain in the N-LV group were lower 
compared to the control group. The mean peak systolic strain rates in the 3 directions in 
the C-LVH group and those in the longitudinal and radial directions in the E-LVH and N-LV 
groups were lower compared to the control group. In addition, the mean peak systolic 
circumferential strain rate was lower in the C-LVH group than in the other 2 HT groups. 
There were no differences in the LV torsion and torsional rate between the control and 3 
HT groups. The mean peak systolic circumferential strain was an independent predictor 
related to LVEF in all patients.
Conclusions: The concentric LV hypertrophy caused deterioration of the systolic 
longitudinal, circumferential, and radial myocardial deformation in patients with HT, whereas 
normal LV torsion was considered to be a compensatory mechanism for preserved LVEF. 
LV torsion and circumferential shortening may be important determinants for maintaining 
LV pump function, and for leading to the evolution of “isolated” diastolic HF.
10:45 a.m.
0916-4 Left Atrial Dimension as a Predictor of Arterial 
Stiffening: Data From the Hippokration Hellenic 
Hypertension Study (3H Study)
Efstathios Taxiarchou, Costas Tsiouﬁs, Dimitris Tsiachris, Eirini Andrikou, Ioannis 
Andrikou, Panagiotis Tolis, Vanessa Tzamou, Dimitris Syrseloudis, Dimitris Tousoulis, 
Christodoulos Stefanadis, First Cardiology Clinic, University of Athens, Hippokration 
Hospital, Athens, Greece
Background: Both, left atrial (LA) enlargement and increased aortic stiffness are 
early sings of hypertensive cardiovascular disease and are associated with adverse 
clinical outcomes. The possible interrelationship between aortic stiffness and LA size in 
hypertensives was investigated in this study.
Methods: A total of 1387 consecutive hypertensives [aged 56±12, 713 males, ofﬁce BP 
= 145/90 mmHg] that were included in the Hippokration Hellenic Hypertension Study 
(3HStudy) (an ongoing registry of hypertension related target organ damage) were 
considered for analysis. All subjects underwent a complete echocardiographic study and 
LA volume was indexed for body surface area to estimate LA volume index (LAVI). The 
study population was divided into those with increased LAVI (>26ml/m2, n=389) and those 
without increased LAVI (a26ml/m2, n=998). Moreover, aortic stiffness was evaluated on 
the basis of the carotid-femoral pulse wave velocity (PWV) measurement by an automatic 
device (Complior SP).
Results: Subjects with increased LAVI compared to those without did not differ regarding 
sex, body mass index and lipid proﬁle. Subjects with increased LAVI compared to those 
without had increased ofﬁce systolic BP (148±20 vs 143±18, p<0.001), ofﬁce pulse 
pressure (59±16 vs 53±15 mmHg, p<0.001), left ventricular mass index (LVMI) (115±29 
vs. 97±23 gr/m2, p<0.001) and relative wall thickness (0.44±0.09 vs 0.42±0.07, p=0.001). 
Moreover subjects with increased LAVI compared to those without had higher c-f PWV 
(8.6±1.8 vs 8.0±1.6 m/sec, p<0.001). In the entire study population, PWV exhibited positive 
relationships with age (r=0.53, p<0.001), body mass index (r=0.17, p<0.01), ofﬁce systolic 
BP (r=0.30, p<0.001), ofﬁce pulse pressure (r=0.34, p<0.001), LVMI (r=0.20, p<0.001), 
and LAVI (r=0.20, p<0.001)
Multiple regression analysis models revealed that age, LVMI, ofﬁce systolic BP and c-f 
PWV were independent predictors of LAVI (B=0.146, p<0.001).
Conclusions: LA enlargement is accompanied by increased aortic stiffness in a large 
cohort of hypertensives. Whether these associations are epiphenomena or part of a 
common pathophysiologic pathway remains to be determined.
11:00 a.m.
0916-5 Isometric Exercise-Induced Hemodynamic Load 
Strongly Predicts Left Ventricular Mass in Hypertension
Julio A. Chirinos, Patrick Segers, Amit Gupta, Abigail Swillens, James Kirkpatrick, 
Martin Keane, Victor Ferrari, Susan Wiegers, Martin St. John Sutton, University of 
Pennsylvania, Philadelphia, PA, University of Ghent, Ghent, Belgium
Background: Although resting hemodynamic load has been extensively investigated as 
a determinant of left ventricular (LV) hypertrophy, little is known about the relationship 
between provocative hemodynamic load and the risk of LV hypertrophy.
Methods: We studied 30 hypertensive adults. We performed simultaneous carotid applanation 
tonometry and Doppler echocardiography at rest and during a 40%-maximal voluntary 
forearm contraction (handgrip) maneuver. Left ventricular outﬂow tract area was measured 
with 3D-echocardiography and used to compute instantaneous volumetric ﬂow from Doppler 
velocities. Aortic pressure-ﬂow relations were assessed at rest and during handgrip using 
custom-designed software. LV mass index (LVMI) was measured with the area-length method 
with normalization for body height to the power of 2.7. Carotid-femoral pulse wave velocity 
(CF-PWV), an index of aortic stiffness, was measured with arterial tonometry.
Results: CF-PWV was the strongest resting predictor of LVMI and remained an 
independent predictor after adjustment for age, gender, systemic vascular resistance, 
wave reﬂection magnitude, proximal aortic characteristic impedance and total arterial 
compliance (B=1.92; Standardized B =0.56; P=0.002). Age, gender and resting indices 
explained 44% of the interindividual variability in LVMI. Although central systolic blood 
pressure (c-SBP) at rest was associated with LVMI (R=0.52; P=0.001), when adjusted 
for each other, c-SBP during handgrip (and not resting c-SBP) independently predicted 
LVMI. When speciﬁc indices of provoked hemodynamic load were examined, total arterial 
compliance emerged as the strongest predictor of LVMI (B=-16.1; Standardized B =-0.92; 
P<0.001). A model that included indices of provoked hemodynamic load explained 69% 
of the interindividual variability in LVMI.
Conclusions: Hemodynamic load provoked by isometric exercise strongly predicts 
LVMI in hypertension. The magnitude of this association is far greater than for resting 
hemodynamic load. Our ﬁndings suggest that provoked testing is necessary to assess LV 
load in hypertension and may have important clinical and epidemiologic implications.
11:15 a.m.
0916-6 Plasma Midregional Pro-Adrenomedullin Is Associated 
With Arterial Stiffness, Left Ventricular Mass and 
Albuminuria in African American Adults With 
Hypertension
Malik AM Al-Omari, Mahyar Khaleghi, Thomas H. Mosley, Jr., Nils G. Morgenthaler, 
Joachim Struck, Andreas Bergmann, Iftikhar J. Kullo, Mayo Clinic, Rochester, MN, 
University of Mississippi Medical Center, Jackson, MS
Background: Adrenomedullin (ADM) is a circulating vasoactive peptide with vasodilatory 
and antiproliferative effects. We tested the hypothesis that in African American adults with 
